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In mental health trials there is concern that the control treatment (therapy) might
be contaminated. For example, this might be due to it being delivered by a clinician
(therapist) who has been trained in the active intervention. It is often suggested by
investigators, reviewers and funders of clinical trial proposals that cluster randomisation,
with clusters defined at the level at which treatment contamination is thought to occur
(e.g. therapists), should be used to prevent contamination. This thesis explores statistical
methodologies used to account for both treatment contamination in the control trial
arm and non-compliance in the experimental arm when estimating treatment efficacy.
It considers trials where treatment receipt is measured on a binary scale and develops
methods to accommodate continuous measures of treatment receipt.
The primary research objective was to compare the efficiency of two competing trial
design options for evaluating efficacy in the presence of contamination. First, treatment
allocation by cluster randomisation together with an estimator of the average treatment
effect that accounts for clustered data. Second, allocation at the participant level, me-
asurement of treatment receipt in all participants, and use of a randomisation-based
estimator to target the complier average causal effect. Monte Carlo simulations under
the two options with a binary measure of treatment receipt showed that the cluster
randomisation design was more efficient under high levels of contamination, modest
intraclass correlation coefficients and small cluster sizes. With a continuous measure of
treatment receipt, the design with cluster randomisation was favoured more frequently
as the difference between potential (counterfactual) doses became smaller, i.e. when
there was greater non-adherence.
The secondary research objective was to develop a novel randomisation-based efficacy
estimator in trials with contamination and non-compliance measured on a continuous
scale. Efficacy estimators were applied to a trial of a psychological intervention for people
with poorly controlled type 2 diabetes. There was some treatment contamination and
non-compliance in the trial but little evidence of treatment efficacy according to the
analyses. The tertiary objective was to review problems and solutions associated with
contamination in published trials of complex interventions in mental health.
A main output from this project is the proposal of a novel valid estimator for evaluating
efficacy and a demonstration of its utility. Another output is the provision of an online
decision support tool (using the results from the simulations) to help those planning
trials choose between the two competing design options for dealing with contamination.
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1.1 Randomised controlled trials
Randomised controlled trials (RCTs) are a mainstay of quantitative research and are often
described as the “gold standard” of study design. This is because, of all study designs,
they provide the most convincing evidence of the effect of a treatment. The evidence
that a well-conducted RCT provides on treatment effect can be described as internally
valid because such a study is capable of giving an answer to a research question that is
unbiased. This is a consequence of treatment allocation being random and therefore not
driven by other factors that affect both the delivery of the exposure and the outcome.
This confers a causal status on the evidence that RCTs provide about the effect of an
intervention. However, trials are often expensive, take years to deliver and, particularly
in mental health, struggle to recruit enough participants (Campbell et al., 2007; Howard
et al., 2009). This implies that it is important that clinical trials are designed to be
effective and efficient. In other words they should provide valid answers to research
questions and make best use of resources and participants’ time and data.
The ideal RCT would recruit a representative sample from a population, allocate treatment
randomly, conceal this allocation from participants, clinicians and outcome assessors, have
no loss of research participants before outcomes are collected, and feature full treatment
adherence with protocol. Therefore, in an ideal RCT, the only difference between trial
arms (the groups of participants who are allocated to different interventions) would be
the treatment that participants are allotted to receive. In reality, trials can experience
problems with all of these ideal characteristics. It is one aspect of the last in the list that
this research project will focus on: treatment contamination.
14
1.2 Treatment contamination in trials of complex interventi-
ons in mental health
The general definition of treatment contamination in RCTs is the receipt of a treatment
that has been allocated to at least one trial arm by participants in another arm. This could
involve the receipt of the comparator treatment by participants in an experimental arm,
the receipt of an experimental treatment by control participants, or the receipt of the
experimental treatment by participants in another experimental trial arm. A narrower
and more common definition of contamination is the “process whereby an intervention
intended for members of the trial (intervention or treatment) arm of a study is received
by members of another (control) arm” (p. 6, Keogh-Brown et al., 2007). This thesis
will use this definition of treatment contamination throughout. There are a number of
synonymous terms for contamination. It is known occasionally as “spillover” (Ell et al.,
2010), “crossover” (Abroug et al., 2011), “diffusion” (Taylor et al., 2005), or “intrusion”
(Pearl, 2009).
In an RCT, treatment contamination is a type of treatment (or protocol) non-adherence.
Non-adherence can be considered separately amongst those allocated to active interven-
tion compared to those assigned to control. Amongst those in the former group, the
problem of participants not receiving the active intervention is known as non-compliance.
On the other hand, non-adherence in the control group is known as treatment contamina-
tion. The problems of non-compliance and contamination are related but may have very
different solutions (for example design methods for preventing contamination that will
be described in Section 1.5.1 would not be used to address non-compliance). Trialists
tend to be more accepting of non-compliance, partly because there is restricted scope
for preventing it by trial design but also because its effects are limited to the individual.
Contamination, on the other hand, causes more concern due to the possibility of it sprea-
ding through a group of participants quickly and widely in extent, and because it can be
harder to measure (e.g. it may be difficult to record what treatments participants have
received outside a trial). On the other hand, as will be described, there is a similarity
in terms of the analytical methods that can be used to address the two problems (see
Section 1.5.3).
Complex interventions, which are defined as packages of medical care with multiple
elements that produce some extra benefit when given together, are a mainstay of tre-
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atment in mental health and psychiatric disease (Craig et al., 2008). However, they
can be especially vulnerable to treatment contamination because their components are
sometimes “transportable and difficult to confine” (quotation used in the description of
another type of complex intervention in health research: educational interventions; p.
ix, Keogh-Brown et al., 2007).
1.3 The problem of contamination
The primary research question of the majority of late-phase trials is concerned with
effectiveness and this is often estimated using an intention-to-treat (ITT) analysis, where
treatment groups are defined by which trial arm participants were randomly allocated to
(more on this in Section 1.5.3). The effect of contamination is to dilute the difference
between trial arms, as the control group becomes more similar to the treatment group. It
is frequently considered that its consequence is to reduce the magnitude of the treatment
effect estimate and increase the size of this parameter’s estimated standard error (e.g.
Torgerson, 2001; Welsh, 2013). In the context of a superiority trial where the target
effect is effectiveness, the impact of both of these processes is to decrease statistical
power and therefore reduce the chance of detecting a statistically significant effect.
An ITT analysis in the context of contamination is often referred to as being “conservative”
due to the fact that the chance of detecting a statistically significant effect is reduced. It
should be emphasised that the impact of contamination is only conservative in the context
of a superiority trial where the treatment shows some evidence of benefit. Its effect
would be to give false evidence of effect if the trial were a non-inferiority (equivalence)
design or of safety if the treatment were harmful. It should also be considered that whilst
a bias towards the null may be reassuring to those in charge of organising a healthcare
system, it is less informative to patients and clinicians who may want to know the effect
of treatment in ideal conditions where the effect is likely to be greatest.
The problem of contamination is seemingly related to lack of blinding in trials. Based
on the focus of trial design and analysis methods in the existing trials literature, the
phenomenon appears to be of concern in educational interventions (Keogh-Brown et al.,
2007), geriatric medicine (Borm et al., 2005; Melis et al., 2008), cancer screening (Cuzick
et al., 1997), and mental health (Dunn et al., 2005). It tends to be difficult or impossible
to keep research participants and clinicians blind to treatment allocation in these areas
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of research. This is because the content of an intervention in these areas is often obvious
to the clinician as they give the treatment and to the patient as they receive it. It is
implicitly assumed by researchers that the presence of such knowledge can somehow
induce clinician or participant behaviour that leads to those in the control arm of a trial
receiving the active intervention.
1.4 The causes, extent and impact of contamination
The trials methodology literature is not entirely clear about the possible processes that
lead to contamination. Many RCTs have described these processes, for example this could
be a clinician providing both active and control interventions who mixes up elements of
the treatments or could be contact between participants in different trial arms leading
to a dilution of the treatment contrast (Borm et al., 2005). However, these processes,
their relative frequencies and their impact on trial arm comparisons have never been
reviewed comprehensively. An understanding of this is important in order to plan what
steps should be taken to address the problem.
It has been argued that the mechanism of contamination depends on the level at which an
intervention is applied: patient, clinician, or member of the general public (Keogh-Brown
et al., 2007). That research envisaged, with particular reference to trials of educational
interventions, that patient-level contamination affects only the individual and is less likely
for more complex interventions whose ingredients are less transportable. At clinician
level, contamination is likely to occur through communication between either active
intervention clinicians and control participants, or between clinicians in different trial
arms. At the population level, contamination might occur by unintended delivery of
intervention throughout the population, e.g. a public health intervention broadcast to
control participants. By surveying trialists, the same study showed that contamination
was more likely in settings where participants interacted closely, where the intervention
was highly desirable, or where the treatment was aimed at increasing knowledge. They
also found that contamination was thought to be more likely for interventions applied at
clinician rather than patient level.
Previous reviews have assessed the extent of contamination in some areas of medicine,
but the scale of the problem in trials of complex interventions in mental health remains
unclear. For example, a literature review of 235 RCTs of guideline dissemination and
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implementation strategies for healthcare professionals identified eight trials that quan-
tified contamination (Keogh-Brown et al., 2007). The review reported the proportion
of patients in the control arm who were assessed as having received treatment and
found a median of 24% of patients to be contaminated (range 0-65%). In oncology, a
large breast cancer screening trial (n=9,780) found that 22% of those in control arm
received a mammogram outside the trial compared to 5% of the intervention group
doing likewise (Goel et al., 1998). It has been argued that a review of cancer trials
using Zelen’s design provided information on treatment switches that was analogous to
contamination (Torgerson, 2001; Altman et al., 1995). Trials that use Zelen’s method ask
patients for consent to allocated treatment before asking for consent to participate in the
study. This means that the proportion of controls not giving consent at stage one may
provide some information on treatment contamination. The review found 11 trials that
reported treatment switches with an average of 18% (range 10-36%). However, many
of the studies in the review described switches from active to comparator treatments
or provided an overall summary of switches in either direction. Given the reported
information, the analogy to contamination was tenuous.
A number of studies have investigated the link between contamination (or the prevention
of it) and the size of estimated treatment effect. Many such studies assume that the impact
of contamination is to blur the distinction between trial arms and therefore hypothesise
that effects will be larger in trials that avoid contamination compared to those that do
not. Research that has tested this prediction has shown mixed results. For example,
the report that investigated contamination in educational intervention RCTs, which was
described earlier (Keogh-Brown et al., 2007), re-assessed an earlier systematic review of
educational, financial, and strategic interventions (Grimshaw et al., 2004). In the original
review the authors had assessed for each trial whether contamination avoidance had
been done, not done, or was not clear. Trials that avoided contamination were usually
those that used cluster randomisation. Surprisingly, the results of the later review showed
that trials where contamination was avoided had smaller estimated effect sizes than did
those where contamination avoidance was not done or not clear. The weakness of this
finding was that the studies represented a wide range of study quality and substantial
heterogeneity of experimental intervention. When the sample was restricted to those
trials that were rated as being of higher quality, estimated treatment effects were again
found to be greater for trials where contamination was not avoided. The set was then
further restricted to trials that were both of higher quality and in addition tested similar
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interventions. These were studies of clinician reminder interventions and provided a
sample of 11 trials. The authors now compared estimated treatment effect sizes between
cluster and individual randomised trials. Average estimated effect size amongst the
cluster randomised controlled trials (CRCTs) avoiding contamination was higher than
the average for the individual randomised trials with possible contamination, implying
that contamination avoidance may have been successful.
Reviews of particular interventions have found similarly mixed results. For example, a
review of 14 hip protector trials showed large beneficial effects of treatment in CRCTs
aimed at avoiding contamination and a mixture of positive and negative effects in RCTs
with patient-level randomisation with suspected contamination (Hahn et al., 2005). The
authors speculated that this difference may have been due to contamination biasing
results in the individual randomised trials. Other explanations were that the settings
may have been different between the two types of trials or that the results of the CRCTs
may have been biased by problems associated with cluster randomisation (see Section
1.5.1). A meta-analysis of 14 individual randomised and 10 cluster randomised trials
of enhanced care for depression provided rather different evidence of the relationship
between level of treatment allocation and estimated effect size (Gilbody et al., 2008).
The review found that estimated mean differences were very similar between groups of
trials as defined by level of treatment allocation. The only difference was that individual
randomised trials demonstrated substantially more heterogeneity between effect sizes
than did the CRCTs.
In summary, it is difficult to draw a conclusion about the relationship between the presence
of contamination and size of estimated treatment effects from the available evidence.
This is partly because of the heterogeneous nature of the interventions being compared
and also because it is difficult to disentangle the impacts of bias due to contamination
and those biases associated with the use of cluster randomisation. The evidence would be
more persuasive if treatment effect estimates were compared between studies where the
only difference was the level of treatment allocation, for example study designs that make
use of both cluster randomisation to avoid contamination and individual randomisation.
1.5 Methods of addressing contamination
I distinguish between three types of methods that are used to address contamination.
These categories are named here as statistical design, trial conduct and analytical met-
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hods. The first refers to structural aspects of trial design such as the level at which
treatment is allocated, sample size inflation, and participant preference designs. The
second includes trial implementation methods that are used to minimise the process by
which participants’ treatment becomes contaminated. The third relies on there being a
measurement of individual treatment receipt and includes comparison of groups based
on treatment received using randomisation-based estimation methods from the causal
inference literature.
1.5.1 Statistical design methods
Cluster randomisation
The most common statistical design method of avoiding contamination is the use of
cluster randomisation, where groups of participants instead of individuals are allocated
to trial arms. This strategy is often advocated by researchers and funders because it can
prevent contamination, provided that treatment allocation is made at the highest level at
which it is thought to take place (Campbell and Grimshaw, 1998). By ensuring that all
participants within a cluster receive the same treatment, contamination of the control
condition due to participants being affected by each other’s treatment receipt can be
avoided.
Cluster randomisation is used frequently in mental health trials, partly because of the
problem of contamination, but also for logistical reasons. For example, cluster randomi-
sation can reduce the number of clinicians who need to be trained in a new treatment in
comparison to an individually-randomised trial. Cluster randomisation can also lead to
a feeling of fairness within communities, as all participants are allocated to the same
treatment. However, the use of cluster randomisation cannot always minimise conta-
mination. There is at least one type where the scale of the problem is independent of
the level at which treatment is allocated: control participants seeking out the active
intervention outside the trial. This is a particular problem in screening trials which are
typically found in other areas of medicine, for example in oncology (Pinsky et al., 2010).
It is also possible that this problem may be becoming greater as patients are encouraged
to take greater responsibility for disease management decisions and with the growth of
online forums.
There are substantial drawbacks of cluster randomisation in terms of estimator efficiency
and bias. The main cost is that the correlation between participants’ outcomes within
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clusters means that each additional observation provides less information than it would
in an individually-randomised trial. This correlation and the number of participants
per cluster must be factored into a power calculation and will inflate the sample size
requirement. The design factor (D) that is used for this inflation is:
D := 1+ I(k− 1)
where I is the intraclass correlation coefficient (ICC) and k is the number of members per
cluster. These two factors can easily lead to a large inflation of the required sample size.
For example an ICC of 0.05 and a cluster size of 20 would almost double the sample size.
The other weakness of CRCTs is increased risk of bias. They have been found to suffer
from three main types: selection bias, attrition bias, and assessment bias. The first of
these is a consequence of the fact that it is often difficult to recruit all participants to a
cluster before allocating a treatment to this group, meaning that allocation concealment
is compromised. A review of 36 CRCTs that were published in three prominent journals
between 1997-2002 found that only 14 trials identified participants before treatment
allocation took place; this represented 41% of the sample where this item could be clearly
assessed (Puffer et al., 2003). The implication of this is that the RCT may suffer from
trial arm imbalance in terms of patient characteristics. In addition to this, it is possible
for whole clusters to be lost to follow-up in CRCTs (attrition bias) and it becomes harder
to blind outcome assessors to participants’ treatment allocation than it is when allocation
is made at the level of the individual (assessment bias; Puffer et al., 2003).
The major report of contamination in educational interventions compared bias in cluster
and individual randomised trials using Monte Carlo simulations (Keogh-Brown et al.,
2007). They investigated the impact of contamination on the bias of effectiveness esti-
mates (presumed to be the bias of the ITT approach for the effect of treatment receipt
on outcome) where cluster randomisation was modelled not to prevent receipt of in-
tervention in the control arm. In the simulations the authors modelled three aspects
of contamination: the proportion of the control group that were exposed to the active
(educational) intervention, the intensity of this exposure, and in CRCTs the timing of
control individuals’ exposure to intervention in comparison to when the cluster was first
contaminated. They simulated levels of sample size, ICCs, cluster size and timing of con-
tamination (using different levels of Weibull distribution parameters). A parameter was
used to relate baseline education level to risk of contamination. The outcome of interest
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in the simulations was bias: the difference between the true treatment effect and the
estimated effect of intervention offer. The findings suggested that cluster randomisation
led to greater bias (than allocation of treatment to individuals) when contamination of
a control cluster resulted in all individuals within that group receiving the treatment,
and when contamination effects were constant over time. CRCTs were found to be more
biased when the interval between the start of the trial and clusters being contaminated
was short. When there was a strong link between control participants’ baseline need for
the intervention and the chance of receiving the active intervention, CRCTs were more
biased when the transferability of the intervention between the trial arms was low.
Sample size inflation of individual randomised trial
A simple way of addressing the problem of reduced statistical power caused by contami-
nation in a superiority trial, when the target treatment effect of interest is the effect of
treatment offer (effectiveness), is to inflate the required sample size (Torgerson, 2001).
Under this method, treatment allocation is applied at the level of the individual and the
proportion of the control group who are anticipated to receive the active intervention
is used to inflate the sample size, thereby recovering the lost power. This method was
compared to a typical CRCT, which was assumed by the study to double the required
sample size and to prevent any contamination. On this basis, the sample size of an
inflated individually-randomised trial was less than that of a CRCT when contamina-
tion was less than 30%. A similar study compared sample size inflation to adjust for
contamination in an individually-randomised trial with cluster randomisation (Slymen
and Hovell, 1997). The study simulated a range of amounts of contamination, cluster
sizes, and ICCs. It found that cluster randomisation led to smaller sample sizes when
cluster size and ICC were low, and when the amount of contamination was high. The
limitation of this method of sample size inflation is that it does not address the effect
of contamination bias on the magnitude of the estimated effect of treatment receipt on
outcome.
Treatment allocation at a mixture of cluster and individual levels
A class of methods that balance the benefits of both cluster and individual randomised
trials and can be used to address contamination are those that apply treatment allocation
at a mixture of levels. For example, pseudo cluster randomised trials with two trial arms
randomly split participants into two portions of clusters. In the first of these, the majority
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of participants within a cluster are randomised to one treatment and a minority to the
other (often using a 80:20 ratio); in the remaining clusters allocation is vice versa (Borm
et al., 2005). This approach is efficient because it reduces the magnitude of clustering in
comparison to a CRCT (not all participants within a cluster receive the same treatment),
and it lessens the possibility of selection bias because an individual’s treatment allocation
is unknown at study entry. It can also reduce the chance of contamination in the specific
circumstance where this is caused by control clinicians learning elements of the treatment
from active intervention participants and then passing these onto control participants
(Teerenstra et al., 2006). Another approach of the same class is to allocate treatment
at the cluster level for a subsample of participants and at the individual level for the
remainder of the trial sample. This method limits contamination (amongst those who
are cluster randomised) and a comparison of treatment effect estimates between the
cluster- and individual-randomised subtrials may provide some information as to the
impact of contamination or the ability of cluster randomisation to prevent it.
Zelen’s and participant preference designs
Two other statistical designs can be used to reduce contamination, although they are
rarely used purely for this purpose. The first randomly allocates treatment to participants
before asking for consent to take part in the trial (Zelen, 1979). In a double consent Ze-
len’s design trial, participants are initially offered the treatment that they were randomly
allocated to and are asked if they consent to receive the treatment. Those who decline
the active intervention are given the control treatment and those who refuse the control
treatment are offered the active intervention. This method can lessen contamination
later on in the trial by reducing feelings of disappointment amongst participants who
are allocated to their non-preferred treatment. In addition, Zelen’s method is useful
for measuring the proportion of the control group whose treatment may be contamina-
tion (as described earlier) and could also be useful for identifying these participants’
characteristics.
The second, minor statistical design for reducing contamination is the participant prefe-
rence design. Trials using this design give a proportion of participants a choice about
which treatment they receive and then allocate treatment randomly for the rest (Floyd
and Moyer, 2010). The article described participants’ preferences in an unblinded rand-
omised trial using a doubly randomised participant preference design. This strategy
initially randomises participants to either a preference controlled trial or a randomised
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trial (Wennberg et al., 1993). Those allocated to the former receive their preferred
treatment; those allocated to the second are randomised again and offered whatever
treatment is the outcome of this second allocation. The trial intervention was classical
music offered to students who were preparing for a college examination. The aim of
the research was to assess whether those who were allocated to treatment by choice
would show lower contamination compared to those allocated to treatment by chance.
Unfortunately, the amount of contamination was too low for this to be assessed (this
could also be interpreted as evidence that allocation by choice or chance did not affect
contamination). The trial showed that whilst those who were allotted to their non-
preferred treatment felt less positive about their experience, this did not affect belief in
effectiveness of treatment. Like Zelen’s design, participant preference design trials can
enable a better understanding of participants’ choice and the impact of this on treatment
effect. They may limit contamination due to feelings of demoralisation, but this is likely
to be effective only when the proportion of the control group who wish to receive the
treatment is small.
1.5.2 Trial conduct methods
Very little methodological research appears to have addressed the trial conduct or imple-
mentation methods that trialists use to minimise contamination. The only study I am
aware of that has attempted to assess these methods was a survey that was conducted
as part of the major report on trials of educational interventions (Keogh-Brown et al.,
2007). The authors designed a questionnaire that was sent to 100 experts in educational
health research. This group included researchers known by the authors, those who were
active in the Cochrane Collaboration and Campbell Collaboration, and members of the
Association for the Study of Medical Education. Thirty-seven people responded in the
first round. The results were summarised and then sent back to the experts who were
then invited to rank responses as to which trial designs might lead to the highest chance
of contamination. Twenty-seven (73%) replied in the second round.
The results provided some information on which trial conduct methods may be most
effective at minimising the chances of contamination. It was thought to be least likely
in trials of interventions where their elements were difficult to transfer or where they
involved attendance of a training programme or event. The chance of contamination was
considered low in settings where participants were unlikely to share social networks and
where they were geographically separated. Finally, the use of education of participants
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against transfer of the intervention to the control arm and provision of clear information
on the purpose of the study were thought to reduce the chance of contamination.
In summary, little research has attempted to review trial conduct or implementation
methods for minimising contamination. The only study I am aware of sought the opinions
of expert trialists. There will therefore be some merit in reviewing the trials literature
and assessing the methods that are used in practice. This knowledge could be used
to provide those designing and funding trials where contamination is a concern with
methods for minimising the problem without the previously discussed and substantial
costs of cluster randomisation.
1.5.3 Analytical methods
Target treatment effects
As described earlier, the primary analysis of a randomised trial often uses the ITT approach.
The ITT approach is typically used as a method of estimating effectiveness, which is
considered to be the effect of treatment offer on outcome (Hernán and Hernández-
Díaz, 2012). This target treatment effect is sometimes known as the de facto effect
(Mallinckrodt et al., 2017). It is of particular interest to those designing and planning the
delivery of health services because it describes the impact of a treatment in real-world
conditions. The ITT approach is described as “conservative” because estimates are biased
towards the null (only in the context of a superiority trial; Hernán and Hernández-Díaz,
2012). The approach is linked to the design of a pragmatic trial. RCTs that are described
as such take place in a ‘naturalistic’ or ‘real-world’ clinical setting and have few exclusion
restrictions – this is in order to maximise external validity, thereby making the findings
generalisable to a wide population (Revicki and Frank, 1999; Sedgwick, 2014).
Another target treatment effect is efficacy, the effect of treatment receipt on outcome
(Hernán and Hernández-Díaz, 2012). This is sometimes known as the de jure effect
(Mallinckrodt et al., 2017). Patients and clinicians wishing to make informed decisions
about the management of medical conditions would often prefer to know the efficacy and
safety of an intervention when taken under optimal conditions (as this will demonstrate
the greatest possible effect; Revicki and Frank, 1999). Trials can be designed to answer
this question and these are known as “explanatory” RCTs (Sedgwick, 2014). Such trials
occur in carefully controlled circumstances and use exclusion restrictions to create a
narrowed population to answer the question, for example excluding those with other
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Figure 1.1: Illustration of typical randomised controlled trial demonstrating the target
effect of effectiveness (the effect of treatment offer on outcome).
health conditions. These trials are said to have high internal validity, meaning that the
estimated treatment effect can be attributed to the intervention and not to other factors.
The cost of this is often reduced generalisability due to the strictly defined nature of the
study population.
A trial where the target effect of interest is effectiveness is shown in Figure 1.1. The
illustration demonstrates that this effect represents the effect of random treatment offer
on outcome; covariates measured at baseline may predict outcome but they do not predict
treatment offer due to randomisation. A typical trial with non-adherence is shown in
Figure 1.2. This figure demonstrates what is meant by the target effect of efficacy. It
shows that the offer of intervention affects what treatment participants receive. The
treatment receipt variable encompasses both contamination (treatment receipt under
offer of control) and non-compliance (non-receipt under offer of treatment). Treatment
receipt will sometimes be referred to in this section as the exposure variable as its effect
is the one of interest. The figure also shows something that is highly likely to occur: the
presence of unmeasured confounding (hence the use of a circle for a latent variable)
affecting the relationship between treatment receipt and outcome. All variables to the
right hand side of random allocation are measured post treatment. Baseline covariates
cannot be related to random allocation but they can be prognostic of outcome and
treatment receipt.
In order to estimate efficacy, a number of conclusions flow from Figure 1.2. For instance,
there must be an individual-level measure of treatment receipt for all participants (or at
the very least a large sample) in the trial. This variable may be measured on a categorical
or continuous scale and it should be used to estimate the effect of treatment receipt on
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Figure 1.2: Illustration of typical randomised controlled trial with non-adherence and
demonstrating the target effect of efficacy (the effect of treatment receipt on outcome).
outcome. In addition, such an estimator should be capable of adjusting for unobserved
confounding between exposure and outcome, and should include prognostic baseline
variables to aid precision.
Non-randomisation-based efficacy estimators
Two approaches that have been used traditionally by clinicians to estimate efficacy
are the as treated and per protocol / on-treatment analyses. The first of these evaluates
participants according to which treatment they received, irrespective of random treatment
allocation. This estimator may be subject to confounding if participants’ treatment
receipt is associated with baseline variables that are prognostic of outcome (Hernán and
Hernández-Díaz, 2012). The expectation is that these variables cannot all be measured
and adjusted for in the analysis. The per protocol or on-treatment analysis estimates
the effect of random treatment allocation on outcome, but only for those who adhere to
allocation. Similarly to the as-treated estimator, this raises the prospect of confounding
biasing the estimate if prognostic variables are predictive of treatment receipt. It has
been argued that the consideration of the per protocol analysis as a supplement to the
ITT approach has considerable shortcomings (White, 2005). This is primarily because
the per protocol and ITT approaches are estimating distinct target effects (efficacy and
effectiveness, respectively). In addition, a per protocol analysis is unlikely to be unbiased.
27
It is argued that in an open trial of an intervention there is no good reason to expect
those who comply with protocol in the treatment and control groups to be comparable
(White, 2005).
In summary, the problem with both the as treated and per protocol analyses is that
they throw away the benefits of random treatment allocation. In effect these estimators
treat an RCT as if it were an observational study, ignoring the bias driving treatment
uptake (selection bias). These estimators risk introducing confounding unless very strong
assumptions are made. Greater detail will be given about these estimators in Chapter 4.
Randomisation-based efficacy estimators
Another class of estimators allows the estimation of unbiased estimates of efficacy for
those who would comply with protocol. Contrary to the as-treated and per protocol
analyses these estimators are randomisation-based. A large volume of work in the last
twenty years has centred around one target treatment effect in particular: the complier
average causal effect (CACE). Full details of the estimation of this parameter and necessary
assumptions will be given in Chapter 4. What follows here is an introduction to the
methods and a summary of their application in the context of contamination in the trials
literature.
CACE is the effect of treatment among those participants who would receive treatment
when offered it and would not receive it when offered control. It is also sometimes known
as a local average treatment effect (LATE) as this parameter refers to an effect within a
subpopulation (Angrist et al., 1996), as distinct to the average treatment effect (ATE)
which is the effect of treatment receipt across the whole population. The subpopulation
is latent because it is not possible to determine whether a given participant belongs to
this class. This group is often given the label of “compliers” (e.g. Frangakis and Rubin,
2002), although to avoid confusion with other uses of this word I will refer to these
participants as “latent compliers”. In order to estimate CACE it is assumed that random
treatment allocation affects treatment receipt, has no direct effect on outcome other
than through treatment receipt, and that there is no variable that affects both treatment
allocation and outcome (this is secured by randomisation). It is also assumed that the
population contains no participants whose treatment receipt is always the opposite to
their allocation, i.e. no people who would not receive treatment when offered it and
would receive it when offered control. This efficacy parameter can be estimated using
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instrumental variable (IV) models, structural mean models, or principal stratification
techniques. Full details of these estimation methods will be given in Chapter 4.
One common IV estimation approach is the two-stage least squares method. This approach
regresses the clinical outcome on residuals from the regression of treatment receipt on
random allocation (Angrist and Imbens, 1995). In the context of this research, it can
estimate the effect of treatment amongst non-contaminators. The method is commonly
applied to estimating the effect of treatment amongst compliers. For example, Dunn et al.
(2003) estimated the effect of treatment amongst those who would attend a full course
of psychotherapy when offered it compared to no intervention when offered control.
The ITT analysis of the trial estimated effectiveness to be just under two points in the
direction of benefit on the Beck Depression Inventory (BDI). The authors found that the
proportion of compliance was just over half. The two-stage least squares estimation of
CACE found an efficacy estimate of about 3 and a half BDI points in favour of treatment.
The main weakness of IV methods is that the assumption of no direct path from random
treatment assignment to outcome is untestable. In unblinded trials, this may be a strong
assumption if it is possible that the offer of treatment could affect outcome via some
route other than treatment receipt, for example by improving healthy behaviour. The
assumption may also be questionable when treatment receipt is dichotomised using a
threshold as it is then necessary to assume that any dose of treatment below threshold
has zero effect.
One of a small number of RCTs that has attempted to account for contamination in the
analysis was a trial of screening in prostate cancer (Roobol et al., 2009). The authors
reported that an earlier analysis of effectiveness of screening on mortality provided
an estimated risk ratio of 0.80. The trial had recorded receipt of post-randomisation
prostate-specific antigen tests for participants in one centre and this enabled an analysis
of efficacy. The study extrapolated from this centre to all participants in the trial and
estimated that 24% in the screened arm did not receive the intervention and 15% in
the control arm did receive screening. The authors used profile likelihood estimation to
obtain a point estimate and standard errors for efficacy, using methodology developed
previously in the context of contamination (Cuzick et al., 1997). Using the estimates of
non-compliance and contamination, the estimated risk ratio (of efficacy) was roughly
0.70.
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The IV methodology has been extended to a continuous exposure variable, i.e. the
relationship between a continuous measure of treatment receipt and outcome (Maracy
and Dunn, 2011). A model must be assumed for the relationship between dose and
response, for example a linear relationship between dose and treatment effect. The
two-stage least squares estimator can then be used to estimate the gradient (and standard
error) of this slope. It is possible to evaluate the shape of the relationship between dose
and response using a sliding window approach (Burgess et al., 2014). However, this
requires a sample size that is considerably larger than that found in typical RCTs in
mental health.
Principal stratification is a framework that parallels IV. It makes a similar set of assump-
tions as described in the context of IV and is more explicit about subpopulations. It does
this by dividing the target population into latent “principal strata” which are defined by
what treatments participants would receive under offer of experimental intervention and
under offer of control (Jin and Rubin, 2008). The drawback of both the IV and principal
stratification approaches is that they reduce the effective sample size, leading to wider
confidence intervals (Dunn, 2013). Thus, the cost of bias correction (defining the ITT
approach as a biased estimate of efficacy) is the inflation of variance.
Comparing the efficiency of analytical methods
The report on contamination in trials of educational interventions (Keogh-Brown et al.,
2007) carried out two data simulations: one that compared bias in cluster and individual
randomised trials (described in Section 1.5.1) and another that compared statistical
power between CRCTs with an ITT approach and individual randomised trials that
estimated CACE. This section will describe the methods and results of the second round
of simulations, and discuss how this type of research could be developed.
The authors compared two design approaches for addressing treatment contamination
in trials using Monte Carlo simulations. In one approach they simulated CRCTs with
two magnitudes of effect size, various levels of cluster size, and a fixed ICC. Cluster
randomisation was assumed to prevent contamination entirely. In the other approach
they simulated individual randomised trials with treatment effect sizes (same sizes as in
the CRCTs) and varying amounts of contamination. They then investigated the sample
sizes that would be needed in order to achieve a particular level of statistical power. They
used the ITT estimator for a CRCT (with no contamination) and the CACE estimator for
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an individual randomised trial (with contamination) as estimators of efficacy.
The results showed that at every cluster size that was investigated (sizes of 10, 30,
50, 100) the sample size needed for the CRCT design was greater than that of the
individual randomised trial design, up to a point that was just under 30% contamination.
At a cluster size of 10, 21% more participants were needed in the former trial design
compared to an individual randomised trial with 20% contamination that estimated
CACE. The ICC was set to 0.04 (in the CRCT trial design) for all comparisons that
they made. This difference in sample size increased with cluster size, e.g. at size 50,
170% more participants were needed relative to an individual randomised trial with
20% contamination that estimated CACE. The authors commented that the individual
randomised trial (CACE) approach maintained a sample size advantage over the cluster
randomised design, unless expected contamination exceeded 30%. However, it is not
clear what this claim was based on considering that they did not simulate more than
this level of contamination. The authors also noted the similarity of these results to
those of Torgerson (2001) and Slymen and Hovell (1997), which were described in
Section 1.5.1. However, these studies and their simulations made different comparisons.
Torgerson (2001) and Slymen and Hovell (1997) contrasted the degree of sample size
inflation in CRCTs due to clustering with that in individual randomised trials due to the
recovery of power as a consequence of the acceptance of contamination and dilution
of the treatment effect. Specifically, both designs were interested in the effectiveness
estimand (and used the ITT estimator) – the comparison was between whether the
effects of clustering or contamination would lead to greater sample size inflation in
order to maintain the original level of power. The data simulations of Keogh-Brown
et al. (2007) instead compared methods for estimating efficacy, a fundamentally different
method of addressing contamination. The CACE approach involves measuring it and
estimating efficacy, as opposed to estimating effectiveness and accepting that it will dilute
the treatment contrast.
A useful development of these data simulations would be to fix sample size and compare
the efficiency of efficacy estimators. The simulations could be extended to a range of
sample sizes (to assess estimator properties) and a range of ICCs. This would provide
information on the levels of ICC, cluster size and contamination that would tip the
balance between the efficiency of cluster randomisation with use of the ITT estimator
and individual randomisation with use of a CACE estimator.
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1.6 D6 trial
This thesis was motivated by a trial where it was suspected that some treatment contami-
nation occurred. Diabetes-6 (D6) was a trial of nurse-delivered psychological treatment
in the primary care setting for people with poorly controlled type 2 diabetes (T2D).
The trial provided an opportunity to collect individual treatment receipt data and then
apply randomisation-based estimators of efficacy. What follows is a background to the
trial, a summary of trial’s methods and then an explanation of why contamination was
suspected.
1.6.1 Background
Diabetes is a disease of the metabolic system that is characterised by high blood glucose
levels, which is due to failure of the transport of glucose across the cell membrane. The
most common forms are type 1 diabetes, where the pancreas fails to produce enough
insulin from the outset of the disease, and T2D, where cells become insensitive and
eventually resistant to the effects of insulin. The risk factors for T2D are both genetic
and environmental. A large increase in the prevalence of T2D has been observed in the
last 20 years (Shaya et al., 2010). It has been estimated that the prevalence of T2D in
the UK in 2013 was 4.5% of the population, or roughly 2,800,000 people (Holden et al.,
2017). This study estimated a threefold increase in its prevalence between 1991 and
2013. This has been linked to changing lifestyle factors, in particular increasing levels of
obesity (Hillier and Pedula, 2001).
Sub-optimal glycaemic control in diabetes is common. Amongst those with T2D in
the USA and UK its prevalence is estimated to be around half when the threshold is
defined as 53.0 mmol/mol (Shaya et al., 2010; Holden et al., 2017). This is despite
the existence of evidence-based medical and educational interventions and national
guidelines (Gæde et al., 2008; Davies et al., 2008; National Institute for Health and
Clinical Excellence, 2017). The reasons for poor glycaemic control are multi-factorial
and include psychological barriers. For example, poor self-care is associated with low
psychological well-being and distress (Peyrot et al., 2005). In particular, patients with
symptoms of depression are likely to have higher non-adherence to medication and
poorer diet (Ciechanowski et al., 2000).
A main aim of a health service such as the NHS is to provide patients with the ability to self-
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manage long-term health problems. As such, the national diabetes guidelines emphasise
the need to provide care that motivates patients to improve lifestyle and therefore better
control the disease (National Institute for Health and Clinical Excellence, 2017). A group
of interventions that can achieve this are psychological interventions, which are defined
as talking therapies that aim to identify, challenge, and replace unhelpful health beliefs,
cognitions, and emotions.
Previous research has demonstrated that psychological interventions when combined
with medical therapies may be promising treatments for improving glycaemic control.
Alam et al. (2009) conducted a meta-analysis of 19 trials (n=1,431 participants) of
psychological interventions on glycaemic control, as measured by effect on HbA1c, in
patients with T2D. Interventions included supportive or counselling therapy (e.g. mo-
tivational interviewing (MI)), brief psychodynamic therapy, interpersonal therapy, and
cognitive behavioural therapy (CBT). Overall, the offer of psychological treatment was
found to lead to a reduction in HbA1c of 5.9 mmol/mol.
Psychological interventions are normally given by highly-trained clinical psychologists,
making them expensive to provide. The average cost to the NHS of a course of low-
intensity psychotherapy was estimated to be £493 in 2011 (Radhakrishnan et al., 2013).
The expense of psychologist-delivered psychological treatment and the impracticality of
providing it to a very large number of people with T2D imply a need for another approach.
Evidence suggests that allied healthcare professionals can be trained to provide basic
psychological interventions and that this is associated with an improvement in glycaemic
control in type 1 diabetes. For example, hospital diabetes nurses have been trained to
deliver diabetes-specific psychological therapy while preserving treatment fidelity (Ismail
et al., 2008), and primary care nurses have successfully been trained to use motivational
techniques to improve oral medication adherence in people with T2D (Hardeman et al.,
2014). An RCT of nurse-led structured care, of which MI was an important part, in
routine diabetes primary care found that nurses had some basic competency but this did
not develop over time (Jansink et al., 2013b). There was no evidence of an effect of
the intervention in comparison to usual care on levels of HbA1c (Jansink et al., 2013a)
after 14 months of follow-up (effectiveness estimate was 1.4 mmol/mol). In summary,
there is limited evidence regarding the delivery of high fidelity psychological treatment
by primary care nurses and the effect of this on outcomes of patients with T2D.
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1.6.2 Trial design
D6 was a multi-centre superiority cluster RCT with two parallel treatment arms (Ismail
et al., 2018). Clusters were primary care surgeries. Its rationale was to evaluate a cost-
effective and practical way of competently delivering diabetes-informed psychological
treatment. It tested the effectiveness of nurse-delivered MI and CBT skills for patients
with T2D in the context of primary care. Recruitment was implemented in two phases as
a consequence of organisational uncertainties in the run-up to the implementation of the
Health and Social Care Act 2012. Patients were recruited in 2010 and the first half of
2011.
Ethical approval was granted by the King’s College Hospital Research Ethics Committee
(reference 09/H0808/97) and by the respective Primary Care Trusts (reference RDLSLBex
534 and 2010/403/W). Informed consent was obtained from all individual participants
included in the study. The trial was registered with ISRCTN (ISRCTN75776892) on 19
May 2010.
1.6.3 Setting and target population
The study setting was five south London boroughs (Lambeth, Southwark, Lewisham,
Wandsworth, and Bexley). The study population was patients with poorly controlled
T2D at large urban primary care surgeries (≥6000 patients). Surgeries were invited to
participate if they had a nurse providing diabetes care. Twenty-three surgeries chose to
participate.
In phase one the inclusion criteria were a diagnosis of type 2 diabetes mellitus based
on WHO clinical criteria, defined as the presence of the disease for at least one year
during which time it was managed by diet or oral medication with no requirement for
insulin therapy; age 18-79 years; presence of diabetes for at least two years; persistent
suboptimal glycaemic control, defined by HbA1c ≥ 69.4 mmol/mol on two occasions,
once in previous 18 months and again when being assessed for eligibility; prescription of
two oral diabetes medications (metformin and one other), and/or requirement of insulin
therapy. In phase two, the inclusion criterium for glycated haemoglobin was lowered to
HbA1c ≥ 64 mmol/mol.
In phase one the exclusion criteria were severe mental disorders; terminal illness and
severe end-stage diabetes complications; morbid obesity (BMI > 40 kg/m2); being
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housebound; no phone or internet access; lack of understanding of English; and current
receipt of psychotherapy. Patients with Patient Health Questionnaire-9 depression scores
> 20 and with psychotic depression or active suicidal ideation were excluded. In phase
two the threshold of morbid obesity was increased to 50 kg/m2.
1.6.4 Active intervention
Participants were offered either the D6 intervention plus standard care or standard care
alone. The D6 intervention was psychotherapy comprised of elements of MI and CBT
skills and was provided by general practice nurses. They were given interactive training
workshops, some training caseload, and a handbook with information about key skills
over a 3-month period. They were given regular supervision including feedback on
training cases, group supervision, and telephone/email support. Patients were offered
four 30-minute individual sessions over two months followed by eight monthly sessions.
The first six were face-to-face and the last six were given in a medium agreed by the
participant and nurse.
1.6.5 Comparator treatment
The comparator treatment was standard care, as recommended by NICE, and was adapted
for the local population (National Institute for Health and Clinical Excellence, 2002). This
was an attention control group where the intention was for patients to see general practice
nurses for the same duration and number of times as those in the active intervention
arm.
1.6.6 Treatment allocation
Random treatment allocation was at the level of the primary care surgery, which was
done partly to avoid treatment contamination that was anticipated if a nurse were
asked to provide both control and active treatments. Other reasons for using cluster
randomisation included variations in local demographics and healthcare delivery, and
preventing a feeling of unfairness within surgeries (which might have led to patients
seeking out the treatment). Treatment assignment was in the ratio 1:1 and was done in
two phases. Treatment allocation was revealed to the trial manager after practice details
were entered.
The intention was for randomisation to take place after all patients had been recruited but
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this led to unacceptable delays in the training of nurses. This meant that some patients
were recruited after randomisation of surgeries but were kept blind to allocation until
the interventions were offered in both groups. Assessors remained blind to treatment
allocation until after baseline data had been collected.
1.6.7 Outcomes
The primary outcome was HbA1c, which was measured at nine, 15 and 18 months after
randomisation. The primary endpoint was 18 months after randomisation. Secondary
outcomes were fasting lipids, blood pressure, body mass index, and psychological state
(PHQ-9 and Problem Areas in Diabetes).
If HbA1c was missing at follow-up, the patient’s medical records were checked in case their
haemoglobin level had been recorded here for another purpose. For those patients with
missing HbA1c at 18 months after randomisation, the missing data point was replaced
by the observation from the medical records that was nearest in time (provided this
data point was recorded within ninety days of the 18-month follow-up date). A similar
procedure was followed in case the 15-month HbA1c measure was missing. However,
any missing data at this time point were only replaced if the substitute observation had
not been used to replace the 18-month observation (and provided it was within ninety
days of the 15-month follow-up date). The same procedure was used for any missing
9-month HbA1c data.
1.6.8 Sample size
The minimal clinically significant difference in HbA1c between the D6 and standard care
groups at 18 months after randomisation was 10.9 mmol/mol (standardised effect size
of d = 0.55). The sample size calculation was 432 participants. This reflected a level of
statistical power of 80%, significance level of 5%, an average cluster size of 15 patients
per general practice, an ICC of 0.05, an assumed participant attrition of 20%, and a loss
of two practices per arm over the course of the trial.
Three hundred and thirty-four patients were recruited in 24 clusters, of which 231
patients had at least one follow-up. The average cluster size was therefore 10 patients
per cluster, smaller than the assumed size of 15 patients per cluster, providing a post hoc
power of 77%.
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1.6.9 Evaluation of clinical effectiveness
The primary, effectiveness analysis used a linear mixed model where the outcome variable
was HbA1c at follow-up (either 15 or 18 months after randomisation) and predictor
variables were treatment allocation, categorical time, an interaction between treatment
allocation and time, borough, recruitment phase, and baseline HbA1c (Ismail et al., 2018).
The model included random effects for nurse and participant number and an unstructured
covariance structure where residual error parameters were estimated separately within
the treatment allocation groups. Estimated effectiveness showed no evidence of an effect
of treatment offer. Using the model reported in the primary analyses, the ITT estimate at
15 months was -0.07 mmol/mol (standard error 2.64; z=-0.03, p=.98; 95% CI -5.24,
5.10) and at 18 months (primary endpoint) was -0.79 mmol/mol (SE 2.53; z=-0.31,
p=.76; 95% CI -5.75, 4.18). The primary analysis did not report the ITT estimate at nine
months after randomisation. However, using the same model as applied to the other time
points but this time including the nine-month data, the estimate was -0.18 mmol/mol
(SE 2.46; z=-0.07, p=.94; 95% CI -5.00, 4.64).
1.6.10 Treatment contamination
It was hypothesised that there may have been some receipt of active intervention amongst
participants in the standard care trial arm. There was anecdotal evidence that one of
the control group nurses provided additional support to patients as a consequence of
participation in the study, although it was not known to what extent this was grounded in
the principles of psychological treatment. It has also been suggested that the differences
between the trial arms in terms of treatment received were smaller than expected. The
fidelity analysis that was performed as part of the primary assessment of the trial used
the Motivational Interviewing Treatment Integrity (MITI) version 3.1.1 to evaluate the
fidelity of MI (Moyers et al., 2005, 2010), and the Behavioural Change Counselling Index
(BECCI) to assess the delivery of CBT skills (Lane et al., 2005). Further information
about these scales will be given in Chapter 3. Treatment sessions of 33 patients in the D6
intervention group and 36 in the standard care group (3.4% of all sessions) were rated
(Ismail et al., 2018).
The results of the fidelity assessment are shown in Table 1.1. There was evidence
for a higher proportion of open questions in the D6 intervention group and a larger
reflection/question ratio in the standard care group. There was no evidence of a difference
37
between the trial arms for the other MITI domains and BECCI Practitioner Score. The
fidelity assessment showed that there may have been some contamination of the control
group. For example, the MITI Global Spirit and Global Empathy scores showed that
nurses may have been using psychological treatment techniques to a limited extent.
Table 1.1: Mean scores of treatment fidelity scales (MITI and BECCI) by treatment group







Global Spirit (mean; SD) 2.87 (0.87) 3.23 (1.13) .14
Global Empathy (median;
IQR)
2.50 (2.00-3.00) 3.00 (2.00-4.00) .19
Percent Complex
Reflections (mean; SD)
40.4 (17.4) 35.2 (19.8) .25
Percent Open Questions
(mean; SD)
24.9 (10.0) 36.4 (17.3) <.01
Reflection/question ratio
(median, IQR)
0.74 (0.53-1.19) 0.57 (0.42-0.72) .03
Percent MI-Adherent
(mean; SD)




1.12 (0.55) 1.33 (0.56) .12
† Based on result of either a t-test or Mann-Whitney U test.
The anecdotal evidence of the standard care nurse who was particularly aware of psy-
chological treatment techniques, the results of the primary analysis treatment fidelity
assessment, and the small estimate of treatment effectiveness suggested that there may
have been some treatment contamination. For this reason, it was decided to measure
treatment fidelity for as many participants as possible and then to account for any con-
tamination or non-compliance in an efficacy analysis of the trial. I will present the
treatment fidelity assessment in Chapter 3 and the efficacy analysis in Chapter 7.
1.7 Other trials motivating this research
I obtained data from three other mental health trials that motivated the research. These
were clinical trials of complex interventions that used cluster randomisation to avoid
contamination. They were REFOCUS, CONMAN and a trial of systematic assessment of
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need and care planning in severe mental illness. They were used primarily to provide
information on typical levels of parameters relating to cluster randomised trials (intraclass
correlation coefficient, cluster size). The trial of systematic assessment of need and care
planning applied randomisation at both cluster and individual participant levels. This
dataset provided an opportunity to assess the impact of contamination avoidance (through
use of cluster randomisation) on outcomes (Chapter 2).
Recovery intervention within community-based mental health teams (REFOCUS)
REFOCUS (ISRCTN02507940) was a cluster RCT of a pro-recovery intervention for
people with psychosis and used treatment allocation at the level of clinical team (Slade
et al., 2015). The intervention consisted of training and reflection activities, a manual
and the practice of partnership working with the aim of encouraging clinicians to promote
recovery in the way they treated patients. The primary outcome was a patient-reported
questionnaire of recovery and was measured 12 months after baseline.
Contingency management for people with heroin dependence and needing hepati-
tis B vaccination (CONMAN)
CONMAN (ISRCTN72794493) was a cluster RCT of contingency management for people
with heroin dependence and needing hepatitis B vaccination and applied randomisation
at the level of drug treatment clinic (Weaver et al., 2014). The primary outcome was
completion of three vaccinations within 28 days and was therefore binary.
Systematic assessment of need and care planning in severe mental illness
The systematic assessment of need and care planning trial (no ISRCTN reference) tested
a complex care intervention for people with schizophrenia, bipolar disorder, depression,
or delusional disorder (Marshall et al., 2004). The trial comprised two subtrials in which
treatment was allocated either to individual participants or to clusters of patients that
were defined by who their care coordinator was.
1.8 Aims of the thesis
The primary research objective was to compare the efficiency of two competing trial
design options that address the problem of contamination and estimate efficacy. The
comparison built on the work by Keogh-Brown et al. (2007) by comparing similar design
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methods. The first option was cluster randomisation at the level at which contamination
was expected (i.e. preventing any contamination) with an estimator of the effect of
treatment receipt on outcome that accounted for clustered data. The second option was
individual randomisation, acceptance that contamination would take place, measurement
of treatment receipt for all participants, and use of a randomisation-based efficacy
estimator of the effect of treatment on outcome within the subpopulation of compliers. I
aimed to make the findings from the comparison of these design options accessible to
those planning trials in the form of an online decision support tool.
The secondary research objective was to summarise and develop randomisation-based
estimators of efficacy in a randomised trial with contamination, where treatment receipt
could be measured on a binary or continuous scale. Having collected individual treatment
receipt data for participants in D6 as part of this research project, the second part of this
objective was to apply these estimators to evaluate the efficacy of the D6 intervention.
The tertiary research objective was to review the problems and solutions associated with
contamination in mental health trials of complex interventions. The aims were to assess
the processes driving contamination, the typical extent of the problem, what researchers
do in order to mitigate it, and the quantity of contamination bias within trials that used
both individual- and cluster-level randomisation.
1.9 Thesis overview
In this thesis I will describe methods that can be used to address the problem of conta-
mination in the design and analysis of trials of complex interventions in mental health.
The following chapters will start with a large scoping review of contamination in trials
(Chapter 2). This will explore the drivers of contamination and the solutions trialists use
to address the problem. It will also describe the extent of contamination and evaluate
whether there is evidence that its occurrence is related to estimated treatment effect sizes.
Chapter 3 will assess treatment fidelity in the D6 trial, the study that motivates much of
this research due to the anticipated presence of contamination. The fidelity assessment
will use a sample of data collected for this doctorate by two clinical psychologists who
were trained in the BECCI and MITI scales. In Chapter 4 I will summarise existing
analytical methods for estimating efficacy in trials with contamination. I will also develop
a novel estimator of efficacy when non-compliance in the active arm and contamination
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in the control arm are measures on a continuous scale. In Chapter 5 I will compare the
efficiency of two competing trial design options for evaluating efficacy in the presence of
contamination using Monte Carlo simulations:
A. Treatment allocation by cluster randomisation with clusters defined at the level
at which contamination takes places together with an estimator of the effect of
treatment receipt on outcome that accounts for clustered data.
B. Allocation at the participant level, measurement of treatment receipt in all partici-
pants, and estimation of efficacy using a randomisation-based estimator to target
CACE.
These competing design/analysis options will be investigated for both binary and conti-
nuous measures of treatment receipt. In Chapter 6 I will describe the development of an
online decision support tool to help those planning trials choose between the two design
options for dealing with contamination. This will use the results from the Monte Carlo
simulations. In Chapter 7 I will apply the existing estimators (of CACE) and the novel
one that is able to estimate efficacy with a continuous measure of treatment receipt in
both trial arms to the D6 trial. Finally, in Chapter 8 I will summarise the findings and
describe the novelty of the research. I will evaluate the limitations of the methods and
explore possible areas for further enquiry.
This methodological research is motivated by D6 and the three other trials in mental
health. Data from all four of these trials were used to guide parameter choices when
comparing two trial design options for addressing contamination (Chapter 5). A list of
these trials and the uses of their datasets in this research can be found in Table 1.2.
Table 1.2: Sources of data in the PhD and uses of the datasets in this research.
Source of
data






Data used in the primary analysis
of trial of psychological treatment
for people with poorly controlled
type 2 diabetes.
1. Selection of parameter levels in data
simulations comparing two trial design
options for addressing contamination
(Chapter 5).






Treatment receipt data using two
scales that measure the fidelity of
psychological treatment. These
data were collected as part of the
PhD (coding of audiotapes by
clinical psychologists).
1. Fidelity assessment of D6 trial
(Chapter 3).
2. Construction of treatment receipt




Cluster RCT of recovery
promotion intervention (training,
reflection activities, manual,
partnership working) for people
with psychosis. Clusters were
clinical teams.
Selection of parameter levels in data
simulations comparing two trial design




Cluster RCT of contingency
management for people with
heroin dependence and needing
hepatitis B vaccination. Clusters
were drug treatment clinics.
Selection of parameter levels in data
simulations comparing two trial design








RCT of complex care intervention
for people with mental health
disorders. Treatment allocation
was at cluster and individual
levels for different parts of the
trial.
1. Selection of parameter levels in data
simulations comparing two trial design
options for addressing contamination
(Chapter 5).
2. Comparison of treatment effects
between cluster and individual





Results of scoping review of
problems and solutions
associated with contamination in
trials of complex interventions.
This was conducted as part of the
PhD (Chapter 2).
Selection of parameter levels in data
simulations comparing two trial design




Scoping review of problems and
solutions associated with
contamination
2.1 Background and aims
The processes leading to contamination in mental health trials have never been reviewed
comprehensively and the literature is unclear about their relative frequencies. This
knowledge is necessary in order to plan what steps should be taken to address the
problem. In mental health trials, some of the methods that researchers use to minimise or
prevent contamination are either little known or poorly formalised within the literature.
Knowledge of these points could provide those planning trials with additional tools
for addressing small amounts of contamination without resorting to the use of cluster
randomisation and the associated increase in sample size requirement.
This chapter addresses the tertiary objective of the research, which was to review the
problems and solutions associated with contamination in mental health trials of complex
interventions. The aims of this chapter were to identify the processes that are considered
to lead to contamination in trials of complex interventions in mental health, to quantify
typical levels of contamination, to summarise what researchers do in order to prevent or
mitigate it, and to compare treatment effect estimates within trials of complex interven-
tions that used both cluster- and individual-level treatment allocation to quantify the
contamination bias. In addition, the chapter aimed to summarise relevant parameters
to be used in later work that will compare different design and analysis options by
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simulation using realistic parameter choices. Here I describe a comprehensive scoping
review that addresses these points.
As mentioned before in Section 1.5, I categorise possible solutions to address contamina-
tion into:
i. Statistical design methods – this includes structural design methods such as cluster
randomisation, sample size inflation, and participant preference designs,
ii. Trial conduct solutions – this relates to methods that can be used in the running of
the trial to reduce exposure to active treatment in the control arm,
iii. Analytical approaches – this consists of using a measure of treatment receipt to
estimate efficacy.
The review I conducted included a small number of trials that allocated treatment at
both cluster and individual levels (including the trial of systematic assessment of need
and care planning in severe mental health; Marshall et al., 2004). This provided an
opportunity to assess the extent to which contamination impacts on outcomes.
This chapter will provide a description of the review’s methodology, summaries of asses-
sments of evidence of trial bias, details of contamination processes and their frequencies,
solutions used to prevent contamination in mental health research, an investigation of
the evidence of the effect of contamination on estimates of treatment effect from four
trials that used random allocation at both the levels of the individual and the cluster, and
summaries of relevant parameters.
The work presented here has been submitted for publication as an article to BMC Medical
Research Methodology.
2.2 Methods
2.2.1 Type of review
I carried out a scoping review of trial design and conduct methods in RCTs of complex
interventions in mental health. This type of review was chosen on the basis that my
objectives were to summarise researchers’ perceptions of and solutions to a trial design
problem where there is limited literature and potentially highly heterogeneous evidence.
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2.2.2 Eligibility criteria
All articles published between 2000 and 2015 that describe contamination in mental
health trials of complex interventions were screened using full texts and were assessed
using five inclusion criteria. First, the text described a trial purporting to have used
random allocation. Second, the intervention was complex, which in this review meant it
comprised multiple components. It was not possible to assess whether these elements
acted together to provide some added benefit (as per MRC guidance definition) so I
used this general and therefore wide definition for this. Third, the publication gave
some information about the process leading to, amount of, or solution used to counter
treatment contamination. Fourth, the abstract and main body of the article were written
in English. And finally, the trial was related to mental health, psychology, or psychiatry
– this meant that a minimum of one of the target population, intervention, or primary
outcome was directly related to one of these fields. Many trials in these fields test
unblinded treatments where the suspicion is that they may be subject to contamination.
The scoping review was limited to these areas of medicine for this reason and because of
the apparent gap in the literature surrounding contamination in these fields.
2.2.3 Information sources
The search for contamination in RCTs of complex interventions in mental health was
done using the Ovid platform and included the databases Medline, Embase and PsycInfo.
Articles that were published between January 2000 and April 2015 were searched. Results
were restricted to those articles published after 2000 because this was the year when the
MRC framework paper on complex interventions was first published (Campbell et al.,
2000). The publication of this framework marked the point at which the design and
evaluation of complex interventions were formalised.
2.2.4 Search
Randomised controlled trials were searched for using the sensitivity-maximising 11-step
process recommended by the Cochrane Collaboration (Lefebvre et al., 2011). The search
terms “contamination” and “spillover” were included in the procedure. it was found that
searching for these words without qualifiers produced a great number of articles that
were not relevant to the review. Instead, these terms were combined with the words
“treatment”, “arm”, “control”, “group”, “outcome”, “trial”, “patient”, or “intervention”
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with a maximum gap of six other words between the two. Synonymous terms for
complex interventions that were used included all combinations of “multicomponent”,
“multifaceted”, “psychosocial”, and “behavioural”, with “interventions”, “treatments”, and
“training”. In order to increase sensitivity, the adjective and the noun could be separated
by three other words. Also included were the terms “psychotherapy” and “therapist”. All
terms were searched for in the main body of the text.
The search was restricted to articles that mentioned “mental health”, “psychology”,
or “psychiatry”. As an additional method of improving specificity, certain terms were
excluded, e.g. “blood contamination”, “microbial contamination”, “device”, “vaccine”,
“microbial”, ‘antimicrobial”, “genes“, “genetic”, “screening”, “decision aid”, and “decision
support”. Many of these terms were only used as exclusion criteria if they were found
within the title, subject heading, or abstract. Full details of the search procedure can be
found in Appendix A.1.
2.2.5 Study selection
Duplicates were removed from the set and the remaining articles were assessed for each
of the exclusion criteria. Any potentially relevant article that was referred to by a paper
in the results of the search and was not already in the set was followed up. If the article
was judged to have met the inclusion criteria it was included in the set and the full text
was reviewed. In order to assess the reliability of study selection, a second reviewer
(another PhD student, Ruth Knight) re-screened 70 articles (11%).
2.2.6 Data collection process
Any studies that were included in the review and featured substudies that used both
cluster- and individual-level treatment allocation were reviewed as two separate subtrials
because of the different contamination processes and methods used to address these.
Treatment effect sizes were extracted for these subtrials that reported effects separately
depending on the level of treatment allocation. Data from any such studies that did
not report results at the different levels of treatment allocation were obtained from the
authors in order to allow the comparison.
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2.2.7 Data items
Abstracted data included an assessment of bias, summaries of trial design (e.g. study
population, intervention, primary outcome, unit of treatment allocation), details about
contamination (e.g. how it was thought to take place, its quantity, steps taken to avoid it),
and records of trial summaries (e.g. extent of clustering, power, sample size, treatment
effect). A full list of data extracted for each trial can be found in Appendix A.2. In order
to assess the reliability of data abstraction, the second reviewer (RK) re-extracted data
from 20 articles (8%) using the same procedure described above.
2.2.8 Risk of bias in individual studies
The review of trial bias included recording the “Jadad score” (a single item measure of
methodological quality of RCTs; Jadad et al., 1996) and all the domains of the Cochrane
Collaboration’s classification scheme for bias (Higgins et al., 2011). In addition to these,
some other domains that were pertinent to cluster randomised trials were used. These
included whether randomisation occurred after participant consent was obtained, base-
line measures were completed before randomisation, baseline outcome measurements
were similar across trial arms, other clinical and demographic characteristics were similar
across arms, and whether attrition was similar in the arms. These additional assessments
of bias were based on outcomes used in reviews of CRCTs (Puffer et al., 2003). Fuller
descriptions of items relating to risk of bias can be found in Appendix A.2.
2.3 Results
2.3.1 Reliability
At the screening stage agreement was 71%; all discrepancies were discussed and subse-
quently resolved. Agreement was 81% for all assessments of bias, and 82% for details of
contamination processes.
2.3.2 Summary of trials
Two hundred and thirty-eight trials were identified as meeting the eligibility criteria.
This included seven trials that were referred to by an article in the main search and
were found to meet the eligibility criteria. The results of the implementation strategy
and numbers of exclusions are summarised in Figure 2.1. Details of the 238 articles in
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the review are given in Table 2.1. The table shows that the overwhelming majority of
articles described the primary analysis of an RCT, with the trials based in either North
America or Western Europe, and were late phase (i.e. not pilot or feasibility trials). Most
target populations were adult patients and the most commonly targeted conditions were
depression, substance abuse, and psychosis. The two most common interventions were
cognitive behavioural therapy and care management; there were many small categories.
A full list of references can be found in Appendix A.3.
Figure 2.1: Flow diagram for searching for relevant articles (articles could be excluded
for more than one reason).
2.3.3 Summary of assessment of bias
Summaries of assessments of bias using the Jadad scale, items recommended by the
Cochrane Collaboration, and items aimed at identifying possible bias in cluster randomi-
sed trials are reported in Table 2.2. The table demonstrates the potential for bias split
by the level of treatment allocation. In general, it shows that the greatest potential for
bias arose due to incomplete outcome data being inadequately addressed, differences in
attrition between trial arms, and randomisation occurring before consent was obtained
and before baseline measures were completed. More potential for bias was found in
cluster randomised trials when assessing whether randomisation took place after consent
and after baseline measures were completed, whether outcome assessment was blind,
and whether attrition was similar between trial arms. There was some suggestion that
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Table 2.1: Summary of characteristics of trials (n=238 trials).
Variable Level Number of
articles
Type of article (n) Results of primary analysis of clinical trial 232 (97.5%)
Design / protocol of clinical trial 3 (1.3%)
Results of secondary analysis of clinical trial 3 (1.3%)
Year (n) 2000-2004 48 (20.2%)
2005-2009 87 (36.6%)
2010-2015 103 (43.3%)






Target population (n) Adult patients 175 (73.5%)
Children / adolescent patients 45 (18.9%)
People at risk 6 (2.5%)
Workers 12 (5.0%)
Target condition (n) Depression 31 (29.2%)






No single target condition 132 (55.5%)
Intervention (n) Cognitive behavioural therapy / CBT skills 33 (13.9%)
Care management / interdisciplinary care 27 (11.3%)
Education 21 (8.8%)
Motivational interviewing / motivational en-
hancement therapy
19 (8.0%)
Other psychotherapy / counselling 16 (6.7%)
Assessment and feedback 8 (3.4%)
Parenting interventions 8 (3.4%)
Others 106 (44.5%)




Participant level 145 (60.9%)
Cluster level 93 (39.1%)
Participant sample
size (median; range)
Participant-level allocation 143 (16-14910)
Cluster-level allocation 251 (13-6076)
Cluster size in CRCTs
(median; range)
10 (3-200)
individual-randomised trials were more prone to bias when assessing whether incom-
plete outcome data were adequately addressed (disregarding those trials where this was
unclear).
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Table 2.2: Summary of assessment of bias in trials.





Jadad score (possible range
of 0-5; higher scores
indicate lower likelihood of
bias)
0 2 (1.4%) 0 (0%)
1 30 (21.1%) 25 (27.2%)
2 63 (44.4%) 38 (41.3%)
3 47 (33.1%) 29 (31.5%)
Allocation sequence
adequately generated
Yes 84 (57.9%) 46 (49.5%)
No 3 (2.1%) 1 (1.1%)
Unclear 58 (40.0%) 46 (49.5%)
Allocation sequence
adequately concealed
Yes 94 (64.8%) 52 (55.9%)
No 3 (2.1%) 2 (2.2%)
Unclear 48 (33.1%) 39 (41.9%)
Randomisation after
consent obtained
Yes 124 (85.5%) 24 (25.8%)
No 5 (3.4%) 45 (48.4%)




Yes 64 (44.1%) 19 (20.4%)
No 20 (13.8%) 49 (52.7%)




Yes 117 (80.7%) 73 (78.5%)
No 6 (4.1%) 9 (9.7%)




Yes 125 (86.2%) 74 (79.6%)
No 3 (2.1%) 14 (15.1%)
Unclear / NA 17 (11.7%) 5 (5.4%)
Knowledge of allocation
adequately concealed
Yes 0 (0%) 1 (1.1%)
No 145 (100%)) 92 (98.9%)
Blinded outcome
assessment
Yes 73 (50.3%) 35 (37.6%)
No 10 (6.9%) 13 (14.0%)
Unclear / NA 62 (42.8%) 45 (48.4%)
Incomplete outcome data
adequately addressed
Yes 48 (33.1%) 41 (44.1%)
No 50 (34.5%) 32 (34.4%)
Unclear / NA 47 (32.4%) 20 (21.5%)
Similar attrition between
trial arms
Yes 98 (67.6%) 52 (55.9%)
No 29 (20.0%) 26 (28.0%)
Unclear / NA 18 (12.4%) 15 (16.1%)
2.3.4 Processes driving contamination
There were perceived to be five main processes that led to contamination. The first
two processes, staff delivering the active intervention in the control arm (n=85, 36%)
and communication between trial arms (n=80, 33%), were the most common. Staff
delivering the active intervention in the control arm happened either due to a given
clinician delivering both the active and control treatments (n=79, e.g. Barkhof et al.,
2013) or due to control participants being exposed to the intervention as a consequence of
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clinicians, who were not directly involved in providing the treatment, treating participants
in both arms and thereby potentially learning about the active intervention and passing
this on to participants in the control arm (n=6, e.g. Beck et al., 2002). The other
main contamination process was communication between individuals in different trial
arms. This could be either at the level of the clinician (n=20, e.g. Johnson et al.,
2007), participant (n=58, e.g. Ersek et al., 2008), or both (n=2). Communication
between providers of interventions was often a worry in environments in which the
people giving the treatment worked closely together, for example GP surgeries, hospital
units, and schools. Communication between participants was thought to be most likely
in environments in which participants came into close contact. Examples of this included
interaction between participants who were family members, patients in a waiting room,
school children, employees working on the same site, and university students. Particular
healthcare settings that were thought to be highly likely to foster communication were
antenatal clinics/childbirth classes, specialist clinics (e.g. substance misuse, dialysis),
and wards for those admitted to hospital.
There were perceived to be three other, more minor processes that drove contamination.
First, participants switching clinicians (n=4, 2%, e.g. Cooper et al., 2013), where control
participants were treated by multiple clinicians of whom one was trained in the active
intervention. Second, participants seeking treatment outside the trial (n=6, 3%, e.g.
Stuifbergen et al., 2010). And finally, what I have called background noise, where the
treatment already existed to some extent within the healthcare system (n=5, 2%, e.g.
Becoña and Vázquez, 2001). Fifty-nine articles did not provide information about the
contamination process.
The five processes driving contamination are shown as a scheme in Figure 2.2. This
figure also includes my interpretation of whether cluster randomisation could be used
to prevent particular types of contamination. Cluster randomisation could be used to
prevent contamination due to communication between clinicians or participants, provided
that clusters are selected at a level that is high enough to prevent this contact. It may
be able to prevent contamination due to crossover of staff between treatment groups.
If contamination is due to the transfer of information about the treatment by clinicians
who are not directly involved in providing active intervention, cluster randomisation may
prevent contamination if clusters are constructed at a high enough level. Its use may be
capable of preventing contamination due to participants switching clinicians (provided
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clusters are constructed at a high enough level) but will not prevent contamination due
to participants seeking treatment outside the trial or due to the treatment being already
available within the healthcare system.
2.3.5 Quantity of contamination
Twenty-nine studies (11%) attempted to quantify contamination. Twenty-five trials
measured individual-level contamination on a binary scale and summaries of these
quantities are given in Table 2.3. The median level of contamination was 13% (IQR
5-33%).
Table 2.3: Quantity of treatment contamination in trials where participants could
















































































































































































































































































i Trial using individual-level randomisation
c Trial using cluster-level randomisation
Contamination was measured using a continuous scale in four trials. These were three
trials of cognitive behavioural therapy and one of cognitive analytic therapy. One created
a treatment fidelity scale and asked participants in each trial arm (behavioural weight
control instructions, cognitive behavioural therapy, standard counselling) about their
knowledge of all three treatments at the beginning and end of treatment (Perkins et al.,
2001). The subscales showed high knowledge of behavioural weight control in the
group allocated to receive behavioural weight control instructions (mean change of 1.1
compared to 0.5 and 0.5 in cognitive behavioural therapy and standard arms), high
knowledge of cognitive behavioural therapy in those allocated to receive this (mean
change of 1.6 compared to 0.0 and 0.8 in behavioural weight control and standard
groups), and high knowledge of standard intervention in the control group (mean
change of 0.5 compared to 0.1 and 0.1 in behavioural weight control and cognitive
behavioural therapy arms). This seemed to indicate receipt of treatment in the control
arm. Three RCTs showed negligible evidence of treatment contamination. Of these RCTs,
one used a cognitive behavioural therapy adherence scale (adapted CTACS) to record
compliance and contamination in the active intervention and control arms (Thorn et al.,
2011). The CTACS means were 98.0 and 98.8 in the cognitive behavioural therapy and
education intervention (control) arms respectively, indicating that contamination did not
occur. Another trial found that the family-focused cognitive behavioural therapy (FCBT;
active intervention) group scored higher than the traditional child-focused cognitive
behavioural therapy (control) group on two scales, Family Focus (mean = 4.90 and 1.55)


































that only the FCBT group incorporated family and parenting interventions and therefore
that there was little evidence of contamination. The fourth trial used a scale to measure
the fidelity of the control intervention, which was good clinical care (Chanen et al., 2008).
This scale included a subscale for cognitive analytic therapy and the mean for this was
very low: 0.52 (SD 0.11). This represented negligible contamination.
2.3.6 Solutions used to counter contamination
Methods that were used to counter contamination are summarised in three categories:
statistical design, trial conduct, and analysis methods. Statistical design includes the
use of cluster randomisation, where clusters are chosen based on groups of participants
who are thought potentially to become contaminated by direct or indirect links (e.g. via
a shared therapist). One trial inflated the sample size in order to account for reduced
statistical power caused in part by contamination bias (Dobscha et al., 2009). The great
majority of other methods for preventing contamination were aspects of trial conduct,
such as recruitment of more clinicians to ensure that each clinician only delivered one
of the interventions. In terms of analysis methods, one trial used per protocol analysis,
meaning that participants whose treatment was contaminated were dropped from the
analysis (Pfiffner et al., 2007). This review found no trials that addressed the problem of
contamination by using methods from the causal inference field.
A summary of trial conduct solutions that were used to avoid treatment contamination
can be found in Table 2.4. These solutions have been presented in an order that matches
the processes of contamination described in the earlier section on this. The majority of
solutions used to prevent contamination related either to preventing staff delivering the
active intervention in the control arm or preventing communication between clinicians
or participants.
Investigators were concerned about contamination during data collection in four trials
and aimed to prevent this by minimising interaction between researchers and participants
(Chan et al., 2013; Chochinov et al., 2011; McLaughlin et al., 2005; Tiwari et al., 2005).
Another temporally separated the control and active treatments with data collection follo-
wing each. This meant that treatment could only influence data from active intervention
participants (Alessi et al., 2005).
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Table 2.4: Trial conduct solutions to treatment contamination. Ninety-two trials (out
of 238) described a trial conduct solution.
Process driving
contamination





Recruiting groups of clinicians, each one of which is
responsible for a single treatment
16
Monitoring contamination using supervision/therapy
session recordings
10
Formalising differences between interventions, e.g.
using structured manual during therapist training
6
Asking clinicians not to use intervention content when
treating those in control arm
3
Providing active intervention within the research project
rather than health service
1
Using a script for contact with control participants
during treatment
1




Blinding usual care clinicians 4












Holding treatment sessions at different times/in
different locations
13
Staggering the scheduling of data collection appoint-
ments / reducing waiting time so that participants do
not meet in waiting room
3
Allocating separate therapists / modes of delivery
for individual and group therapies when usual group
therapy was shared by participants in both arms
2
Asking participants not to share contents of intervention
with others
2
Excluding potential participants who know someone
else attending screening
2
Holding separate sessions of existing group treatments
for participants in separate trial arms in order to prevent
contact
1
Restricting the release of intervention materials in order
to reduce the chance of their being shared with control
participants
1
Recruiting participants in blocks and providing one
treatment at a time, with no new participants recruited
during the final week of each period in order to





Preventing referrals for add-on care by clinicians who
are members of study team
1




Informing participants only about the treatment they
were allocated to receive (Zelen’s design)
8




available to some extent
within the healthcare
system
Making intervention distinct from usual care by
adapting one or other
2
Establishing common treatment for all participants 1































































































2.3.7 Trials using both cluster- and participant-level treatment allocation
The results of the review included four trials that used both participant- and cluster-level
treatment allocation (Clarkson et al., 2009; Lee and Gay, 2011; Marshall et al., 2004;
Richards et al., 2008). The characteristics of these trials are summarised in Table 2.5.
The treatments and patient populations are disparate but have in common the use of
both cluster and individual randomisation.
Treatment effect estimates and confidence intervals for the four trials are shown in Figure
2.3. The figure shows treatment effects arranged such that greater benefit (or less harm)
of treatment is represented by a greater number on the horizontal axis. The figure
enables the comparison of the absolute size of treatment effect between participant- and
cluster-level allocation to assess the impact of contamination on effect size estimation.
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Of the 21 outcomes investigated, just under half of outcomes showed a difference in the
anticipated direction, i.e. smaller estimated absolute effect sizes under participant-level
random allocation. In particular, an attenuated absolute treatment effect size (lesser
distance from the null line in Figure 2.3) was found under participant-level allocation in
eight out of 21 outcomes with a tie in one outcome.
2.3.8 Parameters
Table 2.6 summarises cluster sizes, intraclass correlation coefficients, and sample sizes
for the trials where it was possible to extract this information. The summaries are given
for all trials, and for individual randomised and cluster randomised trials separately.
















Sample size 25 84 153 100
50 144 266 186
75 265 556 372
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(a) Clarkson et al. (2009). Choice of primary outcomes is based on sample
size calculation; estimates are adjusted for baseline measures. Larger (more
positive) treatment effects indicate benefit.
(b) Lee and Gay (2011). Estimates were standardised and calculated from
summaries of means and SDs (mothers’ scores only). Larger (more positive)
treatment effects indicate benefit.
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(c) Marshall et al. (2004). Estimates used same adjustments as in the trial
publication. Larger (more positive) treatment effects indicate benefit.
(d) Richards et al. (2008). Estimates were standardised and calculated from
summaries of means and SDs. Larger (more positive) treatment effects indicate
benefit.
Figure 2.3: Forest plots for four trials that used both individual- and cluster-level
randomisation (P)=primary outcome.
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2.4 Discussion and conclusion
2.4.1 Discussion
The review identified 238 trials that described either the processes driving treatment
contamination, its quantity, or steps that researchers took to prevent or alleviate the
problem in trials of complex interventions in mental health. The principal processes
leading to contamination were found to be clinicians being required to treat partici-
pants in both treatment and control conditions and communication among clinicians
or participants in different trial arms. Typically around one in eight participants in the
control arm of a trial were assessed as having received the active intervention. The
most common steps that researchers took to prevent or mitigate contamination were the
use of cluster randomisation, organising for each clinician to provide only one type of
treatment, monitoring treatment receipt, spatially or temporally separating trial arms,
and informing participants about only the treatment that they were allocated to receive.
There was little evidence of a difference in the magnitude of treatment effects within
trials that used both cluster- and participant-level treatment allocation.
The classification of two main processes and three more minor types of contamination
was based on the processes that researchers and clinicians described in such trials. The
main trial conduct steps that researchers took to minimise contamination were in line
with the processes that were found to be driving it. Many researchers attempted to
design against contamination by carefully controlling the treatment’s delivery. There
were no examples of researchers first having evaluated in detail treatment receipt within
the control arm.
The small number of trials that measured and reported treatment receipt in the control
arm found it to be affecting a minority of the control participants. The distribution of
this was similar to the quantity found previously in other areas of medicine such as
educational interventions (Keogh-Brown et al., 2007), breast cancer screening (Goel
et al., 1998), and cancer trials using Zelen’s design (Torgerson, 2001). Thus while
there is a lot of concern about contamination, it is not clear that this problem is indeed
widespread.
Researchers often used cluster randomisation to prevent treatment contamination,
amongst other reasons. While CRCTs can avoid contamination bias they are at risk
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of other biases. The set of articles included 93 cluster randomised trials. Assessments
of bias suggested that cluster randomised trials were more likely to be affected by bias
when considering whether randomisation took place after consent was obtained and
after baseline measures were completed, whether outcome assessment was blind, and
whether attrition was similar between trial arms. This was consistent with an earlier
review of cluster RCTs that were published in three prominent medical journals which
found evidence of recruitment and attrition biases (Puffer et al., 2003).
The small number of trials that allocated treatment at both cluster and participant levels
did not find any evidence for differences in effect size estimates. The lack of evidence for
a link between the level of randomisation and treatment effect size suggested that either
the employment of cluster randomisation did not prevent contamination, the anticipated
contamination was overstated, or that the use of cluster randomisation led to a similar
degree of bias as that caused by contamination in the participant-randomised trials.
Overall, the finding was consistent with those of a review of trials of enhanced care in
depression (Hahn et al., 2005), and of educational interventions (Keogh-Brown et al.,
2007). Similarly to previous reviews, there was considerable heterogeneity between
trials identified in this study that used both cluster- and participant-level randomisation.
However, the variability here is between trials and not within them because randomisation
implies that the subtrials were balanced for every variable except the level at which
treatment allocation took place. It is possible that the impacts of contamination and
cluster randomisation on bias are dependent on the disease or type of intervention.
There were several limitations to this scoping review. For instance, the processes conside-
red to be driving contamination were often anticipated and then prevented or attenuated
by the designers of trials. The drivers of contamination described here therefore partly
represent researchers’ expectations and not necessarily clinician or participant behaviour.
Regarding trial conduct solutions for preventing contamination, the most common met-
hod was to recruit groups of clinicians where a given group was responsible for providing
a particular treatment. I did not record the methods by which clinicians were allocated to
these groups. This is something that would be interesting to consider in future reviews.
Finally, it is difficult to draw substantive conclusions regarding the effect of treatment
allocation levels on contamination bias from the four trials that used both cluster- and
individual-level randomisation. This is due to the small number of such trials that I found
and the fact that the review did not search for these trials in particular. There would
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be some utility in conducting a systematic review of these trials in future in order to
investigate further the effects of allocation level on contamination bias.
2.4.2 Conclusion
This is the most comprehensive review of contamination in mental health trials to date.
It is the first to identify the processes leading to contamination and the measures that
researchers take in order to minimise the problem. The main limitation is that the trials
were heterogeneous in that they represented a large range of illnesses and interventions.
With regard to the causes of contamination, it is an assumption that the processes
described by authors were the drivers of contamination.
The results of this review suggest that treatment contamination is perceived to be a
significant problem in trials of complex interventions in mental health. However, the
trials that measured and reported it suggest that the phenomenon is often modest (with
a large range). This implies that contamination may not be as large a problem as many
researchers and funders perceive. It is therefore not impossible that the use of cluster
randomisation in some trials may be leading to efficiency loss for little reason. The
seemingly modest extent of contamination points towards the importance of alternative
approaches for addressing the problem. The findings of this review have shown that there
are many such (conduct) methods that researchers can take to minimise contamination
without resorting to cluster randomisation. A caveat to the conclusion about the extent
of the problem is that the number of trials in the review that reported contamination
was low. The reporting of treatment receipt in the control arm is almost certainly not as
commonplace as that of treatment compliance (in the intervention arm). This implies a
need for greater measurement and reporting of treatment receipt in the control arm of
trials in this field.
I found that modern causal analysis methods, including the techniques developed parti-
cularly for addressing contamination (Cuzick et al., 1997; Dunn et al., 2005), are yet to
be utilised to deal with contamination bias at the analysis stage. This may be a reflection
of the infrequency of measurement of treatment receipt for all participants in the control
trial arm. It may also be due to the fact that moderately little research has investigated
the use of randomisation-based efficacy estimators in this context, particularly in the
field of mental health research. I will return to this topic to summarise and develop such
analytical methods in Chapter 4.
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Chapter 3
Assessing treatment fidelity and
contamination in a cluster
randomised controlled trial of
motivational interviewing and
cognitive behavioural therapy skills
in type 2 diabetes.
3.1 Background and aims
The thesis uses the D6 study as a motivating dataset of a trial of a complex intervention in
mental health. D6 was a cluster RCT set in primary care evaluating the effectiveness of an
intervention combining motivational interviewing (MI) and cognitive behavioural therapy
(CBT) skills delivered by practice nurses compared to an attention control which did
not include any psychological components. One reason for using cluster randomisation
at the level of the primary care nurse was to avoid treatment contamination that was
anticipated if a given nurse were asked to provide both control and active treatments.
Treatment in the control arm consisted of standard diabetes care, with primary care
nurses scheduled to meet participants for the same number of times and same duration
as those in the active intervention arm.
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There was a strong rationale for conducting a large fidelity assessment. Despite the
trial having set out to avoid contamination, there was some anecdotal evidence of
delivery of psychological treatment by standard care nurses. This was supported by
the treatment fidelity evaluation in the primary assessment of the trial which showed
some treatment receipt in the control arm (Ismail et al., 2018). In addition, the lack of
evidence of effectiveness warranted a detailed evaluation of treatment fidelity in both
arms of the trial. Therefore I set out to construct a measure of treatment receipt for as
many participants as possible in the study. The trial provided an opportunity to assess
treatment fidelity due to the fact that many treatment sessions had been audio recorded.
The goal was to use individual-level fidelity ratings to assess what level of psychological
treatment participants received and then to evaluate whether the treatments delivered
to the intervention and control arms represented what was expected given the results
of random treatment allocation. From a clinical perspective this treatment fidelity
assessment, which was larger in terms of sample size than that reported in the primary
assessment of the trial, enabled an examination of whether primary care nurses in the
trial could be trained to deliver psychological therapy competently to participants within
the active intervention arm. It also allowed an assessment of whether competencies
improved over time. This chapter describes the fidelity assessment of the treatments
delivered to participants in the two trial arms.
The main aims of this chapter were to measure treatment fidelity in the D6 trial and then
to assess treatment contamination and non-compliance. Specifically, the chapter aimed
to:
i. Assess adherence in delivering randomised treatment within each trial arm,
ii. Determine to what extent the intervention and control treatments represented high
fidelity psychological treatment and standard diabetes care respectively.
Treatment fidelity was assessed for a large subsample of participants and therefore
allowed an assessment of treatment receipt that was more detailed than that of the
primary assessment of the trial (Ismail et al., 2018). Therefore, the clinical aims of this
chapter were to:
i. Assess whether D6 nurses achieved competencies in psychological therapy delivery
at the end of the training period,
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ii. Describe differences in competency between end of training and during the delivery
of intervention,
iii. Compare the levels of receipt of psychological treatment (MI and CBT skills)
between the active intervention and control arms.
This chapter will describe the sampling procedure and the implementation of the fidelity
ratings. The sampling was at the level of the participant as opposed to sampling a
particular number of sessions for each nurse, as done in the primary fidelity assessment
(Ismail et al., 2018). I performed the sampling process and then oversaw the preparation
of the recordings (finding and sorting the tapes) that was done by an administrator
from the trial. The ratings were then performed by two clinical psychologists who had
experience in the scales that were used to rate treatment fidelity. Data that were collected
soon after the end of training (intervention arm) will be used to assess nurse competency.
Data collected as part of the doctorate (on treatment fidelity during delivery of treatment)
will be used to assess contamination and non-compliance. These data will also be used
to evaluate change in nurse competency (intervention arm) and to assess differences
between the trial arms. The data will later be used to construct measures of treatment
receipt for the efficacy analysis of the trial (Chapter 7).
The work presented here has been submitted for publication as an article to BMC Family
Practice.
3.2 Methods
3.2.1 The training programme
The training programme for nurses in the D6 intervention arm was developed and deli-
vered by an experienced clinical psychologist using both didactic and practicum strategies.
Nurses were trained in six MI/CBT skills: active listening, managing resistance, directing
change, supporting self-efficacy, addressing health beliefs, and shaping behaviours. The
initial interactive training workshops were conducted over twelve 3-hourly sessions
and the nurses were given a manual handbook for ongoing reference and for future
replication. The focus was on increasing patients’ motivation to improve their diabetes
control and then collaboratively addressing key self-care behaviours such as medication
adherence, blood sugar testing, physical activity, and dietary changes.
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3.2.2 Techniques taught in MI and CBT
MI is a collaborative, person-centred approach to working with people in order to elicit
and strengthen their motivation and commitment to change (Miller and Rollnick, 2002).
It has been found to be more effective than traditional advice-giving in the treatment
of a range of behavioural problems and diseases, including diabetes (Whittemore et al.,
2003). CBT has been found to be effective at improving adjustment to diagnosis and
self-management of diabetes (Ismail et al., 2004). It aims to achieve this by helping
people to identify and restructure unhelpful cognitions, teaching behavioural strategies,
and supporting people to develop helpful coping strategies.
3.2.3 Clinical supervision
Nurses in the intervention group attended monthly supervision with the trial psychologist
either in person at monthly group sessions or over the telephone if they were not able to
attend throughout the delivery of the intervention. E-mail support was also offered for
individual cases.
3.2.4 Assessment of treatment fidelity and competency
All nurses who participated in the D6 study were required by protocol to record their
treatment consultations with participants digitally. A sample of recordings from nurses in
the intervention arm from shortly after the end of training was used to assess competency.
Another sample of recordings from both trial arms that was representative of participants’
treatment receipt was selected in order to assess fidelity.
The definition, assessment, and difficulties of addressing treatment fidelity in research
studies have been extensively discussed elsewhere in the literature (Madson and Campbell,
2006; Rakovshik and McManus, 2010; Fairburn and Cooper, 2011). A definition that is
consistently used, and will be used for the purpose of this chapter, is that fidelity comprises
both adherence and competence (Fairburn and Cooper, 2011). Adherence refers to
whether the appropriate procedures were followed for that clinical intervention whereas
competence refers to whether these procedures were implemented to an adequate level.
The Motivational Interviewing Treatment Integrity (MITI) Scale, version 3.1.1 (Moyers
et al., 2005, 2010), was used to measure competence and skills used in both groups
of nurses. A Global Spirit score is intended to capture the overall demonstration of
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MI principles, and a Global Empathy score is intended to capture the extent to which
the clinician understands, or attempts to understand the patient’s perspective. Further
measures of clinician behaviours include the use of simple reflections, complex reflections,
open questions, and closed-ended questions. Scores are also calculated for MI adherent
and non-adherent counselling behaviours. The possible ranges and threshold levels for
subscales (as specified by the scale’s authors) are given in Table 3.1.
The Behaviour Change Counselling Index (BECCI) (Lane et al., 2005) was designed to
assist trainers in assessing a clinician’s competence in using behaviour change counselling
in consultations. It was included here in order to assess nurses’ competence in eliciting
patients’ thoughts and cognitions, therefore addressing the CBT element of the interven-
tion. BECCI comprises 11 items which are scored from zero to four (0=“action carried
out not at all”; 1=“minimally”; 2=“to some extent‘”; 3=“a good deal”; 4=“a great deal”).
The mean of these is used as the overall Practitioner Score.
Table 3.1: Minima, maxima, and thresholds for MITI and BECCI scales (Moyers et al.,













1 5 Average of 3.5 Average of 4
Reflection to Question Ratio 0 – 1 2
Percent Open Questions 0 100 50% 70%
Percent Complex Reflecti-
ons
0 100 40% 50%
Percent MI-Adherent 0 100 90% 100%
BECCI summary score
Practitioner Score 0 4 – –
This chapter utilises three datasets: a “nurse competency” sample and two “fidelity
assessment” samples. The nurse competency sample, which was collected previously as
part of the D6 trial, included one tape recording for each intervention nurse (11 nurses).
The first fidelity assessment sample (69 recordings from 21 nurses; sampling at level
of nurse) was used for quantifying the reliability of the ratings made by the clinical
psychologists working on this research. These data had already been collected as part of
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the primary assessment of D6. The second fidelity assessment sample was larger (266
recordings from 151 patients and 17 nurses; sampling at level of participant) and was
used for the fidelity assessment, which is the main focus of this chapter. These fidelity
ratings were collected as part of this doctoral research and the goal was to use these data
to construct a measure of treatment receipt for the efficacy analysis of the trial (Chapter
7).
3.2.5 Nurse competency assessment
The nurse trainer, who was MITI trained, assessed post-training adherence and compe-
tency of all nurses in the intervention group using the MITI and BECCI rating scales.
One tape recording of a treatment consultation was submitted by each nurse soon after
the end of training and then rated on each of the two scales. Nurses were rated as not
MI adherent if MITI MI-Adherence was lower than 90% (the “Beginning proficiency”
threshold, see Table 3.1) and MITI Empathy was lower than 3 (which is defined as
representing modest success of clinician trying to understand the patient’s perspective
(Moyers et al., 2010)). These subscales were chosen because MI-Adherence and Empathy
have been shown to be predictive of treatment success (Apodaca and Longabaugh, 2009;
Moyers and Miller, 2013). The “Beginning proficiency” and “Competency” thresholds
in the MITI manual (Table 3.1) were considered post hoc too high in the context of
D6, where consultations included clinical communications that would not be part of a
standard MI consultation (for example a physical examination, prescribing, and checking
adherence). Any nurses rated as not MI adherent were given extra training and then
reassessed. Nurses who were judged to be adherent but who did not meet the higher
MITI threshold levels were expected to continue to improve with extra supervision.
3.2.6 Sampling for inter-rater reliability assessment
For the first fidelity assessment (collected previously as part of the primary assessment of
D6) a researcher assessed every tape recording and removed duplicates and recordings
where session number could not be identified. Of the tape recordings that were from
treatment sessions two to four, and where there was a recording of a treatment session
that lasted 20 minutes or more, stratified probability sampling was used to select three
recordings from each nurse. Within each nurse stratum, the first tape recording was
chosen at random and the second recording was then chosen at random after removing
recordings from the previously-selected individual and session from the sample set. The
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same technique was used to sample the third recording.
The sample comprised 69 tape recordings (representing 3.4% of the total number of
all treatment sessions, and 4.0% of sessions where a recording had been made). A
20-minute window in the middle of the recording was rated using the MITI (by raters
A and B). Of this sample, 32 recordings were rated using the BECCI by raters B and
C. Recordings in this subsample featured in both the reliability assessment and fidelity
assessment (described in next section). Rater C listened to and coded a 20-minute
window in the middle of the recording whilst rater B assessed the entire recording (raters
B and C’s assessments were originally intended for different purposes). Raters received
suitable training for whichever scale they used and were blind to treatment allocation.
This sample was used in order to check the inter-rater reliability of raters who assessed
recordings in the fidelity study.
3.2.7 Sampling for fidelity assessment
The sampling procedure for the second fidelity assessment sample (data collected as part
of this doctoral research) selected tape recordings from participants who had at least one
recording from sessions two, three, and four, and where treatment centre was identifiable
(there was no minimum duration of session length). This set included 353 recordings
from 154 participants (31 participants with one recording; 47 with two; and 76 with
three). Random sampling stratified by participant was used to select two recordings
from each of the participants with all three recordings. If only one or two recordings
were available for a given participant then these were chosen for subsequent fidelity
assessment.
The sample included 266 usable tape recordings (127 recordings in intervention arm)
from 17 nurses’ consultations with 151 participants and 11 recordings where the con-
versation could not be heard. The usable recordings represented 13.1% of all treatment
sessions and 15.4% of sessions where a recording was made. The whole duration of each
recording was rated using the MITI (rater A) and BECCI (rater B). Raters were blind to
treatment allocation.
3.2.8 Statistical analysis
Statistical analyses were conducted using Stata version 14. In order to assess inter-rater
reliability for the MITI global scores and BECCI Practitioner Scores, intra-class correlation
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coefficients (ICCs) were estimated using a mixed model. The model included a fixed
effect for rater, a random effect for tape recording, and a random effect for primary
care nurse in order to account for clustering. It assessed consistency between individual
ratings by estimating ICCs at the participant-within-nurse level. The MITI global scores
and BECCI Practitioner Score were summarized within the intervention arm shortly after
the end of training and during delivery of intervention. Mixed effects regression models
with random effects for primary care nurse and participant or Somers’ D tests with
sampling from the highest level of the cluster structure (i.e. primary care nurse) were
used to compare the fidelity of the psychological therapy delivery between participants
in the two trial arms.
3.3 Results
3.3.1 Nurse and patient sample characteristics
Twenty-three primary care nurses participated in the trial, with 11 randomised to the
intervention arm, and 12 to control. They were all female, with a mean age of 48 (SD
8.5) years. Fourteen (61%) of the nurses were white, six (26%) black, and 3 (13%)
Asian or other ethnicity.
In terms of previous training in psychological therapies, nine had no previous experience
(4 intervention, 5 control), two had completed a module as part of a degree course (1
intervention, 1 control), two had completed some training in MI as part of a smoking
cessation course (1 intervention, 1 control), two had undertaken one day or less of MI
training (1 intervention, 1 control), one had completed some MI training as part of the
Co-Creating Health Programme (intervention), and one had some experience as part of
a nursing qualification (intervention). Data on previous training were not available for
six nurses.
The participant sample from which the tape recordings were drawn (treatment fidelity
assessment sample) included 151 adults with T2D (45% of the total number of partici-
pants who entered into the trial), of whom 74 (49%) were in the psychological treatment
trial arm. Mean age was 59.4 (SD 11.1) years and 77 (51%) were female. Sixty-eight
(45%) were white, 60 (40%) black, 13 (9%) Asian, and 10 (7%) of another ethnicity.
Median duration of diabetes was 9 (IQR 6-13) years and mean pre-intervention glycated
haemoglobin was 80.1 mmol/mol (SD 18.9).
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3.3.2 Nurse competency
The trial manager assessed post-training treatment adherence and competency using the
MITI and BECCI rating scales. Mean MITI and BECCI competency scores post-training
are presented in Table 3.2. Each nurse’s score was compared against MI-Adherence
(threshold of 90%) and Empathy (threshold of 3). One nurse was not considered MI
adherent post training (using MITI MI-Adherence and Empathy subscales) and therefore
was given extra training by the clinical psychologist. Upon reassessment she was deemed
MI adherent in the therapy.
Table 3.2: Summary of competency scores assessed after training.
Domain Post-training score
Global Spirit (mean; SD) 3.42 (0.67)
Global Empathy (mean; SD) 4.09 (1.04)
Reflection-to-Question Ratio (median; IQR) 0.67 (0.45-0.82)
Percent Open Questions (median; IQR) 45.5 (25.0-72.2)
Percent Complex Reflections (median; IQR) 9.1 (0-28.6)
Percent MI-Adherent (median; IQR) 86.2 (76.9-100)
BECCI (mean; SD) 2.78 (0.50)
3.3.3 Inter-rater reliability
Estimates of intraclass correlation coefficients for the global MITI scores and BECCI
Practitioner Score are reported in Table 3.3. These estimates suggested that inter-rater
reliability was good (between 0.60 and 0.74) or excellent (>0.75) for both scales,
according to previously defined thresholds (Cicchetti, 1994). Reliability was greater for
MITI, where all ratings were for the 20-minute section in the middle of each recording,
compared to BECCI, where one coder rated 20-minute windows and another rated the
full duration of recordings.
Table 3.3: Inter-rater reliability for MITI global scores and BECCI Practitioner Score.
Domain ICC 95% confidence interval
MITI Global Spirit 0.89 0.83–0.93
MITI Global Empathy 0.91 0.86–0.94
BECCI Practitioner Score 0.71 0.52–0.85
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3.3.4 Fidelity analysis
MITI domain scores summarised by trial arm along with the results of the mixed model
or Somers’ D tests comparing trial arms are given in Table 3.4. Estimated standardised
mean differences for the MITI global scores were 1.11 (Spirit) and 0.83 (Empathy).
There was strong evidence of group differences in favour of the intervention for the
global scores of Spirit and Empathy, the percentage of questions that were open, and
of percentage of sessions that were MI adherent. There was no evidence of a group
difference in percentage of reflections that were complex or the reflection-to-question
ratio.
Table 3.4: MITI summary scores during treatment delivery by treatment allocation
group.












Global Spirit 2.63 (1.12) 4.03 (1.05) z = 4.50;
p < .001
0.81–2.06












































Numbers and proportions of sessions in the intervention arm that were rated as above
MITI’s “Beginning proficiency” and “Competency” thresholds for each domain are sum-
marised in Table 3.5 (Moyers et al., 2005). This table summarises how many treatment
sessions were assessed as meeting these thresholds within each of the trial arms.
Mean BECCI Practitioner Score in the control arm was 1.07 (SD 0.48) and in the interven-
tion arm was 1.42 (SD 0.51). A z-test from a mixed effects model showed a significant
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Table 3.5: Numbers and proportions of sessions (percentages are within trial arms) rated
as above MITI’s “Beginning proficiency” and “Competency” thresholds for domains by
treatment allocation group.

























Global Spirit 34 (24.5) 92 (72.4) 30 (21.6) 88 (69.3)




17 (12.2) 9 (7.1) 4 (2.9) 0 (0)
Percent Open
Questions
13 (9.4) 54 (42.5) 5 (3.6) 9 (7.1)
Percent Complex
Reflections
106 (76.3) 98 (77.2) 87 (62.6) 78 (61.4)
Percent
MI-Adherent
1 (0.7) 26 (20.5) 1 (0.7) 25 (19.7)
difference in the BECCI Practitioner Scores between the treatment arms (z = 3.22,
p < .01, 95% CI 0.15-0.62). The estimated standardised mean difference was 0.75.
3.4 Discussion and conclusion
3.4.1 Discussion
This chapter describes the assessment of the delivery of a nurse-led psychological therapy
in the context of a cluster RCT aimed at improving persistent suboptimal glycaemic
control in people with T2D. Treatment fidelity and contamination were evaluated by
measuring and comparing levels of MI and CBT skills in the two trial arms. At the end of
training, nurses in the intervention group were considered competent in D6 skills at a
basic level (according to “Beginning proficiency” thresholds) and it appears that there
was improvement in some MI skills during delivery of the intervention. For example,
MITI Global Spirit and the proportion of reflections that were complex improved. The
active intervention delivered to trial participants was statistically superior in Spirit and
Empathy, open questions, MI-Adherence, and behaviour change scores compared to usual
care. There were no group differences in the proportion of complex reflections or the
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reflection-to-question ratio. In clinical terms, the differences between the trial arms were
smaller than expected. The levels of treatment fidelity suggested that some participants
in the psychotherapy arm did not receive high fidelity treatment, whilst some in the
attention control arm received aspects of the psychological intervention. These findings
highlight the difference between statistical and clinical significance. Statistically signifi-
cant differences primarily reflected the fact that this was an unusually large assessment
of treatment fidelity in an RCT. However, many of these significant differences in MITI
and BECCI scores between trial arms were clinically small. For example, the difference
in the BECCI Practitioner Score was less than half a point (on a scale of zero to four) and
was significant at the 1% level. The lack of clinical significance suggestested that the
estimate of effectiveness of the D6 intervention (ITT analysis) might have been affected
by both non-compliance in the active arm and contamination in the control arm.
In the active intervention arm, findings were partly consistent with the practice of
MI, where the clinician collaborates with, supports, and allows the patient to take
control of the need for change by listening empathically and using open-ended questions.
This was demonstrated by high levels of Spirit and Empathy and a clear majority of
treatment sessions being MI-Adherent. The superiority of MI-Adherence and Empathy
when comparing the trial arms was particularly important as these have been shown to
be predictive of treatment success (Apodaca and Longabaugh, 2009; Moyers and Miller,
2013). However, there were some challenges in providing high fidelity psychotherapy.
Specifically, approximately only half of reflections were complex, a similar proportion
of questions were open, the ratio of reflections to questions was slightly lower in the
intervention group compared to control, and the level of achieved behaviour change
fidelity (from the BECCI) was rated between “minimal” and “to some extent”.
There were a number of possible reasons why nurses may not have exceeded MITI’s
“Beginning proficiency” levels. The most apparent of these is that the nurses did not
self-select to take part in D6. All primary care surgeries meeting the eligibility criteria in
the five boroughs were invited to participate. Of those that agreed, the surgery allocated
a nurse to take part in the study. Some nurses were more enthusiastic about participation
than others. It is also possible that the skills that showed the lower fidelity levels reflected
particular aspects of MI or CBT that are difficult to teach to clinicians who are not
specialists in psychological treatment. An interview study with the nurses suggested
that not all may be suited to the acquisition of psychological skills (Graves et al., 2016).
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For example, nurses expressed concern about over-stepping their professional roles,
feeling that it was inappropriate for them to deliver specialist psychological intervention
and described feeling under pressure to participate in the research. Some felt under-
supported by their primary care surgery and others resented the extra workload as a result
of participating in the trial. Although the surgeries were remunerated for participation,
the trial did not provide direct individual financial compensation. One solution to this
problem may be to assess inherent competencies prior to training, enabling a process of
selection whereby the most suitable nurses are recruited. This is a similar idea to that
put forward in an assessment of treatment fidelity of nurse-led MI in pain rehabilitation,
where the authors suggested that more rigour was necessary in the selection of MI
counsellors (Mertens et al., 2016). It is not currently possible to distinguish whether D6
nurses possessed existing psychological skills, which were not especially built upon, or
whether they learned skills to a basic level but then failed to improve materially upon
them.
In the attention control arm, the moderate levels of Spirit and Empathy of MI, the
ratio of reflections to questions, which was slightly higher than in the psychological
treatment arm, and the fact that just over half of reflections were complex showed clear
evidence that there was delivery of MI. On the other hand, the behavioural change index
summary score was low in this trial arm. The evidence of delivery of active intervention
in the control arm was surprising given that the trial was designed to avoid this. It was
hypothesised before starting the trial that contamination might have been expected if a
given clinician were to be trained in the delivery of the psychological treatment and then
treat participants in both trial arms. The expectation was that if this were to happen,
clinicians would have introduced elements of the active intervention to participants in the
attention control arm. Cluster randomisation was used in part to avoid contamination
occurring in this way. The contamination that took place despite this design must have
been due to other reasons. For instance, some primary care nurses already possessed
skills that were consistent with psychological treatment. Two control nurses are known
to have had experience of MI before the trial: one had received brief training in it and
one had applied it to smoking cessation. Other reasons include the impact of giving extra
time to deliver standard care as part of the attention control design; finally, participation
in the trial may itself have induced nurses to provide a slightly different type of standard
care.
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The primary analysis of D6 included a fidelity assessment of a small sample of therapy
session recordings (n=69) in both treatment groups, using both the MITI and the BECCI
(Ismail et al., 2018). The researchers sampled three tape recordings from each nurse and
rated only a 20-minute window in the middle of each recording. The findings showed
similar trends to those reported here, but the trial arm differences were estimated
to be smaller and had larger standard errors. This demonstrates a benefit of rating
treatment fidelity for participants (ideally a large sample or all of them) rather than
clinicians. For a trial investigating efficacy, a full assessment of treatment fidelity with
a representative sample is needed in order to use a measure of treatment receipt to
estimate this target effect. The limitations of a full assessment are its labour-intensive
nature and the increased costs of employing trained raters. Costs may come down with
developments in machine learning and automated fidelity evaluation.
Future research should ensure that therapists in the experimental arm of a complex
psychological intervention are at higher level of competency in order to make more valid
comparisons with the control.
3.4.2 Conclusion
In summary, the results indicate that the intervention did not represent the highest level
of psychotherapy fidelity. In addition there seemed to be some contamination of the
control arm as those allocated to receive usual care appeared to receive some components
of the intervention. On the basis of these findings it appears that the trial would benefit
from an efficacy assessment in addition to the effectiveness evaluation (ITT analysis)
that has already been carried out. This will be the subject of Chapter 7. To enable this, I
first need to summarise and develop statistical methods for estimating efficacy. This will
be the subject of the next chapter.
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Chapter 4
Efficacy estimators allowing for
non-adherence in trials of complex
interventions
4.1 Background and aims
This chapter addresses the first part of the secondary research objective, which was to
summarise and develop estimators of efficacy in a randomised trial with non-adherence.
This work focuses on trials that contrast an active intervention with a control condition,
where departures from randomised treatment lead to receipt of some or all of the
comparator condition. The work relates to trials with continuous outcomes.
The perfect randomised trial comparing a new treatment (intervention arm) with a
control treatment (control arm) should use random treatment allocation, be double
blind, feature full adherence with randomly allocated treatment, and collect outcome
data from every trial participant. These features are important because they guard against
bias and therefore enable a study to provide a valid answer to the research question.
Judged by such a standard, trials in mental health are often far from ideal. It may be
impossible to blind clinicians or participants to treatment (especially for psychotherapies),
patients may not attend all or any treatment sessions, and participants may be lost to
follow-up before the end of data collection. This has led to recent development in
methods that account for the challenges of non-adherence with allocated treatments and
missing data in particular. Non-adherence is used here as an umbrella term covering
contamination (receipt of intervention) in the control arm and non-compliance (non-
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receipt of intervention) in the active intervention arm of a trial. When compliance is
described as partial, this implies that some active intervention participants did not receive
treatment.
The results of the scoping review of methods for addressing contamination (Chapter 2)
suggested a scarcity of applications of analytical approaches in this context. It appears
that methods from the causal inference literature are not being utilised by researchers to
address the problem of contamination in trials of complex interventions in mental health.
Thus, this chapter will explore whether such methods can be employed when adherence
with randomly allocated treatment has been measured for each trial participant. The
adherence measure could be either a binary treatment receipt measure or a continuous
treatment dose measure.
This chapter aims to:
1. Review existing approaches for addressing non-compliance (in the active arm),
2. Extend these approaches to provide novel efficacy estimators that allow for conta-
mination in the control arm,
3. Tackle some of the associated complications experienced in trials of complex
intervention in mental health, namely clustering of outcome data and missing
values in the outcome variable.
4.2 Estimands
Clinical trials aim to evaluate causal treatment effects. My focus in this thesis is on
estimating the efficacy of treatments. Before proceeding to review ways of estimating
efficacy, I first wish to define the target population characteristic that I want to estimate.
In other words, I wish to define causal estimands. The importance of defining the
quantity targeted by an estimator has recently been emphasized – see Addendum E9
trial regulations (European Medicines Agency, 2018). In order to define these estimands,
I will begin by introducing the concept of potential outcomes.
4.2.1 Rubin causal model
Potential outcomes were introduced by Neyman (1923), originally in the context of rand-
omised experiments. The use of these provides the main approach to causal estimation
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in the Rubin causal model (coined by Holland, 1986), which gives the framework for
investigation of cause and effect (Rubin, 1974; Rubin and Little, 2002).
4.2.2 Potential outcomes
In a clinical trial, certain variables can be directly observed: which treatment a participant
is allocated to, baseline covariates, which treatment they receive, and outcome on a
particular scale. The observed variables, their notation, and their levels are described in
Table 4.1.
Table 4.1: Notation for observed variables.
Notation Description Levels
C Manifest compliance 0 for observed non-complier
1 for observed complier
Missing for those in control arm
K Contamination 0 for observed non-contaminator
1 for observed contaminator
Missing for those in active arm
N Response (non-missingness) 0 for missing
1 for non-missing
R Binary indicator for random treatment
allocation
0 for assignment to control
1 for assignment to active intervention
T Treatment receipt 0 for receipt of control treatment
1 for receipt of active intervention
D Dose of treatment
X Baseline covariate
Y Outcome
Z Baseline variable serving as an instru-
ment (to be defined later)
The relationship between two variables is said to be causal when outcome differs under
the presence of exposure compared to its absence (Hernán and Robins, 2018). For
example, if a participant’s outcome would be improved under treatment compared to
what it would be under no treatment then it can be said that this treatment has a causal
effect for that participant. This concept leads to a need for mathematical notation by
which outcome can be expressed under different levels of exposure. A participant’s
possible outcome under a particular level of treatment receipt can be expressed as:
Yi(T = t) = Yi(t)
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This is known as a potential outcome, or counterfactual. Y (t) represents potential outcome
under treatment receipt (t ∈ 0, 1), and Y (r) is potential outcome under offer of treatment
(r ∈ 0,1). Using potential outcome notation, the causal effect of treatment receipt for
individual i is:
∆T,i := Yi(T = 1)− Yi(T = 0)
The aggregate of these individual effects of treatment on potential outcome among a
population is referred to as the ATE:
ATE := E[∆T,i] = E[Yi(T = 1)− Yi(T = 0)]
This is a measure of efficacy. Another efficacy estimand is the average treatment effect
on the treated (ATT):
ATT := E[∆T,i|T = 1] = E[(Yi(T = 1)− Yi(T = 0))|T = 1]
The causal effect of treatment offer for individual i, or individual randomisation effect
(IRE), is:
∆R,i := Yi(R = 1)− Yi(R = 0)
The aggregate of these causal effects among a population of individuals is known as the
average causal effect (ACE):
ACE := E[∆R,i] = E[Yi(R = 1)− Yi(R = 0)]
This is a measure of effectiveness. If adherence were full then T and R would be the
same and therefore ACE would be equivalent to ATE. Because the average difference is
equal to the difference in averages, the ACE can be rearranged as:
ACE = E[Yi(R = 1)]− E[Yi(R = 0)]
A potential outcome can also refer to treatment receipt under levels of treatment offer:
T (r) is potential treatment receipt under offer of treatment and D(r) is potential dose of
treatment under treatment offer (r ∈ 0,1). The pair T (0) and T (1) is used to divide a
population into subpopulations, or principal strata, that are defined by their potential
82
treatment receipt under treatment and control. It is not possible to observe both T(0)
and T (1) for a given participant and therefore class membership is a latent variable. See
Table 4.2 for a list of these potential compliance types, with conventional nomenclature
(Angrist et al., 1996). The pair D(1) and D(0) describes subsections of the population
defined by doses of active treatment (e.g. number of sessions) they would take were
they offered the control or the active intervention.
Table 4.2: Principal strata.
Ti(R=0) Ti(R=1) Latent compliance class
0 1 Complier
0 0 Never taker
1 1 Always taker
1 0 Defier
The causal effect of treatment defined so far (ATE) refers to the whole target population.
The latent compliance classes, whose construction was described earlier and which were
listed in Table 4.2, can be used to define a LATE within a subpopulation of would-be
compliers. The estimand is known as CACE and is defined as follows:
CACE := E[∆R,i|Ti(1)− Ti(0) = 1] (4.1)
If treatment receipt is continuous instead of binary, then the average causal effect must
be defined slightly differently. The ATE is now dependent on the values d0 and d1 that
treatment receipt takes (e.g. number of sessions attended) under the two treatment
offers:
ACEd1,d0 := E[∆R,i|Di(0) = d0 ≥ 0, Di(1) = d1 > Di(0) = d0]
This is the causal effect of treatment amongst a subpopulation who would receive some
dose of treatment under its offer and some dose under offer of control, where dose under
offer of treatment is greater than dose under offer of control. I refer to this subpopulation
as dose compliers. This generalises the latent compliers in the binary treatment receipt
case to the continuous treatment receipt case.
The next section will address how these estimands can be estimated in a sample.
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4.2.3 Identification assumptions of Rubin causal model
It is apparent from the definition of the causal effect for an individual that this cannot be
observed because a participant can only receive one treatment (active or control) at a
given moment. This is known as the fundamental problem of causal inference and has led
to the consideration of causal estimation as a missing data problem (Rubin, 2005). The
solution to this problem is to take aggregates of outcome under the levels of treatment
offer and then find the difference between the averages of these.
There are three main assumptions necessary for the identification of causal effects within
the potential outcome framework. First, it is assumed that there is no interference, which
is to assume that one person’s potential outcome is unaffected by another’s treatment
receipt (Yi(t) ⊥ T j, i 6= j; Cox, 1958). Second, the assumption of consistency assumes
that the potential outcome is precisely the same as the observed outcome when exposure
takes a particular level; in effect this assumption is that the treatment is well defined. It
can be expressed mathematically as:
Yi(t) = Yi , if T = t
The assumptions of no interference and consistency are together sometimes known as
the stable unit treatment value assumption (SUTVA) (Rubin, 1980). Third, it is assumed
that the distributions of potential outcomes are exchangeable between groups defined by
level of exposure. There are three levels of exchangeability that are relevant to causal
estimation in randomised trials. From strongest to weakest and using similar terminology
and notation to Hernán and Robins (2018), these are:
1. Full exchangeability: for t = 0,1, {Yi(T = 0), Yi(T = 1)} ⊥ Ti
2. Standard exchangeability: for t = 0,1, Yi(T = t)⊥ Ti
3. Mean exchangeability: for t = 0,1, E[Yi(T = t)|Ti = 0] = E[Yi(T = t)|Ti = 1]
Full exchangeability implies that the joint distribution of potential outcomes Y (1), Y (0)
is independent of T . Standard exchangeability, which here is founded on treatment
receipt being dichotomous, assumes that the marginal distributions of the potential
outcomes are independent of T . This implies mean exchangeability, which assumes that
the expectations of potential outcomes are independent of T . Mean exchangeability
does not imply standard exchangeability because it makes no assumption about other
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parameters of the distributions of the potential outcomes. Under ideal circumstances
(full adherence with protocol and no missing data), randomisation ensures that all three
of these assumptions are true because predictors of outcome are equally distributed
between treatment groups.
Another way of expressing this is to say that potential outcomes are independent of the
mechanism of treatment assignment. Simply put, it assumes no unmeasured confounding
between T and Y (t). This untestable assumption is easily defensible in RCTs without
non-compliance and contamination, where assignment is random and therefore cannot
be associated with any measured or unmeasured pre-randomisation variable, but is
more problematic in observational research. It is important to note that the assumption
Y (t) ⊥ T is very different to Y ⊥ T . The first assumes that groups defined by level of
treatment receipt would have the same outcome had they received the same treatment,
whilst the second assumes that treatment receipt has no causal effect on outcome (Hernán
and Robins, 2018).
4.3 Traditional estimation approaches
I first review commonly used estimators in trials, clarifying which estimands they are
targeting and discussing possible biases.
4.3.1 Estimating effectiveness: intention-to-treat estimator
The ITT estimator estimates the difference in outcome between those allocated to active
intervention and those allotted to control (E[(Yi|Ri = 1)− (Yi|Ri = 0)]). For random
trial samples and under random treatment allocation, an unbiased estimator of the ITT
estimator is:
ÛITT effect := Y¯ (R)1 − Y¯ (R)0 = ÛCov(Ri , Yi)Var(Ri)











i=1 Yi, and n1 and n0 are the numbers of active
intervention and control participants respectively. This estimator, which will be referred
to as E-ITT, targets ACE and estimates the effectiveness of treatment. It is unbiased under
mean exchangeability which is ensured by randomisation in a trial. The International
Conference on Harmonisation (1998) introduced the ITT principle which states that this
estimator is the best assessment of a treatment, with analysis based on planned treatment
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Figure 4.1: Structural equation model illustrating the causal effect of intervention
allocation on outcome. Square boxes indicate manifest variables; circles are latent
variables.
regimen (the result of random assignment) rather than treatment receipt. In practical
terms this means that “subjects allocated to a treatment group should be followed up,
assessed and analysed as members of that group irrespective of their compliance to
the planned course of treatment” (p.33). The primary analysis of a superiority trial is
normally always based on this approach because it is a statistically valid approach for
effectiveness (Pocock, 2013) and conservative for efficacy (i.e. estimate of efficacy is
biased towards the null; Hernán and Hernández-Díaz, 2012).
4.3.2 Estimating efficacy: as treated and per protocol
Two simple approaches for estimating treatment efficacy are the use of as-treated and
per protocol (also known as on treatment) estimators. The as-treated estimator estimates
efficacy according to the treatment participants received, irrespective of randomisation
status, in an attempt to estimate ATE. This is parameter β in Figure 4.1. The as-treated
estimator for a continuous outcome is:
ÛAs treated effect := Y¯ (T )1 − Y¯ (T )0 = ÛCov(Ti , Yi)Var(Ti)











i=1 Yi, and m1 and m0 are the numbers of
participants receiving or not receiving the intervention respectively. This is unbiased for
ATE if it can be assumed that mean potential outcome is exchangeable between levels
of treatment receipt. This is a very strong assumption because it is highly likely that
a baseline variable (for example severity of illness) drives treatment receipt and also
affects outcome. Figure 4.1 includes such an unobserved variable as variable U , which
86
would commonly be referred to as a confounder of the effect of T on Y . Therefore this
estimator of β is likely to be subject to bias. Another way of stating this is that the
estimator, which throws away the protection of random allocation, invites bias because
the assumption of exchangeability is implausible (and is also impossible to test). Observed
confounders could be conditioned on, making the estimator unbiased under the less
restrictive assumption of conditional mean exchangeability.
The per protocol estimator estimates efficacy based on the result of random assignment,
but only for those who adhere to their allocation (i.e. it aims to estimate ATT). This
is parameter β in Figure 4.1 for the population who receive active intervention when
offered it. The per protocol estimator for a continuous outcome is:
ÛPer protocol effect := Y¯ (P)1 − Y¯ (P)0










i=1 Yi , and h1 and h0 are the subpopulations who
receive or do not receive treatment when they have been offered/not offered the treatment
respectively. The treatment effect is observed as a contrast between those who were
allocated to intervention and complied versus those in the control arm who received
the control treatment. This estimator is unbiased if it is assumed that mean potential
outcome is exchangeable between levels of treatment allocation and treatment receipt.
For similar reasons to the bias inherent in the as-treated estimator above, this estimator is
also likely to suffer from bias. In summary, both of these methods are likely to suffer from
selection bias because of the influence of unobserved confounding between treatment
receipt and outcome, as shown in Figure 4.1 (Hernán and Hernández-Díaz, 2012; White,
2005).
The major problem which any efficacy analysis must address is the presence of unobserved
confounding (non mean exchangeability) between treatment receipt and outcome. The
as-treated and per-protocol effects do not achieve this. However, there are some methods
that can do this and these will be introduced in Section 4.4.
4.4 Randomisation-based efficacy estimators for addressing
non-compliance
This section will review existing randomisation-based efficacy estimators that can be used
in trials with non-compliance, i.e. non-receipt of the treatment within the active arm.
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This section of the chapter explores these estimators in the simple scenario of binary
treatment receipt and no contamination, for example when the active treatment is not
available other than when offered. I will focus on two major modelling frameworks for
addressing non-compliance: principal stratification and instrumental variables methods.
4.4.1 Principal stratification
Principal stratification is a general framework that is most commonly applied in expe-
rimental settings. The method enables the estimation of principal effects (effects of
random treatment allocation) within strata, which are defined by the levels of binary
treatment allocation and binary treatment receipt (Frangakis and Rubin, 2002), using
structural equation modelling. These strata are partially latent because complier status
cannot be observed for a given participant. The number of principal strata tends to be
four, the product of two levels of allocation and two possible levels for treatment receipt,
as shown earlier in Table 4.2. Principal stratification can provide an estimator of CACE
for binary treatment receipt under various assumptions. In theory it would be possible
to define more than four strata but this would lead to a need for additional assumptions
in order for principal effects to be identified.
Identifiability assumptions
In reality the observed compliance statuses, as shown in Table 4.3, are very different to the
latent compliance classes. The observed compliance statuses (including contaminators
for the moment) do not uniquely map onto the latent compliance classes. In fact each
observed compliance status comprises two latent classes.
Table 4.3: Observed compliance status.
R T Compliance status
Possible latent compliance class
membership
0 1 Control contaminator Always taker or defier
0 0 Control non-contaminator Complier or never taker
1 1 Treatment complier Complier or always taker
1 0 Treatment non-complier Never taker or defier
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Assumption A-S1: Latent class membership is exchangeable between trial arms
In order to identify CACE it is necessary to make some assumptions. Latent compliance
class can be assumed to be independent of random treatment offer, or exchangeable (i.e.
E

Ti(R = 0), Ti(R = 1)
	|Ri = 1 = ETi(R = 0), Ti(R = 1)	|Ri = 0). This is part of
the assumption of full exchangeability, as described earlier, which is reasonable given
the use of random assignment. This has the noteworthy impact that latent compliance
class can be handled as a pre-randomisation variable. This variable can be considered as
a latent effect modifier, allowing the treatment effect to vary between different levels of
treatment receipt.
Assumption A-S2: Monotonicity
It is commonly assumed that there are no defiers within the population, which is known
as the assumption of monotonicity (Ti(1)− Ti(0) 6= −1; Imbens and Angrist, 1994). That
is, there are no people who take the opposite treatment to whatever they are offered.
This simplifies matters greatly because it means that only two latent classes exist: the
compliers and never takers (the lack of contaminators implies no always takers). These
can be directly observed in the active intervention group (observed treatment compliers
and treatment non-compliers, respectively, in Table 4.3) but not the control group.
Assumption A-S3: Exclusion restriction
Finally, it is necessary either to make an assumption about the impact of treatment among
never takers or to find predictors of latent compliance status (see assumption A-S4 later).
Regarding the former, it can be assumed that the effect of treatment among never takers
is zero – this is the so-called exclusion restriction. Put another way, this assumes that the
effect of allocation on outcome is entirely conferred through the receipt of this treatment,
i.e. the offer of treatment has no effect if it does not affect the treatment received. CACE
is consequently identified on the basis of the exclusion restriction, the assumption that
the proportion of latent compliers is the same in the trial arms (assumption A-S1), and
the assumption of no defiers.
Definition of stratification CACE estimator
Principal stratification provides an estimator which is constructed by fitting structural
equation models using maximum likelihood. Under assumptions A-S1–A-S3 this estimator
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Figure 4.2: Structural equation model diagram illustrating use of principal stratification
to address treatment non-compliance. Observed compliance status (C; coded one for
observed compliers in the active intervention arm, zero for observed non-compliers
in the same trial arm, and missing values for controls) is perfectly predicted by latent
compliance status (L; i.e. α= 1) due to the fact that latent compliers and never takers
can be observed as compliers and non-compliers respectively in the active intervention
arm. Latent compliance status is an effect modifier of the relationship between trial arm
and outcome. Parameter βL is constrained to zero for never takers (i.e. βn = 0) and is
freely estimated for compliers to provide an estimate of CACE (i.e. βc = CAC E).
(here named E-STR1) is unbiased for CACE. See Figure 4.2 for an illustration of what is
being estimated with an explanation of the parametrisation of the model in the caption.
CACE can be estimated using a mixture model, which allows a latent factor to predict
subpopulation membership and therefore treatment effects within these strata. This
provides a consistent estimator for CACE and a valid standard error for large samples. The
model can be identified and parameters estimated in any package that allows structural
equation models (SEMs) with latent classes (e.g. in Stata with the ‘gllamm’ package or
in MPlus).
Allowing for baseline predictors of outcome and compliance status
Baseline covariates (X in Figure 4.2) that predict outcome are useful for increasing
the efficiency of the CACE estimate for a continuous outcome (White, 2005). In other
words, such prognostic covariates increase the power of the estimate. Baseline predictors
of latent compliance status are useful for enhancing model identifiability and gaining
precision. Such pre-randomisation variables can be found by searching for predictors of
observed compliance status. When treatment is not available to those in the control arm,
the search for these variables is performed within the active intervention arm. These
variables are then used as covariates to predict class membership in the latent class
model.
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Assumption A-S4: Prediction of compliance status by baseline variables
If compliance status can be predicted this allows assumption A-S3 to be relaxed and
therefore the treatment parameter for never takers to be estimated. This was demon-
strated by Dunn et al. (2012) when estimating the effects of different levels of cognitive
behavioural therapy (full, partial, none) compared to treatment as usual for people with
psychosis. The authors tightened and then relaxed the exclusion restriction in order to
check the sensitivity of the estimate for those who received full therapy. As the number of
principal strata increases so does the number of predictors needed in order to distinguish
between these subpopulations.
Missing outcome data
It is highly likely that a trial of an intervention in mental health research will be subject
to missing outcome data and possible that the missingness will be extensive, despite
the best efforts of those running the trial. The most appropriate analytical method for
addressing missing data depends on the missing data generating mechanism. In the
language of Little and Rubin (2014), when the mechanism is “ignorable” then the latent
class model can assume either missing at random (MAR) or latent ignorability (LI). Under
MAR, it is assumed that the probability of missingness is independent of outcome, given
observed outcome data (Pr(N |Yo, Ym) = Pr(N |Yo), where the indices m and o represent
missing and non-missing outcome). The CACE estimator E-STR1 is valid under MAR
in Figure 4.2. Under the weaker assumption of LI, the probability of an outcome value
being missing is considered to be independent of outcome, given observed outcome
and latent compliance status (Pr(N |Yo, Ym, L) = Pr(N |Yo, L); Rubin and Little, 2002).
The stratification estimator has been shown to be valid under LI in Figure 4.3. These
assumptions can be relaxed by covarying on any pre-randomisation variable that can
predict missingness (Pickles and Croudace, 2010).
Assumption S5: Compound exclusion restriction
In order for the model to be identified under LI an additional (“compound”) exclusion
restriction must be specified. This states that for those participants whose treatment is
different to random allocation, the offer of treatment has no direct impact on missingness.
This is illustrated in Figure 4.3.
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Figure 4.3: Structural equation model diagram illustrating principal stratification with
missing outcome values assumed to be ignorable conditional on latent compliance status.
This model is similar to Figure 4.2 but now allows the effect of treatment on response
(N) to be modified by latent compliance status. This parameter (γL) is assumed to be
zero for never takers and is freely estimated for latent compliers.
Summary
Principal stratification allows the estimation of the causal effect of latent treatment
receipt on outcome. It enables assumptions regarding missing value generating processes
to be relaxed but is restricted to situations where there are finite numbers of latent
classes. Extensions of this framework, for example to more than four principal strata
due to further levels of latent compliance status, demand predictive baseline covariates
in order to allow identifiability (Emsley and Dunn, 2012). The next section will show
how another method, estimation using IVs, can be used to extend causal estimation to
other models of the relationship between treatment and outcome.
4.4.2 Instrumental variables
In a linear model all covariates can be classified as either endogenous or exogenous,
terminology that arose in the economics literature (Wooldridge, 2010). An endogenous
covariate is a predictor variable that is correlated with the error term of the outcome.
A predictor variable that is unrelated to the error term is known as an exogenous
variable. Note that the classification of whether a covariate is endogenous or exogenous
is dependent on how the model is specified. If all the covariates are exogenous then the
ordinary least squares (OLS) estimator of all covariates on outcome estimates the causal
effect of each of these. If a covariate is endogenous then the OLS estimate of its effect is
biased.
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Figure 4.4: Structural equation model diagram assumed to estimate the causal effect of
treatment receipt on outcome (parameter β).
The method of instrumental variables, which was developed in the econometrics literature,
provides an approach for estimating the causal effect of one variable on another that
accounts for confounding between these variables. The effect of such confounding is to
induce a correlation between the predictor variable and error term of the outcome (i.e.
the predictor is endogenous). A variable that is correlated with the endogenous variable
and not with the error term of the outcome (i.e. exogenous) provides what is known as
an instrument. In the context of treatment compliance within a randomised controlled
trial, the endogenous variable is treatment receipt and the parameter of interest is its
causal effect on patient outcome, as shown in Figure 4.4.
Formally, the definition of an IV includes three parts, which are known as the core
conditions. As will be seen, random treatment allocation can be considered to be a
suitable candidate for the choice of instrumental variable for the effect of treatment
receipt in the context of a randomised controlled trial.
Assumption A-I1: Inclusion restriction
One of these core conditions, which is often called relevance or the inclusion restriction, is
that the set of IVs must be predictive of the vector of endogenous variables, such that
the predictions are not linearly related. In order to achieve this, at least as many IVs as
endogenous variables are needed. In the current application there is one endogenous
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variable, T , and one IV, R, and therefore the assumption is R 6⊥ T . In Figure 4.4 the
parameter α represents the predictive effect of R on T . This core condition is the only
one which is testable.
Assumption A-I2: Independence of R and error term of Y
It is assumed that the set of instruments are statistically independent of the error term
of the linear model. In the model represented by Figure 4.4 this means that R must
be independent of ε2. It is assumed that there is no direct pathway from the set of
instruments to outcome and no common cause of both. This is fulfilled by the following
two assumptions.
Assumption A-I2a: Exclusion restriction The assumed absence of a direct relations-
hip between instruments and outcome is known as the exclusion restriction. This is
equivalent to assuming that parameter β = 0 for never takers in the figure.
Assumption A-I2b: No common cause of instrument and error term The final core
condition is that the set of IVs needs to be statistically independent of latent confounders
between the endogenous variables and outcome. In Figure 4.4 this means that the
instrument and outcome must not share any common causes (R⊥ U). This is fulfilled in
a trial because randomisation ensures no drivers of R.
In a trial, assumptions A-I1 and A-I2b are met due to randomisation but the appropriate-
ness of A-I2a needs to be considered. In a trial where either participants or clinicians are
not blind it is possible that the expectations of participants could lead to the exclusion
restriction being violated. For example, the disappointment of participants who are
allocated to the control arm may lead to discouragement or even feelings of retaliation.
This phenomenon is thought to lead to poorer patient outcomes and is known as resentful
demoralisation (Onghena, 2005). Another possible weakness in the assumptions of IV
methods arises when treatment receipt is defined as binary when in fact it is continuous.
In this case non-compliers who receive a small dose are incorrectly assumed to have
received nothing.
Assumption A-I3: Treatment heterogeneity
It is necessary to make a further assumption to allow identification of the causal effect
of T on Y . It can either be assumed that the effect of treatment is constant or that
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there are no defiers in the population. There are different levels of effect homogeneity,
the strongest of which is that the effect of treatment receipt on outcome is the same
for all individuals (Hernán and Robins, 2018). Under this assumption, ATE is equal to
CACE. A weaker effect homogeneity assumption is that the causal effect of T on Y is
the same between levels of treatment offer in observed compliers and non-compliers
(E





Yi(T = 1) − Yi(T = 0)|Ri = 0, Ti = t

for t=0,1). Put another way, this means that the average causal effect of T on Y is
equal within levels of treatment receipt. The major weakness in the plausibility of this
assumption, as pointed out by Hernán and Robins (2018), is the possibility of effect
modification of the causal effect by unmeasured confounders. An alternative assumption
is to assume that there are no individuals within the population who would always receive
the opposite treatment to what they are offered (no defiers; Imbens and Angrist, 1994).
This assumption of monotonicity (described earlier) combined with the assumption of
no treatment effect within the never takers (assumption A-I2a) implies that the the IV
estimand represents the effect of treatment within latent compliers (i.e. CACE, as defined
in Equation 4.1). In this manner the IV estimand is a type of LATE.
Definition of IV estimator
In order to estimate CACE, as defined earlier, an instrumental variables approach assumes
that there are two levels of latent treatment receipt, latent compliers (Ti(1)− Ti(0) = 1)
and everyone else (Ti(1)−Ti(0) 6= 1). Under assumption A-I3 it is assumed that there are
no defiers, meaning that the latent compliers must be observed compliers in the active
intervention arm. When treatment receipt is binary and no controls receive treatment (no
contamination), the never takers are observed non-compliers in the active intervention
arm. It is then possible to estimate treatment efficacy in the following manner. First,
it is assumed that potential outcome among those in the active intervention arm is a
combination of outcome for latent compliers and never takers. Under assumptions A-I1
and A-I2 randomisation, R, provides a suitable instrument, Z .
E[Yi(Z = 1)] = E[Ti(Z = 1)]E[Yi(Z = 1, L = c)] +
(1− E[Ti(Z = 1)])E[Yi(Z = 1, L = n)]
where E[Yi(Z = 1, L = c)] is expected potential outcome under allocation to treatment
and receipt of it (i.e. amongst latent compliers), and E[Yi(Z = 1, L = n)] is expected
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potential outcome under allocation to treatment and non-receipt of it (i.e. amongst never
takers). Based on the assumption of consistency and assuming that the relationship
between treatment assignment and treatment receipt is linear, this can be expressed in
the active intervention arm in the observable world as:
E[Yi|Zi = 1] = αcE[Yi|Zi = 1, Ti = 1] + (1−αc)E[Yi|Zi = 1, Ti = 0] (4.2)
where αc is the proportion of participants who comply in the active intervention arm.
The relationship between potential outcome and treatment receipt can also be expressed
in the control arm:
E[Yi(Z = 0)] = E[Ti(Z = 0)]E[Yi(Z = 0, L = c)]+
(1− E[Ti(Z = 0)])E[Yi(Z = 0, L = n)]
However, latent compliance cannot be observed in the control arm, which therefore means
that an extra assumption is required in order to express this, eventually, in observable
terms. Specifically, it is assumed that the proportion of control participants who would
comply had they been offered active intervention is the same as that observed in the active
intervention arm. This assumption is incorporated in full exchangeability (described
earlier) and is plausible given the use of random treatment allocation. Therefore, on
the basis that the parameter αc is estimable, observed outcome amongst controls is a
weighted average of expected potential outcomes:
E[Yi|Zi = 0] = αcE[Yi(Z = 0, L = c)] + (1−αc)E[Yi(Z = 0, L = n)] (4.3)
Treatment efficacy, the difference in expected outcome between trial arms for those who
would comply, can be expressed as a rearrangement of Equations 4.2 and 4.3. For a
continuous outcome, efficacy (β) can be estimated with an unbiased sample as follows:
β = E(Yi(Z = 1, L = c)− E(Yi(Z = 0, L = c)))
βˆ =
((Y¯1.)− (1− αˆc)(Y¯10))− ((Y¯0.)− (1− αˆc)(Y¯ (Z = 0, L = n)))
αˆc
(4.4)
where Y¯zt is mean outcome given that Z = z and T = t. This equation is not estimable
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because the right side includes a potential mean outcome, (Y¯ (Z = 0, L = n)), which
cannot be estimated in the observable world based on assumptions made so far. However,
the exclusion restriction assumes that the treatment effect amongst those who do not
comply is zero, implying that mean outcome for non-compliers in the active intervention
and control trial arms are exchangeable. Substituting (Y¯10) for (Y¯ (Z = 0, L = n)), and
simplifying by expressing (Y¯1.)− (1− αˆc)(Y¯10) as αˆc(Y¯11), Equation 4.4 can be expressed
in observable terms as an estimator for β:
βˆ =
αˆc(Y¯11) + (1− αˆc)(Y¯10)− (Y¯0.)
αˆc
(4.5)
This estimator is named E-IV1 here. The standard error for this can be found by boots-
trapping.
Alternatively, the treatment efficacy parameter can be expressed as a ratio of the paths in





E[Yi|Zi = 1]− E[Yi|Zi = 0]
E[Ti|Zi = 1]− E[Ti|Zi = 0]
An unbiased estimator for this (here named E-IV2) is:
βˆ =
(Y¯ |Zi = 1)− (Y¯ |Zi = 0)
Pr(Ti|Zi = 1)− Pr(Ti|Zi = 0) =
ÛITT effect of Z on YÛITT effect of Z on T
If there are no missing outcome data, Equation 4.5 simplifies to this (Dunn et al., 2003).
This estimator was introduced by Bloom (1984) and is occasionally known as either
the Bloom IV estimator (e.g. Dunn et al., 2005), Wald estimator (Wald, 1940), or ratio
estimator.
The most commonly used methods for estimating the causal effects of endogenous
variables, which were developed in the econometrics literature, involve two stages
(Wooldridge, 2010). In general, these methods require that the instruments must be
capable of predicting the endogenous variables so that the predictions can be used in
the estimation procedure. The first stage comprises the prediction of the endogenous
variable by the instrument. In the second stage the information from this prediction is
used in place of the endogenous variable in order to estimate the causal parameter of
interest. Methods that can handle multiple endogenous variables are reviewed in the
next section. In the case where there is one endogenous variable (treatment receipt) and
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the instrument is random allocation, this simplifies to Bloom’s IV estimator, as already
described.
In practice, treatment efficacy is often estimated using a regression approach, of which the
most common examples are the two stage least squares (2SLS) and adjusted treatment
response (ATR) methods. Generally speaking, in the first stage they use ordinary least
squares to estimate the effect of the instrument on the endogenous variable and in the
second stage use the post-estimation information from this regression to estimate the
unbiased impact of the endogenous variable on outcome. In the context of treatment
non-compliance (i.e. the model shown in Figure 4.4), T is initially regressed on Z and
the predicted values of T are estimated and saved. Following this, Y is regressed on the
predicted value of T obtained previously (IV(2SLS) method, Wooldridge, 2010). This
method is named here as E-IV3. The second method comprises first regressing T on
Z , saving the residuals from this, and then regressing Y on T and the saved residuals
(introduced in the biostatistics literature by Nagelkerke et al., 2000). This is referred to
here as the IV(ATR) approach but is also sometimes referred to as the control function
method in the econometrics literature (Wooldridge, 2015) or the two stage residual
inclusion method in health economics (Terza et al., 2008). Provided the causal effect is
linear, the two approaches are equivalent and therefore produce the same estimate of the
effect of treatment receipt on outcome. IV estimation can be performed using existing
packages in Stata (‘ivregress’) or R (‘tsls’ or ‘ivreg’). The 2SLS procedure fits the model
in one go and provides model-based standard errors. In contrast, the methods involving
creation of predictions of treatment receipt (or residuals) must use bootstrapping to
generate correct standard errors in the second stage.
Maracy and Dunn (2011) show that these approaches are equivalent to another two-stage
method named structural mean modelling. All three methods are based on the same
model for the relationship between receipt of treatment and treatment effect. Using this
type of modelling, the treatment efficacy parameter can be estimated by g-estimation,
as developed by Robins (1994) and Fischer-Lapp and Goetghebeur (1999). This review
will not go into much detail about structural mean models but some basic information
about the overlap between these and IV methods is given here briefly. The stages of
g-estimation involve predicting potential outcomes (of the endogenous variable and
outcome) under treatment and control separately for all participants and then regressing
the difference between these on the predicted values of the endogenous variable. The
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basic rationale behind g-estimation and IV methods is that random allocation can be
used to create strata that are conditionally exchangeable, within which it is possible to
estimate causal treatment effects.
There are other IV estimation approaches apart from the two-stage methods. Full
information maximum likelihood (FIML), sometimes shortened to simply maximum
likelihood (ML), is one such alternative (Imbens and Rubin, 1997; Jo and Muthén, 2001).
Under this estimation technique, outcome is predicted by latent compliance status and an
interaction between it and random treatment group allocation. The model is identified if
the effect for latent non-compliers is assumed to be zero (i.e. the exclusion restriction)
or if there are baseline variables that predict latent compliance status membership. The
model is then fitted using the expectation maximisation algorithm (Dempster et al.,
1977). Another estimation approach is limited information maximum likelihood (LIML)
(Anderson and Rubin, 1949).
Multiple endogenous variables and multiple instruments
In order for a model to be identified when more than one covariate is endogenous, the
number of instruments needs to be at least as large as the number of endogenous variables
(Dunn and Bentall, 2007). This means it is necessary to search for potential instruments.
Any candidate instrument must meet the core conditions, meaning that an instrument
must be relevant to the intermediate variable, not directly related to outcome (other
than through the endogenous variable) and not share common causes with outcome.
In practice, this means that instruments must be pre-randomisation covariates that are
predictive of the endogenous variables but not effect modifiers of the causal relationship
between the endogenous variables and outcome. Possible candidates for these in trials
are interaction terms between such predictive covariates and random allocation. The
interaction with randomisation fulfils the assumption that the IV and outcome have no
common cause. It must still be assumed that there is no direct effect of the instrument
on outcome in order for the interaction term to satisfy all core conditions necessary for
being an IV. This assumption can be a strong one in trials where blinding is not possible,
as described earlier.
For example, Goldsmith et al. (2015) evaluated the causal effect of two endogenous
variables, number of treatment sessions and the interaction between sessions and therapist
alliance, in order to investigate the impact on treatment effect of sessions attended (at
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particular levels of alliance) and of a one-unit increase in alliance when therapy took
place. They found that duration of illness, years of education, outcome score at baseline,
and treatment centre predicted number of treatment sessions attended. They then created
interaction terms of these variables with random allocation and used these as IVs. The
participant-level predictions of sessions and the interaction between sessions and alliance
were then used to estimate the effect of the endogenous variables on outcome.
Dose-response relationships for continuous treatment receipt
Up until this point it has been assumed that participants either receive or do not receive
the active intervention, and that the effect of intervention is zero amongst those who do
not receive it. It is possible to extend IV methods to include a dose-response relationship
between a continuous measure of dose of treatment (e.g. number of sessions attended)
and treatment effect, as shown by Maracy and Dunn (2011). In this case, the model in
effect stratifies the population (based on dose of treatment received if offered) and then
estimates the change in treatment effect between the subpopulations.
For instance, the causal effect of treatment offer (∆r,i) can be modelled with a linear
dose-response relationship (Maracy and Dunn, 2011):
∆r,i|(Di(R = 1) = d) = βd + εi (4.6)
This constitutes the treatment effect resulting from attending d sessions (only taken if
offered) where the causal parameter β represents the change in treatment effect due to
a one-unit increase in dose, i.e. β = ACEd1+1,d0 −ACEd1,d0 . This demonstrates that the
latent complier population has been split into strata defined by the level of d1. Never
takers remain the same as for binary treatment receipt (Di(R = 0) = 0, Di(R = 1) = 0).
The residual term ε represents unaccounted variability in the treatment effect in a
subpopulation defined by the level of d.
Certain assumptions must be made in order for the causal effect of dose on outcome
to be identified. The assumptions of the inclusion restriction (assumption A-I1), the
exclusion restriction (assumption A-I2a), and no common cause of instrument and the
error term of the outcome (assumption A-I2b) are made. The meaning of the exclusion
restriction here is that the treatment effect is zero for those who would attend no sessions.
This is represented by the lack of an intercept term in Equation 4.6 and the assumption
that the expectation of the residual term is zero. The final identifiability assumption
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relates to treatment heterogeneity and includes two parts. The first is a more general
monotonicity assumption which now assumes that the endogenous variable is a non-
decreasing function of the instrument. In the context described here, this means that the
offer of treatment is assumed not to lead to any participant attending fewer sessions of the
treatment compared to what the patient would have done had he or she not been offered
the treatment (Di(R = 1) ≥ Di(R = 0)). The second part is the assumption that the
endogenous variable and residual term in Equation 4.6 are not related (Cov(D,ε) = 0).
In econometrics this is known as the assumption of no essential heterogeneity. This means
that it must be assumed that there is no unmeasured confounding between these two
terms.
This linear model can be easily extended to allow a non-linear dose-response relationship
by including further terms. For example, Maracy and Dunn (2011) modelled treatment
effect with linear and quadratic terms for number of treatment sessions, therefore allowing
this relationship to be non-linear. This type of modelling relies on an expectation or
expert theory about the relationship between the exposure and outcome. Burgess et al.
(2014) introduced a non-parametric method for stratifying the population and estimating
strata-specific causal effects of exposure. This method can therefore be used to investigate
the shape of the relationship between exposure and outcome. The approach is to stratify
the population based on residual variation in the exposure after conditioning on the
instrument. The authors then used the ratio method to estimate the local average causal
effect of exposure on outcome within these strata. A more general method, which the
authors also describe, is to order individuals according to the values of the residuals
found after regressing the exposure on the instrument and then use a sliding window to
estimate the local average causal effect within these windows. Estimates can then be
plotted against median exposure level (within each window) to explore the shape of the
exposure-outcome relationship. The choice of window size (i.e. number of observations)
influences the profile of the plot: a smaller size leads to a sharper resolution in the
estimated shape of the relationship; a larger window provides greater precision. The
drawbacks of these methods is that they require a large number of observations and data
from a wide range of exposure values.
The IV methods described above (IV(2SLS) or IV(ATR)) can be used to explore the
relationship between continuous exposure and outcome and to estimate the change in
the causal efficacy parameter (i.e. ACEd1+1,d0−ACEd1,d0 where d0 = 0, defined earlier).
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The bottom line is that such methods can estimate the change in treatment effect for
each additional dose (e.g. session) of treatment received. Where there is more than one
dose variable, further instruments must be found as described in the context of multiple
binary endogenous variables. The dose-response estimator is referred to here as E-IV4.
Allowing for predictors of outcome
Baseline covariates which predict outcome can be included in the two stage least squares
methods. These covariates are included as explanatory variables in both stages of
the methods. They are typically variables which are anticipated to be predictive of
outcome (such as the outcome variable measured pre-randomisation) or variables which
predict outcome by design (e.g. randomisation stratifiers). Commonly the effect of
such covariates on outcome is constrained to be the same in the various compliance
classes, especially if they are included as effect modifiers in the prediction of endogenous
variables.
Missing outcome values
So far it has been assumed that there are no missing outcome data, which in effect
makes estimators E-IV1 (modified Bloom/ratio estimator with proportions of observed
compliance and non-compliance predicting outcome), E-IV2 (Bloom/ratio estimator),
E-IV3 (2SLS estimator for binary observed compliance), and E-IV4 (2SLS estimator for
continuous treatment receipt in intervention arm) equivalent. When there are missing
outcome data, it is necessary to make assumptions regarding the missing data generating
mechanism under which the estimator remains valid. Of the four estimators described
in this section, E-IV2, E-IV3 and E-IV4 make the strongest assumptions regarding the
mechanism leading to missing data. They assume that, given observed outcome data, the
missingness generating mechanism does not depend on the missing data (Pr(N |Yo, Ym) =
Pr(N |Yo)). This is to assume that missingness is ignorable and that missing data are
MAR. Estimator E-IV1 additionally allows observed compliance to predict missingness
(Pr(N |Yo, Ym, C) = Pr(N |Yo, C)).
Another method for addressing missing data that accounts for the process that generated
the incomplete data is MI (originally proposed by Rubin, 1978, 2004). In general, MI is
a technique for replacing missing data with a range of plausible values; this provides
a series of imputed datasets whose analyses are pooled together to provide estimates
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that are valid under the expected missing data generating mechanism. The method
includes two main stages: imputation and analysis. In the imputation step missing data
are replaced by values that maintain associations between variables in the model whilst
at the same time reflecting the uncertainty of these predictions. This can be done using
chained equations (a parametric approach introduced by Van Buuren et al., 1999) or
Monte Carlo Markov chains which assume multivariate normality (Schafer, 1997). In the
second step, the series of imputed datasets are each analysed and the results are combined
using Rubin’s rules (Rubin, 2004). In practice, MI can be used to allow predictors of
missingness (including observed compliance) and therefore relax the assumptions of
estimators E-IV2, E-IV3, and E-IV4.
Accounting for clustering
It is possible that outcome data could demonstrate lack of independence between indivi-
duals’ observations, for example due to groups of participants sharing therapists. The
prognosis of participants who share a therapist might be related due to shared treatment
techniques. An estimation model for outcome that does not address this assumes that
data are independent and therefore will (usually) tend to underestimate standard errors.
In this section I review existing methods that account for clustered outcome data and
specify how I will apply these to the ITT and IV estimators that I have described.
It is possible to take an estimation approach that assumes the existence of a multi-level
structure within the data, i.e. levels of residual error terms for participants and therapists.
Mixed-effects models can be used to handle such data dependency and therefore provide
correct estimation of standard errors when all covariates can be considered exogenous.
These models allow the hierarchical data structure to be acknowledged within the
procedure for estimation of coefficients by modelling error terms at all levels. Let us
return to the E-ITT estimator and assume a linear model for outcome Y with random
treatment allocation R, outcome measured at baseline X , level-two residual error term
ω j (with subscript j labelling clusters and i labelling patients within the j
th cluster), and
level-one residual error term "i j:
Yi j = α+ β1Ri j + β2X i j + "i j +ω j
In this model, terms "i j and ω j can be modelled as random effects, i.e. terms that
take expectation zero and some variance. Coefficients for intercept α, slopes β1 and
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β2, variances and covariances can be estimated using an estimation procedure such as
maximum likelihood.
Generalised two stage least squares (G2SLS) method
A collection of methods exist that enable estimation of parameters where data take this
multi-level structure and where some covariates are endogenous. These are generalisati-
ons of the 2SLS estimator. One of these, the G2SLS method, passes exogenous variables
through the feasible generalised least squares transformation and then uses the results
of this as instruments (Balestra and Varadharajan-Krishnakumar, 1987). Endogenous
variables and outcome are also passed through the same transformation, enabling un-
biased and consistent estimation of coefficients, variances and covariances using the
familiar 2SLS approach. Error terms are handled as random variables that are assumed
to be independent and identically distributed over clusters. The G2SLS method can
be performed in Stata using the ‘xtivregress’ command and specifying random error
(‘re’) in the options. In R it can be done using the ‘plm’ function with the Balestra and
Varadharajan-Krishnakumar (‘bvk’) method. I will use the G2SLS approach as a method
of accounting for clustering in the efficacy analysis of simulated trials with measures of
treatment receipt in Chapter 5.
Clustered robust variance estimator approach
A separate approach is to use OLS estimation and account for lack of independence
between outcome data by allowing for correlations within groups. Observations are then
assumed to be independent between groups (but not within them), i.e. residual errors
are correlated within clusters but not across them. This method relies on the use of robust
standard errors (White, 1984). I will briefly describe how the robust variance estimator
is derived. I return to the OLS estimator for outcome Y , with independent variables
random treatment allocation R and outcome measured at baseline X . For the moment I
assume there are participant-level residual errors ("i) and no level-two errors. I refer
to the vector of the dependent variable as y and the 2× n matrix for the independent
















I now return to the linear model for outcome with level-one residual error "i j and level-
two residual error ω j. The clustered robust variance estimator for the coefficient is










where n j is the number of clusters and u j =
∑n j
j "ixi. I will use the clustered robust
variance estimator in conjunction with IV estimators in the efficacy analysis of D6 in
Chapter 7.
Summary
The IV framework provides a flexible parametric approach for modelling treatment
efficacy. This section described how, in the context of non-compliance (treatment non-
receipt in the active intervention arm), IVs can be used to estimate the causal effect
of treatment. This included treatment on dichotomous and continuous scales, and
circumstances in which there could be more than one measure of treatment receipt
(multiple endogenous variables). The use of IVs to identify causal parameters relies upon
a large number of assumptions, some of which are untestable. These include the three core
conditions of IVs (relevance, exclusion restriction, and no common cause of instrument
and error term of outcome), an assumed parametric relationship between the endogenous
variable and outcome (often assumed to be linear), the same proportion of compliers
in the active intervention and control arms, and, for a dose-response relationship, no
treatment effect heterogeneity.
In comparison to principal stratification, IV methods enable more flexible modelling of
causal parameters because they are less restricted by the definitions of strata. However,
they make stricter assumptions about missing data because any predictors of missingness
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that are included in the model must be observable variables.
4.5 Randomisation-based efficacy estimation approaches for
addressing contamination
So far the efficacy analysis approaches have assumed that there is no contamination,
implying the existence of only three latent classes (compliers, never takers, defiers). I
will now expand the methodology and assumptions to accommodate contamination (i.e.
the presence of always takers). My novel contribution will be an analysis method for
estimating efficacy with continuous measures of treatment receipt in both active and
control arms, i.e. in the presence of both non-compliance and contamination.
4.5.1 Principal stratification
As described in Section 4.4.1, principal stratification provides a framework for the
identification of causal effects within population strata, which are latent and defined by
levels of treatment allocation and treatment receipt. These so-called principal effects can
be estimated using structural equation modelling. This provides an estimator of CACE
for binary treatment receipt.
It is assumed that latent class membership is exchangeable between trial arms and
that there are no defiers among the population (assumptions A-S1 and A-S2 described
earlier). Where there is some receipt of the active intervention among those in the
control arm and full compliance within the intervention arm, it is also assumed that
the effect of treatment is zero amongst the stratum of participants who would always
receive treatment irrespective of what they are offered. This is the exclusion restriction
(assumption A-S3) and now applies to always takers rather than never takers (as was
specified earlier). Where there is contamination and non-compliance, it is assumed that
the treatment effect is zero within always takers and never takers.
Definition of stratification CACE estimator
Principal stratification allows CACE to be estimated by fitting a structural equation model
in the context of a mixture model, where parameters and inference can be calculated using
maximum likelihood. Under assumptions A-S1, A-S2, and the revised A-S3 assumption,
this estimator (named E-STR2) is unbiased for CACE. Figure 4.5 illustrates how the
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Figure 4.5: Structural equation model diagram illustrating the use of principal stratifi-
cation to address treatment contamination. Observed contamination status (K; coded
one for observed contaminators in the control arm, zero for observed non-contaminators
in the same trial arm, and missing values for those in the active intervention arm) is
perfectly predicted by latent compliance status (L; i.e. α= 1) due to the fact that latent
compliers and always takers can be observed as control non-contaminators and control
contaminators. Latent complier status is an effect modifier of the relationship between
trial arm and outcome. Parameter βL is constrained to zero for always takers (i.e. βa = 0)
and is freely estimated for compliers to provide an estimate of CACE (i.e. βc = CAC E).
model is specified. With a representative sample, CACE can be estimated on the basis
that latent compliance status, which perfectly predicts observed contamination status,
is an effect modifier of the effect of treatment allocation on outcome. As before, this
provides a consistent estimator and valid standard error for the parameter.
Where there is both treatment contamination and non-compliance, a similar approach
can be taken in order to estimate CACE. Under the assumptions A-S1 and A-S2, and now
assuming no effect of treatment in both always takers and never takers, the SEM mixture
model provides an unbiased estimator (named E-STR3) for CACE. Figure 4.6 shows how
observed contamination and compliance status are predicted by latent compliance status,
which interacts with random treatment allocation to provide an estimate for the effect of
this among latent compliers.
Allowing for baseline predictors of outcome and compliance status
Predictors of outcome, contamination status, or both can be incorporated into the model.
Prognostic covariates increase the precision of the CACE estimate, whilst predictors of
contamination aid model identifiability. When searching for predictors of contamination,
K should be coded in a similar manner to manifest C above (in particular with missing
values for those in the active intervention arm). If contamination can be predicted by
the vector of baseline covariates (revised assumption A-S4), this enables the exclusion
restriction to be relaxed.
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Figure 4.6: Structural equation model diagram illustrating the use of principal stratifica-
tion to address treatment contamination and non-compliance. Observed contamination
status (K; 1=observed contaminator, 0=observed non-contaminator, missing for those
in the active intervention arm) and observed compliance (C; 1=observed complier,
0=observed non-complier, missing for those in control arm) are perfectly predicted by
latent compliance status (L). Always takers and never takers can be observed as control
contaminators and treatment non-compliers respectively; the residue are latent compliers.
Latent compliance status is an effect modifier of the relationship between trial arm and
outcome. Parameter βL is constrained to zero for always takers and never takers (i.e.
βa,n = 0), and is freely estimated for compliers to provide an estimate of CACE (i.e.
βc = CAC E).
Where there is both treatment contamination and non-compliance, the vector of baseline
covariates must be capable of predicting always takers and never takers. For example,
Hirano et al. (2000) performed a secondary analysis of a randomised controlled trial
of the encouragement of clinicians to provide influenza vaccine to adults at high risk
of the disease. In such an unblinded trial it is known that there will be substantial
subpopulations of clinicians who always and never give the treatment to those at high
risk. The researchers found that two covariates predicted both always takers and never
takers. The authors used this to relax the exclusion restrictions amongst always and never
takers and concluded that there was evidence for the direct effect of random treatment
allocation on outcome. The sets of covariates that distinguish always and never takers
from latent compliers can be the same, as in this example, or can be different.
Missing outcome data
The models in Figures 4.5 and 4.6 make the assumption that any missing data are MAR.
This is because they assume that missingness is predicted by treatment allocation and
any baseline covariates that are included. The weaker assumption of LI allows latent
compliance status to predict missingness. In the context of treatment contamination, a
further assumption is necessary in order for the model to be identified under LI. The
compound exclusion restriction (revised assumption A-S5) assumes that the effect of
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random treatment allocation on missingness is zero amongst always takers, allowing the
parameter to be freely estimated for latent compliers. Where there is both treatment
contamination and non-compliance, this parameter is assumed to be zero for both always
takers and never takers.
Summary
Principal stratification provides a framework for estimation of the causal effect of latent
treatment receipt on outcome and a flexible method for addressing missing data. The
framework enables a stratification estimator to calculate treatment effect amongst latent
compliers in the analysis of a trial with non-compliance and contamination. Baseline
predictors of non-receipt of treatment in the intervention arm and receipt of treatment in
the control arm provide a gain in the precision of the estimated causal treatment effect.
The next section will demonstrate and extend the use of instrumental variables methods
to calculate causal treatment effect in other models of the relationship between exposure
and outcome.
4.5.2 Instrumental variables
Treatment contamination is a process variable that occurs after randomisation. This
means that randomisation provides no protection against the possibility of confounding
between it and outcome. More formally, treatment receipt amongst participants in the
control group is likely to be an endogenous explanatory variable because it is expected that
it is correlated with the error term of Y (due to the likelihood that the two variables share
common causes). IV methods provide estimators for the effect of receipt of treatment on
outcome whilst accounting for confounding.
Assumptions
The assumptions necessary for estimation are similar to the core conditions (assumptions
A-I1 and A-I2) and assumed monotonicity (assumption A-I3) described in Section 4.4.2.
The difference is that under the problem of contamination there are always takers
but no never takers among the population. Where there is contamination and non-
compliance then always takers can be identified in the control arm (described here as
control contaminators) and never takers can be identified in the active intervention arm
(treatment non-compliers). Latent compliers cannot be identified but their proportion
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can be – it is simply the residual part of the population after summing together the
proportions of always takers and never takers.
Estimation approaches
In order to estimate CACE in the context of treatment receipt in the control arm of a trial,
the IV approach assumes two levels of latent treatment receipt, compliers (Ti(1)−Ti(0) =
1), and everyone else, (Ti(1) − Ti(0) 6= 1). If full compliance is observed within the
intervention arm then it can be assumed that there are no never takers. This implies that
that the population is comprised solely of latent compliers (Ti(1)− Ti(0) = 1− 0 = 1)
and always takers (Ti(1)− Ti(0) = 1− 1 = 0). The latent compliers and always takers
can be observed as compliers and contaminators in the control arm, making it possible
to estimate their proportions in the population.
Potential outcome under the offer of treatment is a weighted average of potential outcome
for non-contaminators (latent compliers; L=c) and for contaminators (always takers;
L=a). Under the assumption of consistency, this can be partially identified under offer of
intervention in the observable world as:
E[Yi|Zi = 1] = αkE[Yi(Z = 1, L = c)] + (1−αk)E[Yi(Z = 1, L = a)] (4.7)
where αk is the proportion of participants who are not contaminated in the control arm
(i.e. proportion of latent compliers). Similarly, potential outcome under the offer of
control treatment can be identified in the observable world as:
E[Yi|Zi = 0] = αkE[Yi|Zi = 0, Ti = 0] + (1−αk)E[Yi|Zi = 0, Ti = 1] (4.8)
Rearranging Equations 4.7 and 4.8, treatment efficacy (with a continuous outcome) can
be expressed using the following estimator for an unbiased sample:
β = E(Yi(Z = 1, L = c)− E(Yi(Z = 0, T = 0)))
βˆ =
((Y¯1.)− (1− αˆk)(Y¯ (Z = 1, L = a)))− ((Y¯0.)− (1− αˆk)(Y¯01))
αˆk
(4.9)
where Y¯zt is mean outcome given that Z = z and T = t. This is not estimable because
one term (Y¯ (Z = 1, L = a)) cannot be estimated based on assumptions made so far.
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However, under the exclusion restriction it can be assumed that mean outcome for always
takers in both trial arms is exchangeable. Replacing (Y¯ (Z = 1, L = a)) with (Y¯01), and
simplifying by expressing (Y¯0.)− (1− αˆk)(Y¯01) as αˆk(Y¯00), Equation 4.9 can be expressed
in observable terms as an estimator for β:
βˆ =
Y¯1. − αˆk(Y¯00)− (1− αˆk)(Y¯01)
αˆk
(4.10)
Similarly to the steps described in Section 4.4.2, when there are no missing outcome
data Equation 4.10 simplifies to the ratio between the ITT effect of Z on Y and that of Z
on T (estimator E-IV2 from earlier).
If there is contamination and also treatment non-receipt in the intervention arm then
this implies that the population includes (latent) compliers, always takers, and never
takers (Ti(1)− Ti(0) = 0− 0 = 0). The always takers are observed as contaminators
in the control arm and never takers are non-compliers in the intervention arm. The
proportion of compliers is the residue after the always and never takers have been
identified. Following the assumptions and argument described above, an unbiased
estimator for efficacy (named E-IV5 here), as given by Dunn et al. (2005) is:
βˆ =
αˆ11Y¯11 + αˆ10Y¯10 − αˆ01Y¯01 − αˆ00Y¯00
1− αˆ10 − αˆ01 (4.11)
where αˆzt is the estimated proportion receiving treatment t conditional on being randomly
allocated to receive treatment z and Y¯zt is mean outcome given that Z = z and T = t.
Cuzick et al. (1997) followed a similar approach to that above in order to provide an
estimator for evaluating the effect of treatment receipt on a binary outcome (motivated
in this case by the effect of breast cancer screening on mortality) when addressing
non-compliance and contamination. The estimator they developed was for a risk ratio.
The standard error for the estimator E-IV5 can be calculated by bootstrapping. The
causal parameter and its standard error can also be estimated in a regression framework
using the Bloom IV estimator (here referred to as estimator E-IV6), or the IV(2SLS)
method as described in Section 4.4.2 (estimator E-IV7).
Dose-response relationships for continuous treatment receipt
Where there is continuous treatment receipt in the control arm (and a measure of it)
and no observed treatment non-compliance, it is possible to estimate the causal effect of
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treatment on outcome. First, it is necessary to state the causal assumptions needed for
the specification of the causal parameter. These are:
C1. Monotonicity (Di(R = 1)≥ Di(R = 0)), i.e. there is nobody who would receive a
larger dose if allocated to control compared to what they would receive if allocated
to treatment;
C2. Linear dose-response model:
(a) Yi(R = 0) = Yb +γDDi(R = 0)+τi , where Yb = µi + ei (µi is baseline outcome
and may be a function of some baseline covariates), τi is the error term, and
Di(R = 0) ranges from 0 to a maximum dose of g;
(b) Yi(R = 1) = Yb +λDDi(R = 1)+εi , where Yb = µi + ei (µi is baseline outcome
and may be a function of some baseline covariates), εi is the error term, and
Di(R = 1) ranges from 0 to to a maximum dose of g;
C3. No effect of random treatment allocation on outcome other than through the
exposure (the exclusion restriction):
E

εi −τi|Di(R = 1)− Di(R = 0) = 0
	
= 0




εi −τi|Di(R = 1)− Di(R = 0) 6= 0
	
= 0
C5. Exchangeability of potential dose and of potential patient outcome between levels
of random treatment allocation:
(a) Di(R = 1), Di(R = 0)⊥ Ri
(b) Yi(R = 1), Yi(R = 0)⊥ Ri
Under assumptions C1, C2, C3, C4 and C5b, the average causal effect for a participant
who would receive the full dose if offered it and would receive dose d0 when allocated
to the control condition (where the difference in potential doses is positive) is:
ACEd0 = E





λD g − γDd0|D(R = 1) = g, D(R = 0) = d0
	
= λD g − γDd0
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The term λD g is a constant that represents the maximum possible treatment effect when
control participants do not receive any treatment (d0 = 0). The causal parameter γd0
represents the change in treatment effect due to a one-unit increase in dose under offer
of control. This parameter is preceded by a minus sign which implies that the impact of
receiving greater doses of treatment under offer of control is to reduce the treatment
effect. Put another way, the more an individual is contaminated the less the benefit (or
harm) of treatment would have been.
Continuous dose of treatment in both control and active intervention arms
Where there is a continuous dose of treatment in both the control and active intervention
arms, the average causal effect if a participant receives a particular dose of treatment
can be defined using assumptions C1, C2, C3, C4 and C5b:
ACEd1,d0 = E





λDd1 − γDd0|d0 ≥ 0, d1 > d0
	
= λDd1 − γDd0
where d0, d1 = {0,1, ..., g} with d1 ≥ d0. The motivation for defining the estimand in
this way is to divide the latent compliers into subpopulations that are defined by what
dose of treatment a participant would receive under intervention and control. This
implies that the change in the causal parameters for a one-unit increase in dose when
offered treatment is ACEd1+1,d0−ACEd1,d0= (λD(d1 + 1)− γDd0)− (λDd1 − γDd0) = λD.
In Table 4.4, which provides the causal parameters at different levels of d1 and d0, this
is equivalent to moving between rows (i.e. d1 to d1 + 1) at a particular value of d0.
The change in the causal parameter for a one-unit increase in dose under control is
ACEd1,d0+1−ACEd1,d0= (λDd1 − γD(d0 + 1))− (λDd1 − γDd0) = −γD. In Table 4.4 this is
equivalent to moving between columns (i.e. d0 to d0 + 1 at a particular value of d1).
If it is assumed that λD = γD = θ , then θ is the change in ACEd1,d0 as the difference in dose
under the two counterfactual situations increases by one unit. Assuming constant effects
of doses on potential outcomes (λ = γ) is reasonable under the assumption that potential
dose is exchangeable between levels of random treatment allocation (assumption C5a).
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Table 4.4: Grid of ACEd1,d0 at levels of dose when offered control (d0) or active inter-
vention (d1).
d0
0 1 2 3 . . . g
d1
0 0 – – – –
1 λ 0 – – –
2 2λ 2λ− γ 0 – –
3 3λ 3λ− γ 3λ− 2γ 0 –
...
g gλ gλ− γ gλ− 2γ gλ− 3γ 0
New estimator for ACEd1,d0 and correspondence with linear model
Observed outcome is expressed as whichever potential outcome is seen in the observable
world:
Yi =(1− Ri)Yi(R = 0) + RiYi(R = 1)
=(1− Ri)





Yb +λD(Di(R = 1)) + εi

=Yb + γDDi(R = 0) +τi − RiYb − RiγDDi(R = 0)− Riτi
+ RiYb + RiλD(Di(R = 1)) + Riεi
=Yb + γD(1− Ri)Di(R = 0) + RiλD(Di(R = 1)) + (1− Ri)τi + Riεi
=Yb + γDD0 +λDD1 + (1− Ri)τi + Riεi (4.12)
The linear dose-response model is substituted for potential outcome between steps one
and two using assumption C2. In the final step, D0 is dose if R=0 and zero otherwise,
and D1 is dose if R=1 and zero otherwise. Assuming that γD = λD = θD under C5a,
θD represents the effect of dose on outcome among compliers. Further defining ηi =
((1− Ri)τi + Riεi), this means Equation 4.12 can be expressed simply as:
Yi = Yb + θDD +ηi (4.13)
where D = D0 + D1 is the observed dose under either condition. It is notable that this
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equation includes no parameters which describe the effect of treatment offer (randomi-
sation) on outcome. This is the impact of the assumption that the effect of treatment
offer on outcome is conducted entirely by dose (i.e. the exclusion restriction).
An unbiased estimate of the parameter θD cannot be obtained using an ordinary least
squares regression of Y on D. This is because the error term η is a function of D, i.e. D
is correlated with η and therefore endogenous. Despite this, the effect of D on Y can
be estimated because R is an instrument for D (assumptions A-I1 and A-I2). Therefore
Equation 4.13 can be expressed in the following expectations:
E[Yi|Ri] =Yb + θDE[Di|Ri] + E[ηi|Ri]
=Yb + θDE[Di|Ri]
Including a vector of baseline covariates, this would be expressed as:
E[Yi|Ri ,Xi] =Yb + θDE[Di|Ri ,Xi] + E[ηi|Ri ,Xi]
=Yb + θDE[Di|Ri ,Xi]
The causal parameter of the effect of dose on treatment effect can be estimated using
either the IV(2SLS) or IV(ATR) methods described earlier. The parameter estimated is the
change in treatment effect associated with a one-unit increase in dose. The dose-response
estimator for this causal parameter in the context of continuous dose of treatment in
both the control and active intervention arms is referred to here as E-IV8.
Missing outcome values
This section has described four estimators: E-IV5 (modified Bloom/ratio estimator with
proportions of observed compliers, non-compliers, contaminators, and non-contaminators
predicting outcome), E-IV6 (Bloom/ratio estimator), E-IV7 (2SLS estimator with binary
treatment receipt in both arms) and E-IV8 (2SLS with continuous measure of treatment
receipt in both trial arms). In a trial in which there are missing outcome data, estimators
E-IV6, E-IV7, and E-IV8 make the strongest assumptions regarding the missing data
generating mechanism. They assume that the probability of missingness is unrelated to
the values of missing data (i.e. Pr(N |Yo, Ym) = Pr(N |Yo)); this is assume that missing data
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are MAR. Estimator E-IV5 makes a less restrictive missingness assumption as it allows ob-
served compliance and contamination to predict it (Pr(N |Yo, Ym, C , K) = Pr(N |Yo, C , K)).
Multiple imputation, as described in Section 4.4.2, can be employed to allow predictors
of missingness (including observed compliance and contamination), thereby relaxing the
assumptions of the estimators described in this section.
Summary
The instrumental variable methods that I have derived in this section provide a flexible
approach for estimating the causal effect of treatment receipt using a semi-parametric
model. They are capable of accounting for treatment non-compliance and contamina-
tion and allow manifest baseline variables to predict treatment receipt, outcome, or
missingness of outcome. The causal effect of treatment receipt and its precision can be
estimated using the Bloom or 2SLS estimators. In this section I have extended existing
methodology for estimating the change in causal treatment effect for a one-unit increase
in the difference of potential dose, where there are continuous measures of treatment
receipt in both intervention and control trial arms.
4.6 Discussion
This chapter began with a statement about the challenges of conducting RCTs in mental
health. Trials in this area of medicine often test complex interventions where there is
scope for appreciable non-adherence with treatment regimen. It is not a strong statement
to assume that the phenomenon of non-adherence is likely to be linked to drop-out from
data collection and therefore estimators that address non-adherence must be capable of
handling a variety of missingness assumptions.
Two types of efficacy estimand were defined. The first, ATE, is the effect of observable
treatment receipt on outcome. This could be estimated using the as-treated estimator.
It was shown that this estimator is unbiased only under the assumption that potential
outcome is exchangeable between levels of observed treatment receipt. This is also
true of the per protocol estimator, which estimates ATT. Exchangeability is a strong
assumption because of the likelihood of confounding, given that these estimators throw
away the protection of randomisation. The second type of efficacy estimand involves
a conceptual leap into the world of potential outcomes. For binary treatment receipt,
CACE is the effect of treatment amongst a subpopulation who would receive treatment
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when offered it and would not when offered the comparator treatment. ACEd1,d0 was
defined as the causal effect of some difference in potential dose on outcome amongst that
subpopulation where potential dose is greater under offer of intervention than control.
CACE can be estimated using a stratification estimator (under the framework of principal
stratification) or an IV estimator. These estimators make very similar sets of assumptions
regarding the data. In mental health trials, where many treatments cannot be kept
blind, the most problematic of these is the exclusion restriction. This may be particularly
vulnerable in trials of interventions where it is possible that simply the offer of treatment
may lead to participants altering their behaviour. If this were to happen it would open
a pathway from random treatment allocation to outcome that does not go through
treatment receipt (and would lead to bias).
I have described the development of a novel consistent estimator for ACEd1,d0 . This
extension of the method of Maracy and Dunn (2011) allows the estimation of efficacy
where there is both non-compliance and contamination. This estimator relies on similar
assumptions to those when treatment receipt was a binary measure together with an
assumption regarding the shape of the relationship between dose and effect. The parame-
ter is interpreted as the causal effect of treatment associated with a one-unit increase in
the difference in dose between the counterfactual worlds. It may improve interpretability
if this parameter were converted into the ATE at a particular level of this difference in
potential dose. For example, it could be converted into the causal effect at the maximum
difference. This might be of interest where treatment receipt is a measure of therapy
session attendance. This would inform patients and clinicians what they might expect to
be the maximal effect of treatment.
Comparing the utility of the stratification and IV estimator types, only the former class is
able to make the assumption of LI (the weakest missingness assumption). A comparison
between estimators making various LI and MAR assumptions and a discussion of their
relative merits is particularly important in the efficacy analysis of a trial. The other major
point of note when comparing the estimator types is that currently only the IV estimators
have been developed to handle continuous measures of treatment receipt. There is
potentially some opportunity for likewise development of the stratification estimators.
As mentioned in Chapter 1, the randomisation-based efficacy estimators in effect swap
the bias of the ITT approach (if we define this as a biased estimator of efficacy) for
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variance inflation. This implies a limitation in the model for the CACE estimator: it is not
identifying who the latent compliers are, it is simply using an estimate of their relative
frequency. The stratification and IV estimators can be made considerably more powerful
by the inclusion of predictors of treatment receipt. This has trial design implications
regarding the selection of variables at baseline. For instance, it is worth considering
whether to ask participants at this point how enthusiastic they are to receive treatment
(such a measure would likely be predictive of latent class membership).
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Chapter 5
Monte Carlo simulation study
comparing two trial design options
for addressing contamination
5.1 Background and aims
This thesis aims to evaluate methods for estimating efficacy in trials of complex interven-
tions with contamination. Specifically, it aims to inform trialists and funders about the
best trial design to facilitate efficacy assessment in the presence of contamination.
I have described two prominent design methods for addressing the problem of con-
tamination in trials that target treatment efficacy. The first, which was shown to be
common in the scoping review in Chapter 2, is to use cluster randomisation together
with an estimator of ATE that accounts for clustering of outcome data. Provided that
clusters are defined at the level at which contamination is thought to occur, this option
prevents contamination by design and estimates efficacy. I refer to this as design option
A throughout this chapter. The second design option is to allocate treatment randomly
to individuals, accept that contamination will take place, measure treatment receipt for
all participants, and then use a randomisation-based estimator of efficacy as captured by
a local estimand such as CACE. I refer to this as design option B. This chapter aims to
compare the statistical performance of these two approaches and therefore addresses
the primary research objective of this project.
Existing theory suggests that estimator E-ITT under design option A is consistent for
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ATE provided that selection, attrition and assessment biases can be avoided in the CRCT.
Estimators of efficacy under design option B were summarised and developed in Chapter
4. In particular, estimators E-IV7 and E-IV8 provide consistent estimation of CACE (binary
treatment receipt) and ACEd1+1,d0−ACEd1,d0 (continuous treatment receipt), respectively.
In this chapter I use simulation techniques to evaluate the relative efficiency of the two
designs. This builds upon the work by Keogh-Brown et al. (2007) which compared
similar designs, although they did not explicitly target treatment efficacy (the research
was described in Chapter 1). Their results suggested that the relative efficiency of the
design options was driven by strength of clustering and amount of contamination. The
results indicated that at a low strength of clustering and large amount of contamination
design option A was favoured. However, the research simulated only a very small number
of trial scenarios and fixed the ICC at a single level. In addition they compared sample
sizes required to achieve a certain level of power rather than assessing the performance
of the estimators at a range of sample sizes.
This chapter will simulate plausible trials of complex interventions in mental health
using parameter values suggested by relevant datasets (the D6, CONMAN, REFOCUS
and systematic assessment of care needs trials, and the results of the scoping review).
The chapter targets the contamination process that was found to be most common in
Chapter 2, which was clinicians being trained in both treatments under examination and
then providing the active treatment to those in the control arm. The chapter is organised
in two sections, a simulation substudy where contamination is measured on a binary
scale and a second substudy where contamination is measured on a continuous scale
(i.e. dose of treatment). The first substudy, but not the second one, will also investigate
the impact on the relative efficiency of the two design options of the presence of never
takers (stratum observed as non-compliers in the treatment arm). I will use simulation
to evaluate the statistical properties of relevant efficacy estimators for data generated
under designs A and B.
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5.2 Simulation study 1: Binary measure of treatment receipt
under design option B
5.2.1 Contamination process in therapy trial
The imagined scenario is a trial evaluating a new therapy in addition to treatment as
usual (TAU) therapy against TAU alone. Both therapies are delivered by a set of therapists.
In this first simulation substudy receipt of therapy is binary. That is to say a patient either
receives the active condition (T = 1) or not (T = 0). It is not possible for patients to
receive therapies other than those tested in the trial. In other words not receiving the
active condition implies receipt of the control condition and vice versa.
Clustering
Post-randomisation outcomes of patients treated by the same therapist (therapist clusters)
may be correlated as a result of the following processes:
• Cluster-level variables affect the level of outcome: the therapists have catchment
areas from which their patients would be recruited and patients from the same
catchment area share the cluster environment (e.g. area deprivation). In addition,
characteristics of accessible patient populations might differ between such therapist
clusters (e.g. the patient population potentially being treated by a female therapist
may include a larger proportion of females). Thus baseline outcomes are cluste-
red at the level of the therapist and this clustering will persist in post-treatment
outcomes to some extent.
• Cluster-level variables affect the change in outcome under the control condition: it
is possible that under therapist-delivered TAU, disease progression is more similar
between patients who share the same therapist than between those who do not
due to shared cluster environments (e.g. facilities in clinic, interaction with the
same therapist) or characteristics of patient populations.
• Cluster-level variables affect the size of the intervention response: it is possible
that the treatment response, that is the difference in change over time under the
control and the active treatment, is more similar between patients treated by the
same therapist due to shared cluster environments (e.g. clinic where treatment
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takes place, interaction with the same therapist) or characteristic of the patient
population.
To reflect this two-level population structure – patients are nested in therapist catchment
area clusters – I use the subscript j to label the clusters and the subscript i to label the
patients within the j th cluster.
Non-compliance and contamination
The process whereby non-compliance or contamination is thought to take place is ther-
apists being trained in both therapies, and the patient either not receiving a sufficient
dose when offered active therapy (non-compliance with active condition T (R = 1) = 0),
or receiving a sufficient dose when offered control therapy (contamination of control
condition T(R = 0) = 1). Therapists’ being trained in both therapies may or may not
lead to participants receiving a sufficient dose. This is to say that treatment receipt
varies within therapist clusters. For simplicity it is assumed that if therapists were only
trained in delivering one or the other therapy then their patients would always receive
the therapy that was offered to them (i.e. no contamination or non-compliance). Thus
the patient population can be partitioned into four strata according to the therapy they
would receive from a therapist who is trained in both conditions as follows:
• Compliers (S = 1): Receive therapy when active condition is offered and receive
control therapy when the control condition is offered [T (R = 1)− T (R = 0) = 1],
• Never takers (S = 2): Do not receive active therapy under either offer [T (R = 1) =
T (R = 0) = 0],
• Always takers (S = 3): Receive active therapy irrespective of offer [T(R = 1) =
T (R = 0) = 1],
• Defiers: Receive control therapy when active condition is offered and receive active
therapy when the control condition is offered [T (R = 1)− T (R = 0) = −1].
It is assumed that there are no defiers in the patient population and I define the following
relative sizes of the subpopulations: p1 = Prob(Complier), p2 = Prob(Never taker) and
p3 = Prob(Always taker), p1 + p2 + p3 = 1.
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Simulation hypotheses
I made the following predictions regarding the statistical performance of the competing
design options under this contamination process:
1. A cluster randomised trial design (design option A) with therapy allocated at
the level of the therapist and the therapist trained in only one of the therapies,
and analysed using estimator E-ITT (intention-to-treat estimator) will provide an
unbiased estimate of efficacy formalised by ATE.
2. An individual randomised trial design (design option B) with the therapist delive-
ring both therapies, treatment receipt measured and analysed using the as-treated
estimator will provide a biased estimate of efficacy.
3. The magnitude of the bias of the as-treated estimator (design option B) will be
driven by parameters determining the strength of hidden confounding.
4. An individual randomised trial design (design option B) with the therapist deli-
vering both therapies, treatment receipt measured and analysed using estimator
E-IV7 (two stage least squares estimator) will provide an asymptotically unbiased
estimate of efficacy formalised by CACE.
5. The relative efficiency of the two competing approaches will be driven by parame-
ters describing the population cluster structure and those determining the strength
of respective instrumental variables.
5.2.2 Data generating models
The simulation study mimicked the clustered structure of the target population before
any trial took place, and simulated observed post-treatment outcomes under two trial
design options:
A. Cluster randomisation at the level of the therapist with the therapist only trained
in one of the competing therapies.
B. Individual level randomisation with therapists being trained and delivering both
competing therapies; measurement of binary therapy receipt for each participant.
Data resulting from either trial design were then analysed using the respective estimation
approach.
123
I proceeded in the following steps:
1. Simulation of the distribution of outcome in the target population before any
intervention took place (baseline outcome);
2. Simulation of four potential post-intervention outcomes in the target population:
• Outcome that would be observed if patients were offered the control condition
(i.e. R = 0) and were treated by a therapist who is only trained in that therapy
(i.e. Q = 0), that is I simulated Y (R = 0,Q = 0),
• Outcome that would be observed if patients were offered the control condition
and were treated by a therapist who is trained in both therapies (i.e. Q = 1),
that is I simulated Y (R = 0,Q = 1),
• Outcome that would be observed if patients were offered the active condition
and were treated by a therapist who is only trained in that therapy, that is I
simulated Y (R = 1,Q = 0),
• Outcome that would be observed if patients were offered the active condition
and were treated by a therapist who is trained in both therapies, that is I
simulated Y (R = 1,Q = 1);
This allowed me to define individual therapy offer effects (IREs) under both treat-
ment delivery options as the contrasts:
• If the treatment was delivered as planned under trial design A: IREA :=
Yi j(R = 1,Q = 0)− Yi j(R = 0,Q = 0),
• If the treatment was delivered as planned under trial design B: IREB :=
Yi j(R = 1,Q = 1)− Yi j(R = 0,Q = 1);
3. Simulation of the patient sampling and treatment allocation implied by trial design
options A and B, and mapping of potential outcomes onto observed Y under the
design options;
4. For each data set generated under design options A or B respectively I calculated
the proposed estimator and its SE. I repeated the process to determine the sampling
distributions of the estimators.
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Step 1) – Baseline outcome
Baseline outcome Y0,i j had a hierarchical structure as it was made up of a random variable
that varied at the level of the individual, "i j , and another random variable that varied at
the level of the therapist cluster, v j . For convenience I scaled var(Y0,i j) = 1.
I generated Y0,i j := ei j + v j with ei j ∼ N(0, 1−ρ) and independently v j ∼ N(0,ρ).
Here parameter ρ ∈ [0, 1] denotes the intraclass correlation coefficient (ICC1) measuring
the proportion of variance in Y0 that was due to factors that varied at the therapist
catchment area level.
Step 2) – Potential post-intervention outcomes
To start with I generated the three strata of patients according to the therapies they
would receive from a therapist who is trained in both conditions (Q = 1):
Si j ∼Mu[(p1, p2, 1− p1 − p2), 1]
It then followed that under design option B,
Ti j (R = 0) =
 0 if Si j = 1 or Si j = 21 if Si j = 3 and Ti j (R = 1) =
 0 if Si j = 21 if Si j = 1 or Si j = 3
I then generated the four potential post-treatment outcomes.
Potential outcome Yi j(R = 0,Q = 0):
This is the outcome that would be observed if patients were offered the control condition
and were treated by a therapist who is only trained in that therapy and is given by:
Yi j(R = 0,Q = 0) := αY0,i j + "i j +ω j with "i j|S = s ∼ N[µs, 1 − α2 − ξ − g] and
independently ω j ∼ N(0,ξ).
For simplicity it was assumed that the mean did not change over time under the control
condition, i.e. E[Yi j(R = 0,Q = 0)] = 0. Parameter α ∈ [0,1] was the effect of baseline
on post-intervention outcome.
Parameter ξ ∈ [0, 1] denotes the intraclass correlation coefficient (ICC2) measuring the
proportion of variance in baseline-adjusted Yi j(R = 0,Q = 0)−αY0,i j that is due to factors
that varied at the therapist level.
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Random variable "i j represents variables that explain variability in change over the
treatment period. Such variables can include post-randomisation variables and can thus
be affected by (pre-randomisation) stratum membership. Thus I allowed their mean to
depend on stratum membership, i.e. E("i j|S = s) = µs with E("i j) = p1µ1+p2µ2+p3µ3 =













3. It was assumed that the outcome
variance was not increased under the control condition, i.e. var[Yi j(R = 0,Q = 0)] =
var(Y0,i j) = 1. And to ensure that this held I set var("i j) = var("i j|S) + g = 1−α2 − ξ.
Potential outcome Yi j(R = 0,Q = 1):
This is the outcome that would be observed if patients were offered the control condition
and were treated by a therapist who is trained in both therapies. It can be affected by
treatment that is actually received in this situation, T (R = 0).
I generated Yi j(R = 0,Q = 1) := αY0,i j + βTi j(R = 0) + "i j +ω j .
Here parameter β represents the effect of receiving the therapy. Such contamination
can increase the variance in the presence of always takers since var[Yi j(R = 0,Q = 1)] =











The expression for the covariance between the error term and treatment receipt under
offer of control was found as follows:
cov["i j , Ti j(R = 0)] = E["i j Ti j(R = 0)]− E["i j]E[Ti j(R = 0)]
= p3E["i j|Ti j(R = 0) = 1]−

p3E["i j|Ti j(R = 0) = 1]+














Potential outcome Yi j(R = 1,Q = 0):
Next is the outcome that would be observed if patients were offered the active condition
and were treated by a therapist who is only trained in that therapy. This is given by
Yi j(R = 1,Q = 0) := αY0,i j + γ+ "i j +ω j +τi j(Q = 0) with τi j(Q = 0)∼ N(0,ϑ)
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Here parameter γ = E{IREA}, i.e. this parameter was the causal effect of treatment
receipt, ATE. The added error term τi j(Q = 0) introduced treatment effect heterogeneity
in that var{IREA} = var{τi j(Q = 0)} = ϑ. Such treatment effect heterogeneity is allowed
to increase the variance of the post-treatment outcome under active condition compared
to that under the control condition; specifically var[Yi j(R = 1,Q = 0)] = 1 + ϑ. (For
simplicity I assumed that this latest error term did not include therapist effects.)
Potential outcome Yi j(R = 1,Q = 1):
Finally, the outcome that would be observed if patients were offered the active condition
and were treated by a therapist who is trained in both therapies. This can also be affected
by the treatment that was actually received in this situation, T(R = 1). The potential
outcome was modelled,
Yi j(R = 1,Q = 1) := αY0,i j + βTi j(R = 1) + "i j +ω j +τi j(Q = 1)
Here parameter β again represents the effect of receiving the active condition (it models
non-compliance). The error term τi j(Q = 1) also represents treatment effect hetero-
geneity, but this time under treatment delivery by therapists who are trained in both
therapies (Q = 1). Under such treatment delivery the population can contain never
takers (S = 2) and always takers (S = 3) as well as compliers (S = 1). It was assumed
that the expected error term within a stratum was zero; i.e. E

τi j(Q = 1)|S = s

= 0,
that is random treatment effect variability within a stratum. This implies two exclu-
sion restriction assumptions as follows for never takers, E

Yi j(R = 1,Q = 1)− Yi j(R =
0,Q = 1)|S = 2	 = Eτi j(Q = 1)|S = 2	 = 0, and for always takers, EYi j(R = 1,Q =




τi j(Q = 1)|S = 3
	
= 0. In words, the offer of treatment
is assumed not to have a (mean) effect on outcome for never takers or always takers.
From this also follows that CACE = E






τi j(Q = 1)|S = 1
	
= β .





= p1(β − p1β)2 + p2(0− p1β)2 + p3(0− p1β)2 =
(1− p1)p1β2 (proof below). It was assumed that an individual’s treatment effect relative
to the stratum mean does not depend on the therapist’s training and this ensured that
the total treatment effect heterogeneity was the same for both delivery options, that












= p1(β − p1β)2 + p2(0− p1β)2 + p3(0− p1β)2
= p1(β
2 − 2p1β2 + p21β2) + p2(p21β2) + p3(p21β2)
= p1β
2 − 2p21β2 + p31β2 + p2p21β2 + p3p21β2
= β2(p1 − 2p21 + p31 + p2p21 + p3p21)
= p1β
2(1− 2p1 + p21 + p2p1 + p3p1)
= p1β
2(1− 2p1 + p1(p1 + p2 + p3))
= p1β
2(1− 2p1 + p1) = p1β2(1− p1)
Step 3) – Observable trial data
Next, the generation of trial data was mimicked under either trial design. Let n denote the
trial sample size and k the number of patients recruited from each therapist catchment
area. A trial sample was generated of n patients and m therapists (k = n/m patients
per therapist catchment area) by first randomly sampling m units at the therapist level
and then randomly sampling k patients for each of the selected catchment areas. Under
either design baseline outcome Y0,i j was measured for i = 1, ..., k; j = 1, ..., m.
Under trial design option A treatment offer was randomly allocated at the level of
the therapist with 50:50 allocation ratio captured by binary variable R(A), j (with levels
1=“active”, 0=“control”). The allocation ratio was fixed at exactly 50:50 (or as close
as possible to this if there was an odd number of clusters). This led to therapists being
nested within trial arms. Observed post-randomisation outcomes could then be generated
by mapping values onto respective potential outcomes under design A:
Y(A),i j := R(A), jYi j(R = 1,Q = 0) + [1− R(A), j]Yi j(R = 0,Q = 0)
Note that post-randomisation outcome Y(A),i j has a hierarchical structure due to incorpo-
rating two clustered variables: (i) the baseline levels of the outcome and (ii) change in
the outcome under the control condition (natural progression).
The set of variables available for analysis under trial design A was then given by: Y0,i j,
R(A), j and Y(A),i j .
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In contrast, under trial design option B treatment offer was randomly generated at the
patient level. Stratified randomisation (here the stratum is the therapist) was used to
ensure that half the patients of a therapist received either treatment offer (in 50:50
allocation ratio). This allocation was captured by variable R(B),i j (with levels 1=“active”,
0=“control”). This type of randomisation led to therapists being crossed with trial arms
(and consequently having to be trained in both therapies). Again, clustered observed post-
randomisation outcomes were generated by mapping values onto respective potential
outcomes under design B:
Y(B),i j := R(B),i jYi j(R = 1,Q = 1) + [1− R(B),i j]Yi j(R = 0,Q = 1)
Design option (B) further stipulated that binary treatment receipt T (with levels 1=“re-
ceived” and 0=“not received”) was measured. Thus to produce this observable variable,
potential treatment receipt was mapped as such:
Ti j = R(B),i j Ti j(R = 1) + [1− R(B),i j]Ti j(R = 0)
The set of variables available for analysis under trial design (B) was then given by: Y0,i j ,
R(B),i j , Ti j and Y(B),i j .
Step 4) – Efficacy estimators
Design A: ITT maximum likelihood estimator with random intercept for cluster (therapist).
This estimator, without the random effect, was referred to in the estimation methods
chapter as estimator E-ITT (Section 4.3.1). The estimator included baseline outcome
as a covariate in order to reflect the fact that this was strongly related to outcome at
follow-up. A random intercept was needed in order to allow for correlations within
therapist clusters (this approach was described in Section 4.4.2).
Design B1: As-treated maximum likelihood estimator of outcome on treatment receipt
with random effect for cluster (therapist). This estimator, without the random effect, was
described in Section 4.3.2. The estimator included baseline outcome as a covariate in
order to reflect the fact that this was strongly related to outcome at follow-up. A random
intercept was needed in order to allow for correlations within therapist clusters (this
approach was described in Section 4.4.2).
Design B2: Generalised 2SLS estimator with random effect for cluster (therapist). This
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model, without the random effect, was referred to previously as estimator E-IV7 (Section
4.5.2). The estimator included baseline outcome as a covariate in both stages in order to
reflect the fact that this was strongly related to outcome at follow-up. A random intercept
was needed in order to allow for correlations within therapist clusters (this approach
was described in Section 4.4.2).
5.2.3 Simulation study design
Seven simulation parameters were varied and three were held constant. I investigated
all combinations (4,752 trial scenarios) of these parameters and used 1000 iterations
per scenario. A list of input parameters and their levels is given in Table 5.1.
Table 5.1: Summary of input levels of simulation parameters when simulating a binary
measure of treatment receipt.
Parameter Description Levels of parameter
Sample size (n) 100; 200; 500; 1000
Treatment effect: β CACE (design option B) 0.2; 0.5; 0.8
Treatment effect: γ ATE (design option A) 0.2; 0.5; 0.8
ICC2 (ξ) Level 2 clustering; due to
variance at level of therapist
0.01; 0.02; 0.05; 0.10
Size of clusters (k) 5; 10; 20
µ2 −µ2 and µ3 −µ1 Confounding due to
non-adherence
0.2; 0.5; 0.8
Strength of instrument (p1) This is also the proportion of
latent compliers
0.4; 0.5; 0.6; 0.7; 0.8; 0.9
Proportion of never takers
(p2)
This is also the proportion of
non-compliers within the active
intervention arm
0; 0.2
α Effect of outcome at baseline on
outcome at follow-up
0.7
ICC1 (ρ) Level 2 clustering; due to





This is the variance of IREA 0.2
Number of trial scenarios: 4 sample sizes, 3 treatment effect sizes, 4 intraclass correlation
coefficients (ICC2), 3 cluster sizes, 3 magnitudes of confounding, 6 strengths of instrument with
no treatment non-compliance, 5 strengths of instrument with a typical amount of treatment
non-compliance, i.e. 4,752 trial scenarios.
Those parameters that were varied were sample size (to study estimators’ asymptotic be-
haviour), treatment effect size, ICC2, cluster size, confounding bias due to non-adherence
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(design option B), strength of IV (design option B), and proportion of never takers (design
option B). Confounding bias was varied in order to assess its predicted impact on the
as-treated estimator (design option B1; this was simulation hypothesis 3). ICC2, cluster
size and strength of IV were varied in order to assess their anticipated impact on the
relative efficiency of the design options A and B2 (simulation hypothesis 5). I selected
two levels of the proportion of never takers in order to investigate whether there was
any impact of the presence of non-compliance on the relative efficiency of these design
options. The levels that I chose for these parameters were as follows.
• Sample size was varied (n=100, 200, 500, 1000). These levels reflected the range
of sample sizes that were observed in the systematic review (median 186, IQR
100-372). This choice also reflected the range of sample sizes in the four mental
health trial datasets that partly motivated this research (Marshall et al., 2004;
Weaver et al., 2014; Slade et al., 2015; Ismail et al., 2018). The range of sample
sizes in these trials was 210 to 403.
• Two target parameters: β (CACE) and γ (ATE). For simplicity ATE was assumed to
be the same as CACE, irrespective of whether the therapist was trained in one or
both treatments. Three levels of standardised effect sizes (β and γ) were selected:
small (0.2), medium (0.5) and large (0.8).
• Strength of clustering in outcome: Clustering was driven by ICC1 (see below)
and ICC2 for the data generating models. A realistic range of levels for ICC2 was
chosen. This was based on the results of the systematic review and four mental
health trial datasets research (Marshall et al., 2004; Weaver et al., 2014; Slade
et al., 2015; Ismail et al., 2018). The systematic review found a median ICC of
0.05 and interquartile range of 0.03-0.09. The ICCs for primary outcomes in the
motivating datasets ranged from <0.001 to 0.1. Based on this and the systematic
review, four levels of ICC were selected: 0.01, 0.02, 0.05, 0.1.
• Cluster size: the levels of cluster size were chosen to represent realistic trials of
complex interventions within the context of mental health. The systematic review
suggested a median of 10 and interquartile range of 6-27. Mean cluster sizes in
the four motivating mental health trial datasets ranged from 4 to 18 (Marshall
et al., 2004; Weaver et al., 2014; Slade et al., 2015; Ismail et al., 2018). These
numbers were rounded to some extent in order for all clusters to be complete at
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all the levels of sample size listed earlier. Therefore three levels were chosen: 5,
10, 20.
• Hidden confounding of the treatment effect under design option B was driven by
µ’s (stratum effect on treatment-free outcome). I considered µ2 − µ1 “strength
of confounding due to non-compliance with active treatment offer” and µ3 −µ1
“strength of confounding due to contamination of the control treatment offer”.
Since they represented standardised effects of S, I chose small (d = 0.2), moderate
(d = 0.5) and large (d = 0.8) differences.
• Strength of IV R under design option B: the IV assumptions for R were implemented
by all of the effect of R on Y being through T , by R being unrelated to unobserved
confounders, and by assuming there were no defiers when constructing T (R = 1)
and T(R = 0). The strength of R as an IV was measured by p1 (proportion of
latent compliers). Parameter p1 was varied from 0.4 to 0.9, in steps of 0.1. This
was consistent with the results of the systematic review which found a median
proportion of the control group receiving intervention (contamination) of 0.13
(IQR 0.05-0.33), with a few outlying values around 0.6. When there was some
non-compliance (see below), the maximum strength of IV was adjusted so that it,
added to the proportion of non-compliance, did not rise above one.
• Proportion of never takers under design option B: the proportion of never takers
was also the proportion of those within the active intervention arm who did not
receive intervention (i.e. non-compliers). I chose two levels of p2: 0, 0.2. I.e. no
non-compliance (which ensured that design options A and B were comparable)
and a typical level of it (see DiMatteo, 2004; Nose et al., 2003).
Those parameters that were held constant were the effect of outcome at baseline on
outcome at follow-up, ICC1 and the treatment heterogeneity. These were set as follows.
• Effect of outcome at baseline on outcome at follow-up: α. This parameter was
fixed at a level that implied that outcome measured at baseline and follow-up were
strongly related. This parameter was set to 0.7.
• Clustering due to ICC1 could be removed by the estimators, which covaried on
baseline outcome. ICC1 was set to 0.1.
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• Treatment heterogeneity: Note that in the plan described earlier, the variance of





, where w was a factor affecting the variance of
τi j(Q = 0). This implied a restriction that (1− p1)p1β2 < ϑ. Theta was set to 0.2
as this was the lowest (round) level that could be sustained given the levels of p1
and β .
Sampling distribution of estimates:
For each trial scenario, output was saved from the 1000 simulated datasets. The following
output was saved for each trial scenario in order to assess the sampling distribution of
the estimates:
• Mean of the estimates,
• Median,
• SD of the mean (i.e. the true SE for the sampling disribution; also known as the
empirical SE (EmpSE)),
• Minimum,
• Lower 2.5 percentile,
• 25th percentile,
• 75th percentile,
• Upper 2.5 percentile,
• Maximum,
• Proportion of simulations where associated 95% CI includes true efficacy estimand
(“nominal confidence level”).
Properties of estimator:
The following output was saved in order to explore properties of the estimators:
• Bias = E[γˆ]− γ for option A; E[βˆ]− β for options B1 and B2,
• Mean SE of estimator (i.e. the estimated SE),
• Mean t-statistic,
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• Monte Carlo standard error (MCSE) = EmpSEp
2(nsim−1) , where nsim is the number of
simulation iterations.
Comparison of estimators:
In order to calculate the relative efficiency of the estimators under design options A and
B2, I generated the ratio of their SEs:
• Ratio of SEs = SE from option A / SE from option B2.
5.2.4 Simulation findings
I have split the results from the simulations into three parts: an investigation of the
bias of the estimators under designs options A, B1 and B2, an assessment of the model-
based SE compared to true SE (for the unbiased estimators), and an evaluation of the
relative efficiency of the unbiased estimators using the true SEs. The assessment of bias
provides results for simulation hypotheses 1-4, and the relative efficiency of the unbiased
estimators gives results for hypothesis 5.
Bias
The results of the Monte Carlo simulations showed that the ITT estimator (named earlier
E-ITT), which was the estimator of efficacy under design option A, was an unbiased
estimator of ATE (parameter γ in these data simulations). Mean absolute bias of this
estimator in the scenario in which there was no non-compliance in the intervention arm
is shown in Table 5.2. The table summarises bias to three decimal places by levels of
sample size and strength of confounding. It shows that there was negligible bias at all
levels of these variables.
Table 5.2: Absolute bias of ITT estimator (option A) rounded to three decimal places,
with binary treatment receipt and no non-compliance in the intervention arm. Results
were averaged over cluster sizes and magnitudes of treatment effect sizes.
Sample size Strength of confounding
0.2 0.5 0.8
100 0.000 −0.001 0.000
200 0.000 0.000 0.000
500 0.000 0.000 0.000
1000 0.000 0.000 0.000
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Mean absolute bias of the as-treated approach as an estimator of efficacy, which was part
of design option B1, is displayed in Table 5.3. The results are summarised by sample size,
strength of confounding, and proportion of compliers. There was considerable bias at
every level of these variables. The amount of bias appeared to be related to strength of
confounding and proportion of compliers, with the most when there was large amounts
of confounding and when the proportion of compliers was low.
Table 5.3: Absolute bias of as-treated estimator (option B1) rounded to three decimal
places, with binary treatment receipt and no non-compliance in the intervention arm.




0.4 0.5 0.6 0.7 0.8 0.9
100
0.2 0.150 0.134 0.115 0.093 0.068 0.038
0.5 0.377 0.337 0.289 0.232 0.171 0.093
0.8 0.606 0.538 0.462 0.374 0.273 0.149
200
0.2 0.151 0.134 0.117 0.094 0.068 0.037
0.5 0.378 0.336 0.289 0.234 0.170 0.094
0.8 0.604 0.538 0.463 0.376 0.272 0.149
500
0.2 0.151 0.134 0.116 0.094 0.069 0.037
0.5 0.378 0.336 0.289 0.235 0.170 0.093
0.8 0.604 0.539 0.463 0.376 0.272 0.150
1000
0.2 0.152 0.135 0.116 0.094 0.068 0.037
0.5 0.378 0.337 0.290 0.235 0.171 0.094
0.8 0.605 0.539 0.463 0.376 0.273 0.150
Mean absolute bias of the IV estimator (named earlier E-IV7) as an estimator of efficacy
(CACE, parameter β in this chapter), which was part of design option B2, is shown in Table
5.4. Results are summarised by sample size, strength of confounding, and proportion of
compliers. Bias was very small at all levels of these variables. This demonstrated that it
was consistent for all levels of confounding.
The as-treated estimator was dropped because of the clear evidence of bias. The asympto-
tically unbiased estimators (E-ITT and E-IV7) were investigated further. The next section
will compare the model-based SE with the true SE for these two estimators.
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Table 5.4: Absolute bias of IV estimator (option B2) rounded to three decimal places,
with binary treatment receipt and no non-compliance in the intervention arm. Results




0.4 0.5 0.6 0.7 0.8 0.9
100
0.2 −0.004 −0.003 −0.002 −0.002 −0.001 0.000
0.5 −0.009 −0.007 −0.001 −0.004 −0.001 0.000
0.8 −0.012 −0.009 −0.007 −0.004 −0.001 −0.001
200
0.2 −0.002 −0.002 0.001 −0.001 0.000 −0.001
0.5 −0.004 −0.004 −0.002 −0.002 0.000 0.001
0.8 −0.007 −0.007 −0.002 −0.001 −0.002 −0.001
500
0.2 0.000 0.000 0.000 0.000 0.001 0.000
0.5 −0.002 −0.002 −0.001 −0.001 −0.001 0.000
0.8 −0.005 −0.002 −0.002 −0.001 −0.001 0.000
1000
0.2 0.001 0.000 −0.001 0.000 0.000 0.000
0.5 −0.002 0.000 0.000 −0.001 0.000 0.000
0.8 −0.002 −0.001 −0.001 −0.001 −0.001 0.000
SE estimation
Summaries of the ratio between mean model-based SE and the true SE (the standard
deviation of the point estimates) showed that the two were very similar for estimator
E-ITT. At the smallest sample size of 100 participants, the model-based SE was roughly
10% smaller than the true SE. As sample size increased this ratio approached one. In
other words the model-based estimate of the SE was correct for estimator E-ITT for large
sample sizes. The ratio was unrelated to strength of confounding. Summaries of the
ratio, which are displayed by sample size and strength of confounding, are given in Table
5.5.
Summaries of the ratio between mean model-based SE and true SE showed that estimator
E-IV7 performed well. At the smallest sample size the model-based SE was a slight
underestimate of the true SE, but not to the same extent as for estimator E-ITT. As
sample size increased, so did the ratio, suggesting that the SE was consistent. However,
at the largest sample size the model-based SE was overestimated by roughly 3%. There
was little evidence of a relationship between this ratio and strength of confounding or
proportion of compliers. Summaries of this ratio, displayed by sample size, strength of
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Table 5.5: Model SE / true SE of ITT estimator (option A) rounded to three decimal
places, with binary treatment receipt and no non-compliance in the intervention arm.
Results were averaged over cluster sizes and magnitudes of treatment effect sizes.
Sample size Strength of confounding
0.2 0.5 0.8
100 0.899 0.901 0.897
200 0.946 0.947 0.944
500 0.978 0.974 0.975
1000 0.987 0.988 0.989
confounding and proportion of compliers, are shown in Table 5.6.
Table 5.6: Model SE / true SE of IV estimator (option B2) rounded to three decimal
places, with binary treatment receipt and no non-compliance in the intervention arm.




0.4 0.5 0.6 0.7 0.8 0.9
100
0.2 0.984 0.989 0.986 0.989 0.984 0.976
0.5 0.978 0.999 0.985 0.987 0.988 0.980
0.8 0.984 0.994 0.993 0.990 0.990 0.978
200
0.2 1.005 1.004 1.005 1.003 1.004 1.001
0.5 1.001 1.005 1.000 0.999 1.005 0.999
0.8 1.005 1.005 0.999 0.998 1.000 1.005
500
0.2 1.014 1.011 1.014 1.021 1.017 1.016
0.5 1.024 1.014 1.019 1.015 1.017 1.023
0.8 1.015 1.016 1.026 1.016 1.022 1.016
1000
0.2 1.034 1.025 1.023 1.024 1.029 1.020
0.5 1.026 1.034 1.027 1.025 1.025 1.031
0.8 1.026 1.028 1.027 1.022 1.017 1.016
Monte Carlo standard error
Summaries of the MCSE under design option A (estimator E-ITT) were always less than
0.01. I found that MCSE decreased with increasing sample size. Summaries of the MCSE,
which are displayed by sample size, are given in Table 5.7. The MCSE was small in
comparison to the estimator’s standard error.
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Table 5.7: Monte Carlo standard error for ITT estimator (option A) rounded to three







Summaries of the MCSE under design option B2 (estimator E-IV7) were always less
than 0.01. I found that MCSE decreased with increasing sample size and with increasing
proportion of compliers. Summaries of the MCSE, which are displayed by sample size
and proportion of compliers, are given in Table 5.8. The MCSE was small in comparison
to the estimator’s standard error.
Table 5.8: Monte Carlo standard error for IV estimator (option B2) rounded to three
decimal places, with binary treatment receipt and no non-compliance in the intervention
arm.
Sample size Proportion of compliers
0.4 0.5 0.6 0.7 0.8 0.9
100 0.009 0.007 0.006 0.005 0.004 0.004
200 0.006 0.005 0.004 0.003 0.003 0.003
500 0.004 0.003 0.003 0.002 0.002 0.002
1000 0.003 0.002 0.002 0.002 0.001 0.001
Relative efficiency
The efficiency of estimator E-ITT (design option A) relative to E-IV7 (design option
B2) is displayed in Table 5.9 for the scenario in which there was no treatment non-
compliance and in Table 5.10 for the scenario in which there was contamination and
non-compliance (20% of intervention arm did not receive treatment). Mean relative
efficiency is summarised by sample size, proportion of compliers, ICC, and cluster size.
Cells where the ratio was greater than one are shaded in grey. These cells indicate the
instances in which the SE of E-ITT is greater than that of E-IV7, i.e. the estimation of
efficacy under design option B2 is more precise.
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When there was no non-compliance, in general the results showed that the estimation of
efficacy under design option B2 was more precise than that under design option A when
the proportion of compliers was large, cluster size was high, and ICC was large. The
simulated trial scenarios provided a large range of efficiency ratios, from 0.397 to 2.062.
When the amount of contamination was very large (60%, i.e. proportion of compliers
of 0.4) design option A was favoured at every simulated level of cluster size and ICC.
At 50% and 40% contamination, design option A was almost always favoured, with the
exception of the largest levels of cluster size and ICC. When the amount of contamination
was 30%, design option A was favoured at most levels of cluster size and ICC, except
at the highest level of ICC. The picture was more mixed at 20% contamination. When
the amount of contamination was 10%, design option B2 was favoured at most levels
of cluster size and ICC. The exceptions to this were when ICC was very low (0.01) and
when both ICC was moderately low (0.02) and cluster size was also low.
When strength of clustering was low (small cluster size, or ICCs of 0.01 or 0.02), de-
sign option A was often favoured, apart from in some instances where the amount of
contamination was small. At moderate levels of either cluster size (10) or ICC (0.02 or
0.05) and when contamination was 30% or under, design option B2 was favoured in
roughly half the scenarios. For combinations of moderate to large cluster sizes (10 or
20) and ICCs (0.05 or 0.1), design option B was usually favoured when contamination
was 30% or under. Within levels of proportion of compliers, an increase in cluster size
was associated with a shift in the efficiency ratio towards option B (i.e. greater ratio).
The pattern of the increasing ratio became increasingly pronounced as ICC increased.
When there was some treatment non-compliance, the pattern was similar when comparing
the relative efficiencies of the two design options. The difference was that the proportion
of compliers was capped at 0.8, which was now indicative of no treatment contamination.
The meant that all the descriptions above were now true at 20 percentage points of
contamination lower than previously described. For example, it was stated previously
that at 30% contamination, design option A was favoured at most levels of cluster size
and ICC, except at the highest level of ICC. With 20% non-compliance, this statement
would be true at 10% contamination.
139
Table 5.9: Relative efficiency of design options A and B2, with no non-compliance in the intervention arm. Cells represent ratios of mean estimated
standard errors of design option A divided by design option B2. The results are summarised by sample sizes and proportions of compliers (rows), and
intraclass correlation coefficients and cluster sizes (k) (columns). Results were averaged over magnitudes of effect size and strength of confounding.
Sample size;
proportion of compliers
ICC=0.01 ICC=0.02 ICC=0.05 ICC=0.1
k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20
100
0.4 0.397 0.421 0.481 0.419 0.444 0.536 0.450 0.539 0.688 0.544 0.676 0.881
0.5 0.508 0.538 0.614 0.531 0.571 0.680 0.579 0.684 0.882 0.682 0.876 1.148
0.6 0.610 0.661 0.720 0.645 0.717 0.828 0.709 0.831 1.053 0.844 1.047 1.381
0.7 0.720 0.776 0.882 0.743 0.825 0.935 0.823 0.981 1.223 0.977 1.224 1.614
0.8 0.817 0.871 0.962 0.846 0.961 1.100 0.943 1.133 1.376 1.102 1.419 1.857
0.9 0.917 0.980 1.086 0.935 1.041 1.197 1.042 1.227 1.551 1.232 1.571 2.062
200
0.4 0.407 0.438 0.475 0.420 0.476 0.531 0.466 0.558 0.671 0.565 0.681 0.893
0.5 0.518 0.543 0.601 0.541 0.594 0.663 0.597 0.699 0.840 0.725 0.885 1.124
0.6 0.635 0.669 0.712 0.654 0.709 0.798 0.712 0.825 1.023 0.822 1.033 1.338
0.7 0.733 0.760 0.847 0.744 0.839 0.928 0.837 0.971 1.188 0.978 1.218 1.574
0.8 0.809 0.897 0.939 0.849 0.962 1.051 0.967 1.129 1.354 1.129 1.411 1.824
0.9 0.911 0.979 1.060 0.941 1.058 1.180 1.066 1.242 1.495 1.242 1.577 2.006
500
0.4 0.408 0.441 0.479 0.421 0.480 0.531 0.478 0.566 0.682 0.553 0.709 0.889
0.5 0.512 0.557 0.597 0.531 0.598 0.662 0.593 0.694 0.869 0.706 0.894 1.138
0.6 0.631 0.669 0.727 0.649 0.720 0.799 0.718 0.842 1.014 0.851 1.051 1.352
0.7 0.715 0.774 0.843 0.754 0.833 0.930 0.836 1.009 1.184 0.984 1.258 1.606
0.8 0.811 0.888 0.951 0.857 0.939 1.054 0.961 1.123 1.376 1.101 1.414 1.806
0.9 0.920 0.992 1.063 0.948 1.042 1.174 1.061 1.262 1.522 1.248 1.573 2.041
1000
0.4 0.415 0.443 0.480 0.431 0.466 0.541 0.479 0.576 0.680 0.568 0.715 0.927
0.5 0.523 0.561 0.597 0.542 0.598 0.679 0.599 0.706 0.873 0.706 0.894 1.150
0.6 0.617 0.669 0.714 0.653 0.709 0.801 0.725 0.856 1.039 0.859 1.074 1.359
0.7 0.720 0.782 0.825 0.755 0.848 0.926 0.833 0.977 1.214 0.972 1.274 1.565
0.8 0.835 0.878 0.947 0.849 0.936 1.053 0.949 1.144 1.355 1.122 1.404 1.796
0.9 0.919 0.975 1.085 0.960 1.060 1.173 1.065 1.226 1.519 1.210 1.548 2.000
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Table 5.10: Relative efficiency of design options A and B2, with some non-compliance in the intervention arm. Cells represent ratios of mean
estimated standard errors of design option A divided by design option B2. The results are summarised by sample sizes and proportions of compliers




ICC=0.01 ICC=0.02 ICC=0.05 ICC=0.1
k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20
100
0.4 0.372 0.397 0.470 0.385 0.447 0.530 0.437 0.499 0.663 0.511 0.655 0.879
0.5 0.505 0.538 0.602 0.516 0.565 0.691 0.575 0.684 0.844 0.672 0.842 1.135
0.6 0.607 0.645 0.737 0.630 0.694 0.825 0.703 0.840 1.042 0.818 1.044 1.357
0.7 0.728 0.770 0.859 0.738 0.831 0.961 0.832 0.981 1.224 0.964 1.223 1.618
0.8 0.806 0.872 0.972 0.845 0.922 1.080 0.948 1.108 1.383 1.097 1.387 1.853
200
0.4 0.392 0.434 0.464 0.414 0.464 0.519 0.459 0.548 0.666 0.554 0.682 0.867
0.5 0.520 0.550 0.596 0.518 0.586 0.669 0.601 0.707 0.844 0.701 0.876 1.115
0.6 0.628 0.666 0.714 0.652 0.697 0.789 0.705 0.838 1.034 0.838 1.078 1.348
0.7 0.718 0.773 0.847 0.753 0.833 0.932 0.848 0.991 1.206 0.989 1.221 1.548
0.8 0.817 0.869 0.940 0.845 0.935 1.067 0.942 1.122 1.359 1.121 1.399 1.770
500
0.4 0.406 0.431 0.476 0.421 0.467 0.538 0.480 0.562 0.669 0.564 0.699 0.905
0.5 0.523 0.554 0.589 0.538 0.598 0.658 0.600 0.704 0.846 0.694 0.884 1.119
0.6 0.620 0.655 0.727 0.645 0.727 0.808 0.734 0.845 1.037 0.850 1.072 1.357
0.7 0.713 0.778 0.846 0.746 0.830 0.934 0.835 0.986 1.219 0.989 1.254 1.612
0.8 0.815 0.884 0.965 0.849 0.946 1.067 0.937 1.107 1.362 1.105 1.404 1.817
1000
0.4 0.411 0.447 0.478 0.432 0.484 0.525 0.478 0.568 0.687 0.563 0.707 0.922
0.5 0.523 0.552 0.610 0.536 0.584 0.657 0.602 0.713 0.856 0.707 0.882 1.134
0.6 0.629 0.668 0.728 0.643 0.711 0.807 0.733 0.865 1.035 0.859 1.064 1.377
0.7 0.743 0.785 0.831 0.745 0.822 0.940 0.851 0.991 1.194 0.987 1.233 1.592
0.8 0.837 0.874 0.937 0.842 0.955 1.049 0.953 1.136 1.361 1.128 1.396 1.832
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5.3 Simulation study 2: Continuous measure of treatment re-
ceipt under design option B
5.3.1 Contamination process in therapy trial
The scenario is similar to that described earlier in that I am imagining a trial that
investigates the effect of therapy in addition to TAU therapy compared to TAU alone;
therapies are delivered by a therapist. The difference is that treatment receipt is now a
continuous measure. Therefore a patient receives some dose of active therapy (D > 0)
or not (D = 0), or they receive a fixed dose of TAU (control) therapy. It is assumed that
this therapy has a full dose (which I call m). As before, it is not possible for patients to
receive therapies other than those tested in the trial.
Clustering:
As before, post-randomisation outcomes of patients treated by the same therapist (thera-
pist clusters) may be correlated as a result of the following processes:
• Cluster-level variables that affect the level of outcome,
• Cluster-level variables that affect the change in outcome under the control condi-
tion,
• Cluster-level variables that affect the size of the intervention response.
Non-compliance and contamination
The process by which non-compliance and contamination are thought to take place is
the same as in simulation substudy 1: therapists being trained in both therapies leading
to non-receipt of active therapy amongst those offered it and receipt of active therapy
amongst those offered the TAU therapy. The difference is that receipt of active therapy
is now defined as a continuous measure (dose). More specifically, it is on a ratio scale
because zero indicates an entire lack of treatment receipt. Non-compliance with active
therapy takes place when D(R = 1) < m and contamination of the control condition
occurs when D(R = 0)> 0. Once again it is assumed that if therapists were trained in
only one therapy then their patients would always receive the therapy that was offered
to them (i.e. D(R = 1) = m and D(R = 0) = 0). Generalising definitions from binary to
continuous treatment receipt, the patient population can be divided into strata according
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to the therapy they would receive from a therapist who is trained in both conditions as
follows:
• Dose responders: receive a greater dose of active therapy when active condition is
offered than they do when control condition is offered [D(R = 1)− D(R = 0)> 0],
• Dose never takers: receive no dose of active therapy when either active or control
conditions are offered [D(R = 1) = D(R = 0) = 0],
• Dose always takers: receive the same, non-zero dose of active therapy when either
active or control conditions are offered [D(R = 1) = D(R = 0)> 0]
• Dose defiers: receive a smaller dose of active therapy when active condition is
offered than they do when control condition is offered [D(R = 1)− D(R = 0)< 0].
It is assumed that there are no dose defiers in the patient population and define q1 =
Prob(Dose complier), q2 = Prob(Dose never taker), q3 = Prob(Dose always taker); q1 +
q2 + q3 = 1.
Simulation hypotheses:
1. A cluster randomised trial design with therapy allocated at the level of the therapist
and the therapist trained in only one of the therapies, and analysed using estimator
E-ITT (intention-to-treat estimator) will provide an unbiased estimate of efficacy
formalised by ATE.
2. An individual randomised trial design with the therapist delivering both therapies,
treatment receipt measured, and analysed using the as-treated estimator will
provide a biased estimate of efficacy as formalised by ATE.
3. The magnitude of absolute bias of the as-treated estimator will be driven by
parameters determining the strength of hidden confounding.
4. An individual randomised trial design with the therapist delivering both therapies,
treatment receipt measured, and analysed using estimator E-IV8 (two stage least
squares dose-response estimator) will provide an asymptotically unbiased estimate
of efficacy formalised by ACEm,0.
5. The relative efficiency of the two competing unbiased approaches will be driven by
parameters describing the population cluster structure and those determining the
strength of respective instrumental variables.
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5.3.2 Data generating models
The simulation study mimicked a clustered structure in the target population (before
trial took place) and simulated post-treatment outcomes under the two design options
in a manner similar to before. The difference was that in design option B there was a
continuous measure of treatment receipt for each participant.
I proceeded following the same four steps.
Step 1) – Baseline outcome
This was the same as in simulation substudy 1. Specifically, I generated outcome at
baseline with level-one and level-two random effects: Y0,i j := ei j + v j with ei j ∼
N(0, 1−ρ) and independently v j ∼ N(0,ρ).
Step 2) – Potential post-intervention outcomes
Dose of active therapy under offer of control therapy, Di j(R = 0):
To start with I generated potential dose under the offer of control according to the therapy
patients would receive from a therapist who is trained in both conditions (Q = 1). All
values in this distribution must be non-negative, with a possible peak at zero representing
those who received no dose of active intervention under the offer of control (if dose
never takers were present in the population).
In order to generate potential dose under offer of control I created two separate random
variables. These variables allowed the zero-inflation caused by the possible presence of
dose never takers and the distribution of dose on a continuous scale for dose compliers
and dose always takers. The product of the two variables represents potential dose of
active therapy under offer of control.
First, I sampled from a binomial distribution, where zero values represent dose compliers
or dose never takers and ones indicate dose compliers or dose always takers:
Ai j(R = 0)|q3 > 0∼ bin(1, 1− q4), with q4 := q2(q2+q3) . The fraction q2(q2+q3) represents the
proportion who receive a potential treatment dose of zero of those who do not adhere to
treatment offer. This was done in order to preserve the ratio of dose never takers to dose
always takers as determined by q2 : q3. When there is no treatment receipt under offer
of control (i.e. q3 = 0), each value of treatment receipt is zero and therefore:
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
Ai j(R = 0)|q3 = 0

= 0
For full dose mD > 0, where mD represents the full dose of active therapy a participant
could receive when offered control and where mD ≤ m, I sampled from a uniform
distribution in order to obtain dose under offer of control (for dose compliers and dose
always takers).
Bi j(R = 0)|mD > 0∼ unif(0, mD)
No treatment receipt under offer of control could arise when maximum dose under offer
of control is set to zero:

Bi j(R = 0)|mD = 0

= 0
Potential dose amongst those who are offered control is then:
Di j(R = 0) := Ai j(R = 0)Bi j(R = 0)
Difference in dose of active therapy between trial arms, Fi j:
I then generated a binary random variable (S∗) that represented latent compliance (where
1=dose compliers and 0=dose never takers and dose always takers). The requirement
for this variable was to preserve the proportions of dose compliers amongst those who
received no dose under offer of control and amongst those who received some dose under
offer of control. For simplicity I assumed that the ratio of dose compliers between these
two groups was equal to the ratio of dose never takers to dose always takers (i.e. q4).
When dose of active therapy under offer of control was zero, I generated the distribution
of S∗ as follows,
















When dose of active therapy under offer of control was positive, I generated the distribu-
tion of S∗ as follows,















The difference in potential dose under the offers of control and treatment is denoted
by random variable F where Fi j := Di j(R = 1)− Di j(R = 0). I generated Fi j rather than
Di j(R = 1) because of the requirement that there are no dose defiers in the population
(i.e. Di j(R = 1)≥ Di j(R = 0)). I allowed for this requirement by generating Fi j so that
all values were non-negative. I wanted the flexibility to vary the minimum level of Fi j
and I refer to this minimum as nF , where 0 ≤ nF ≤ m. In order to prevent dose of
active therapy under offer of this treatment being greater than full dose m, the uniform
distribution that Fi j was sampled from had an upper limit that was bounded by the dose
of active therapy under offer of control.
Fi j is conditional on the level of S
∗. The distribution of Fi j for dose compliers when the
maximum difference in potential dose under the offers of control and treatment was
greater than the minimum difference was,
Fi j|S∗ = 1, nF < m∼ unif
 
nF , m− D(R = 0)

For the extreme case where all dose compliers receive the maximum difference in dose of
active therapy between the trial arms, this implies that nF = m. When these parameters
were set in such a way, Fi j was fixed at the level of the maximum difference.
Fi j|S∗ = 1, nF = m

= m
Dose never takers and dose always takers receive the same dose of active therapy under
offers of control and treatment,
Fi j|S∗ = 0

= 0
A separate way of viewing the generation of Fi j is to proceed in a similar manner to the
generation of Di j(R = 0), as described earlier in this section. Say that Fi j is the product
of two random variables, called Ji j and Hi j , where Ji j enables zero inflation (for possible
presence of dose never takers and dose always takers) and Hi j represents the measure of
treatment dose (for the difference in potential dose amongst the dose compliers). These
variables are distributed in the following manner:
Ji j ∼ bin(1, q1)
Hi j ∼ unif(nF , m− Di j(R = 0)
I have described the generation of Fi j in this alternate way because this greatly simplifies
matters later on when finding an expression for the variance of Fi j .
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Dose of active therapy under offer of active therapy, Di j(R = 1):
Having generated both dose of active therapy under offer of control therapy and the
difference in potential dose under the offers of control and active therapies, I then
generated potential dose under offer of treatment, Di j(R = 1) := Di j(R = 0) + Fi j .
Potential outcome Yi j(R = 0,Q = 0):
Next, I generated the four potential post-treatment outcomes. The outcome that would
be observed if patients were offered the control condition and were treated by a therapist
who is only trained in that therapy is given by
Yi j(R = 0,Q = 0) := αY0,i j + "i j +ω j with "i j|D(R = 0) = d0, F = f ∼ N[µd0 f , 1−α2 −
ξ− g] and independently ω j ∼ N(0,ξ).
As a reminder, "i j is a level-one random effect and represents patient-level heteroge-
neity during follow-up. ω j is a level-two random effect and represents therapist-level
heterogeneity during follow-up, and ξ is the variance component (it is also ICC2).
Random variable "i j represents variables that can explain variability in change over the
treatment period. Its mean, conditional on the levels of treatment receipt under the offer
of control and the difference in potential dose, is defined as follows. E["i j|D(R = 0) =
d0, F = f ] = µd0 f , with E["i j] = −∆(d0 − E[Di j(R = 0)]) +∆( f − E[F]) = 0. ∆ is the
confounding effect of either receiving some dose of treatment when offered control or of
non-compliance with treatment when offered active intervention. It is the parameter that
represents the change in the (standardised) level-one error term for Y associated with
a one-unit increase in either potential dose under offer of control or the difference in
potential dose between the offers of treatment and control. The different signs before ∆,
depending on whether the explanatory variable is D(R = 0) or F , reflect the fact that the
confounding effects of greater contamination (greater d0) and non-compliance (smaller
f ) are in the same direction.
It was assumed that the variance of outcome under control was not increased by the
presence of these population strata, i.e. var[Yi j(R = 0,Q = 0)] = var(Y0,i j) = 1. And
to ensure that this held I set var("i j) = var("i j|D(R = 0) = d0, F = f ) + g = 1− α2 −















= var("i j|D(0) = d0, F = f ) + g,










. These terms for g
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could be expressed in terms of knowable quantities. Starting by expressing the first term







































Prob(J = 0) varF

F |D(0) = d0, J = 0

+ Prob(J = 1) varF
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m2 − 2 E[D(0)]m+ var[D(0)] + E[D(0)]2 − 2mnF























−∆ d0 − E[D(0)]|D(0) = d0+ EF∆ F − E(F)|D(0) = d0©
= varD(0)
¦−∆D(0) +∆E[D(0)]+ EF∆F |D(0) = d0−∆E(F)©
= varD(0)
¦−∆D(0) +∆E[D(0)]+∆EJEF [F |D(0) = d0, J = j]−∆E(F)©
= varD(0)
¦−∆D(0) +∆E[D(0)]+∆(1− q1)EF [F |D(0) = d0, J = 0]
+ q1EF [F |D(0) = d0, J = 1]
−∆E(F)©
= varD(0)
¦−∆D(0) +∆E[D(0)]+∆q1EF [F |D(0) = d0, J = 1]−∆E(F)©
= varD(0)
¦−∆D(0) +∆E[D(0)]+∆q1 (m− d0 + nF )2 −∆E(F)©
= varD(0)






























In order to express these terms for g, I need expressions for the expectation of D(0) and
the variance of D(0). They can be found as follows.
Expectation of Di j(0):
I now demonstrate how I found an expression for the expectation of Di j(R = 0). As
a reminder and letting Ai j(R = 0) = A and Bi j(R = 0) = B, D(0) is the product of A
(random variable for the balance between those patients who receive some dose of active
therapy under offer of control and those who receive zero dose) and B (random variable
for dose of active therapy), where A∼ bin 1, q3(q2+q3) and B ∼ unif(0, mD).








Variance of Di j(0):
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The expression for the variance of D(0) can be found as follows.






























































































Potential outcome Yi j(R = 0,Q = 1):
I then generated the potential outcome that would be observed if patients were offered
the control condition and were treated by a therapist who is trained in both therapies:
Yi j(R = 0,Q = 1) := αY0,i j + βDi j(R = 0) + "i j +ω j
Here parameter β represents the effect of receiving some dose of the active therapy on
outcome. Specifically, β measures the effect of dose of active therapy (when offered
control therapy). Note that β is ACEd1,d0 −ACEd1,d0+1, i.e. it is the change in the causal
parameter associated with a one-unit change in dose between the counterfactual worlds.
Such contamination can increase the variance in the presence of dose always takers since
var[Yi j(R = 0,Q = 1)] = var[Yi j(R = 0,Q = 0)] + var[βDi j(R = 0)] + 2βcov["i j , Di j(R =






E["i j Di j(R = 0)]

.
Potential outcome Yi j(R = 1,Q = 0):
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Next, the potential outcome that would be observed if patients were offered the active
condition and were treated by a therapist who is only trained in that therapy is given by,
Yi j(R = 1,Q = 0) := αY0,i j + γ+ "i j +ω j +τi j(Q = 0) with τi j(Q = 0)∼ N(0,ϑ)
Parameter γ= E[IREA], i.e. this parameter is the causal effect of receiving full dose, or
ATE. The added error term τi j(Q = 0) introduced treatment effect heterogeneity in that
var[IREA] = var[τi j(Q = 0)] = ϑ. Such treatment effect heterogeneity was allowed to
increase the variance of the post-treatment outcome under active condition compared
to that under the control condition; specifically var[Yi j(R = 1,Q = 0)] = 1 + ϑ. (For
simplicity it was assumed that this latest error term did not include therapist effects.)
Potential outcome Yi j(R = 1,Q = 1):
Finally, I generated the potential outcome that would be observed if patients were offered
the active condition and were treated by a therapist who is trained in both therapies.
This potential outcome can also be affected by the dose of treatment that is actually
received in this situation D(R = 1). The potential outcome was modelled,
Yi j(R = 1,Q = 1) := αY0,i j + βDi j(R = 1) + "i j +ω j +τi j(Q = 1)
The parameter β represents the effect of receiving a one-unit increase in dose of active
condition on outcome. Note that this is the same parameter that was used in the
construction of Yi j(R = 0,Q = 1). This is because the effect of some dose of active
therapy under offer of it on outcome is equal to the effect of it under offer of control
therapy. The error term τi j(Q = 1) also represents treatment effect heterogeneity, but this
time under treatment delivery by therapists who are trained in both therapies (Q = 1).
As previously, it was assumed that the expected error term within every strata (defined by
the difference in potential dose) was zero; i.e. E

τi j(Q = 1)|F = f

= 0, that is random
treatment effect variability within a stratum. This implied two exclusion restriction
assumptions as follows for dose never takers, E

Yi j(R = 1,Q = 1) − Yi j(R = 0,Q =
1)|D(R = 1) = D(R = 0) = 0 = Eτi j(Q = 1)|D(R = 1) = D(R = 0) = 0 = 0, and for
dose always takers, E






τi j(Q = 1)|D(R = 1) = D(R = 0)> 0

= 0. In words, the offer of treatment was
assumed not to have a (mean) effect on outcome for dose never takers or dose always
takers.
Variability in mean treatment effects within the dose compliers and across strata (dose






= var(βF) = β2var(F). It was assumed that
an individual’s treatment effect relative to the stratum mean did not depend on the
therapist’s training and this ensured that the total treatment effect heterogeneity was the
same for both delivery options, that is var[IREB] = var[IREA] = ϑ. To this end I defined
τi j(Q = 1) := wτi j(Q = 0), with w := (1− vϑ )0.5, where v = β2var(F). Expression v
could be expressed in terms of known quantities as follows. Let Fi j = F , Ji j = J , and
Hi j = H. As described earlier, random variable F is the product of J and H. J has
variance q1(1− q1). I will demonstrate how to find the expectation and variance of H,
and then finally give the variance of F .
Expectation of Hi j:



































2(nF + m)(q2 + q3)−mDq3
4(q2 + q3)

given that mD > 0, m> nF , and nF ≤ m−mD.
Variance of Hi j:
The variance of H could be found as follows, initially using the Law of Total Variance:
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12m2q22 − 24mnF q22 + 12n2F q22 + 16m2Dq2q3 − 12mDmq2q3 + 24m2q2q3
+12mDnF q2q3 − 48mnF q2q3 + 24n2F q2q3 + 7m2Dq23 − 12mDmq23
+ 12m2q23 + 12mDnF q
2
3 − 24mnF q23 + 12n2F q23
144(q2 + q3)2
given that mD > 0, m> nF , and nF ≤ m−mD.
Variance of Fi j:
This allows me to express the variance of F in terms of the expectations and variances of
J and H:
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var(F) = var(J)var(H) + var(J)E(H)2 + var(H)E(J)2
= q1(1− q1)
12m2q22 − 24mnF q22 + 12n2F q22 + 16m2Dq2q3 − 12mDmq2q3
+24m2q2q3 + 12mDnF q2q3 − 48mnF q2q3 + 24n2F q2q3
+7m2Dq
2
3 − 12mDmq23 + 12m2q23 + 12mDnF q23








12m2q22 − 24mnF q22 + 12n2F q22 + 16m2Dq2q3 − 12mDmq2q3
+24m2q2q3 + 12mDnF q2q3 − 48mnF q2q3 + 24n2F q2q3
+7m2Dq
2
3 − 12mDmq23 + 12m2q23 + 12mDnF q23
− 24mnF q23 + 12n2F q23
144(q2 + q3)2
q21





12m2q22 − 24mnF q22 + 12n2F q22 + 16m2Dq2q3 − 12mDmq2q3
+24m2q2q3 + 12mDnF q2q3 − 48mnF q2q3 + 24n2F q2q3
+7m2Dq
2
3 − 12mDmq23 + 12m2q23 + 12mDnF q23








12m2q22 − 24mnF q22 + 12n2F q22 + 16m2Dq2q3 − 12mDmq2q3
+24m2q2q3 + 12mDnF q2q3 − 48mnF q2q3 + 24n2F q2q3
+7m2Dq
2
3 − 12mDmq23 + 12m2q23 + 12mDnF q23




Step 3) – Observable trial data
The patient sampling, treatmet allocation and mapping of potential outcomes onto
observed outcomes were similar to before (see 5.2.2). This time continuous potential
dose was mapped onto observed dose as follows,
Di j = R(B),i j Di j(R = 1) + [1− R(B),i j]Di j(R = 0)
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Step 4) – Efficacy estimators
Design A: ITT maximum likelihood estimator with random intercept for cluster (therapist)
and inclusion of baseline outcome as a covariate. This was the same estimator as used in
design option A.
Design B1: Adapted as-treated maximum likelihood estimator of effect of continuous
treatment receipt on outcome with random effect for cluster (therapist). The as-treated
estimator, without the random effect, was described in Section 4.3.2. The estimator
included baseline outcome as a covariate in order to reflect the fact that this was strongly
related to outcome at follow-up.
Design B2: Generalised 2SLS estimator with random effect for cluster (therapist). This
model, without the random effect, was referred to previously as estimator E-IV8 (Section
4.5.2). The estimator included baseline outcome as a covariate in both stages in order to
reflect the fact that this was strongly related to outcome at follow-up. A random intercept
was needed in order to allow for correlations within therapist clusters (this approach
was described in Section 4.4.2).
5.3.3 Simulation study design
Seven simulation parameters were varied and three were held constant. I investigated
all combinations of these parameters (10,368 trial scenarios) and used 1000 iterations
per scenario. The simulation design is generally similar to simulation substudy 1, the
main difference being that dose is now continuous. A list of input parameters and their
levels is given in Table 5.11.
Those parameters that were varied and were the same as in simulation substudy 1 were
sample size, ICC2, cluster size, treatment effect size under design option A (ATE; γ). The
parameters that have now changed or been added are treatment effect size under design
option B (ACEd1+1,d0−ACEd1,d0; β), confounding bias due to non-adherence, strength
of IV (proportion of latent dose compliers) under design option B, and the strength of
compliance within dose compliers (governed by mD and nF , which were varied in pairs).
The levels that I chose for these parameters were as follows:
• The size of the causal effect in design option B: The target effect (ACEd1+1,d0−ACEd1,d0 ;
parameter β) represents the change in the causal effect associated with a one-unit
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Table 5.11: Summary of input levels of simulation parameters when simulating a conti-
nuous measure of treatment receipt.
Parameter Description Levels of parameter
Sample size (n) 100; 200; 500; 1000
Treatment effect: β ACEd1+1,d0–ACEd1,d0 (design option
B)
{0.2; 0.5; 0.8} / m
Treatment effect: γ ATE (design option A) 0.2; 0.5; 0.8
ICC2 (ξ) Level 2 clustering; due to variance
at level of therapist
0.01; 0.02; 0.05; 0.10
Size of clusters (k) 5; 10; 20
∆ Confounding due to either receipt
of treatment in control arm or
non-receipt in the intervention arm
{0.2; 0.5; 0.8} / m
Proportion of latent
dose compliers (q1)




m Full dose of treatment 10
Minimum D(0) Minimum dose of treatment
received under offer of control for
dose always takers and dose
compliers
0
mD (maximum D(0)) Maximum dose of treatment
received under offer of control for
dose always takers and dose
compliers
0; 2; 5; 10 (varied in pairs
with nF )
nF (minimum F) Minimum difference in dose
between the counterfactual
situations for dose compliers
10; 8; 5; 0 (varied in pairs
with mD)
Maximum F Maximum difference in dose
between the counterfactual
situations for dose compliers
10− D(0)
α Effect of outcome at baseline on out-
come at follow-up
0.7
ICC1 (ρ) Level 2 clustering; due to variance




This is the variance of IREA 0.2
Number of trial scenarios: 4 sample sizes, 3 treatment effect sizes, 4 intraclass correlation
coefficients (ICC2), 3 cluster sizes, 3 magnitudes of confounding, 6 proportions of dose compliers,
and 4 levels of minimum D(0) / maximum F, i.e. 10,368 trial scenarios.
increase in the difference in potential dose between the counterfactual worlds.
This was converted into the change in causal effect associated with the maximum
difference in potential doses (i.e. full dose). For simplicity, I set γ = mβ . The
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estimand of interest here is a LATE and was described in Section 4.5.2.
• Confounding bias under design option B is driven by parameter∆, the confounding
effect due either to receipt of treatment in the control arm or to non-compliance in
the active intervention arm. This parameter was varied in order to determine small,
medium, and large effects of confounding. Note that the parameter represents
standardised effects of contamination/non-compliance due to a one-unit increase in
contamination or non-compliance. I considered small (d=0.2), moderate (d=0.5)
and large (d=0.8) differences, where these differences must be divided by the
maximum dose of treatment receipt in order to obtain the change in confounding
for a one-unit increase in dose.
• Proportion of dose compliers (q1) under design option B: this parameter is similar to
the proportion of latent compliers in part 1 (p1) in that it represents the proportion
of the population who receive a greater level of active therapy under its offer than
they do under offer of control. Proportions were set to the same levels as the
proportion of latent compliers in part 1, i.e. q1 was varied from 0.4 to 0.9 in steps
of 0.1.
• The range of possible doses under offer of control under design option B for the dose
always takers and dose compliers was given minimum zero and some maximum
limit (mD). This was set to zero, two, five and 10. These maxima enabled an
investigation of the effects of the distribution of treatment receipt under offer of
control on estimator properties. This parameter was varied in tandem with the
following parameter.
• The range of possible differences in dose between offer of control and offer of
treatment under design option B for the dose compliers. The upper limit for this
is the full dose of treatment minus each participant’s level of treatment receipt
under offer of control. This subtraction was to ensure that no participant’s dose
of treatment receipt under offer of treatment was more than m. nF was set to
10, eight, five and zero. These minima enabled an investigation of the effects of
the distribution of the difference in dose between the counterfactual situations on
estimator properties.
Parameters mD and nF were simulated in four pairs. The four levels of dose compliance
that I simulated were given the following labels:
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• Full dose compliers. These participants received zero dose when offered control and
full dose when offered treatment. This was effectively the same as the generation
of binary treatment receipt in part 1 and meant that the dose compliance strata
mapped onto the original principal strata.
• Strong partial dose compliers. These participants received a dose of between zero
and two when offered control and between eight and 10 when offered treatment.
• Moderate strength partial dose compliers. These participants received a dose of
between zero and five when offered control and between five and 10 when offered
treatment.
• Weak partial dose compliers. These participants received a dose of between zero
and 10 when offered control and between zero and 10 when offered treatment,
with a positive difference between offers of treatment and control. This meant
that a participant who received a dose of, for example, zero under offer of control
would receive a dose of anything between zero and 10 under offer of treatment. A
participant who received a dose of, for example, nine under control would receive
a dose of between nine and 10 under offer of treatment.
Note that for all four levels of this parameter, all participants in the dose complier stratum
received a greater dose when offered treatment compared to when offered control. Also
note that as strength of dose compliance becomes weaker, the lower limit of the range of
the difference in dose between offer of treatment and contol becomes smaller. This has
the effect that with weaker strength of dose compliance, the expectation of the difference
in potential dose for the stratum becomes smaller.
Parameters that were fixed and were the same as in simulation substudy 1 were effect
of outcome at baseline on outcome at follow-up, ICC1, and treatment heterogeneity. In
this simulation substudy I set one further parameter, full dose of active therapy, and also
fixed the proportion of dose never takers:
• The full dose of treatment under either offer of control or treatment was m. This
was set to 10 on the basis that this represented a plausible upper limit of treatment
sessions for a psychological treatment regimen.
• I fixed the proportion of dose never takers (q2) to zero (i.e. random variable Ai j is
always one). This simulation substudy was primarily focused on generalising the
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results from substudy 1 to continuous treatment receipt and did not investigate the
effect of the presence of dose never takers on the relative efficiency of the design
options.
For each trial scenario the same output as described in part 1 was saved.
5.3.4 Simulation findings
Distribution of D(0) and F
The distributions of dose of active therapy under offer of control and of dose under
offer of treatment were investigated under the four different levels of strength of dose
compliance. As a reminder, this parameter represented the magnitude of difference in
potential dose between trial arms for those participants in the population who would
receive a greater dose under offer of treatment compared to control. This was done using
data simulations that followed the steps above. I used a large sample size (n=100,000)
and a large dose complier stratum of 0.7. For the population with full dose compliers,
all participants received no dose under offer of control (hence this was not plotted) and
dose under offer of treatment of either zero (30% of sample) or 10 (70% of sample).
This is plotted in Figure 5.1a. For the population with strong partial dose compliers,
dose under offer of control varied uniformly between zero and two (Figure 5.1b) and
dose under offer of treatment was distributed either uniformly between zero and two
(30% of sample) or exponentially between eight and 10 (70% of sample; Figure 5.1c).
The distribution of this second group was not uniform because for a given participant its
upper bound was reduced by the value of dose under offer of control. For the population
with moderate strength partial dose compliers, dose under offer of control was a uniform
distribution between zero and five (Figure 5.2a) and dose under offer of treatment was
distributed either uniformly between zero and five or exponentially between five and 10
(Figure 5.2b). For the population with weak partial dose compliers, the distribution of
dose under offer of control was uniform between zero and ten (Figure 5.2c), and dose
under offer of treatment ranged between zero and 10 (30% had a difference of zero;
Figure 5.2d)). In summary, Figures 5.1b, 5.2a, and 5.2c represent progressive amounts


























(a) Distribution of D(1) when simulating a




















(b) Distribution of D(0) when simulating a


















(c) Distribution of D(1) when simulating a
population with strong partial dose compliers.
Figure 5.1: Distributions of D(0) and D(1) for the simulations of populations with
full dose compliers and strong partial dose compliers. Sample size was set to 100,000,
strength of confounding was 0.5, and proportion of dose compliers was 0.7. The dis-
tribution of D(0) for the simulations where dose compliers were full compliers is not





















(a) Distribution of D(0) when simulating a po-



















(b) Distribution of D(1) when simulating a po-





















(c) Distribution of D(0) when simulating a
















(d) Distribution of D(1) when simulating a
population with weak dose compliers.
Figure 5.2: Distributions of D(0) and D(1) when simulating populations with moderate
strength and weak partial dose compliers. Sample size was set to 100,000, strength of
confounding was 0.5, and proportion of dose compliers was 0.7.
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Table 5.12: Absolute bias of as-treated estimator (option B1) rounded to three decimal
places, with a continuous measure of treatment receipt and when dose responders were
full dose responders. For those with F > 0, this assumed that participants received zero
dose when offered control and full dose when offered treatment. Results were averaged
over ICCs, cluster sizes and magnitudes of treatment effect sizes.
Sample size;
strength of confounding
Proportion of dose responders
0.4 0.5 0.6 0.7 0.8 0.9
100
0.2 0.145 0.129 0.110 0.087 0.062 0.034
0.5 0.364 0.323 0.272 0.217 0.156 0.083
0.8 0.584 0.517 0.438 0.350 0.250 0.134
200
0.2 0.146 0.129 0.110 0.087 0.062 0.034
0.5 0.366 0.321 0.275 0.218 0.156 0.084
0.8 0.584 0.516 0.437 0.350 0.248 0.135
500
0.2 0.146 0.128 0.109 0.087 0.062 0.032
0.5 0.365 0.322 0.274 0.219 0.156 0.084
0.8 0.584 0.516 0.439 0.351 0.250 0.134
1000
0.2 0.145 0.128 0.110 0.088 0.062 0.033
0.5 0.365 0.322 0.273 0.218 0.156 0.084
0.8 0.585 0.516 0.438 0.350 0.250 0.134
Bias
The results from the data simulations showed a similar story in terms of bias as those
for part 1. Specifically, estimator E-ITT is the same estimator as part 1, where it was
shown to be unbiased (I have not tabularised this again). The as-treated estimator for
dose was biased for efficacy under design option B. Table 5.12 shows that there was
considerable bias at all levels of sample size, strength of confounding, and size of dose
complier stratum. Bias was greatest when strength of confounding was high and size
of dose complier stratum was small. Estimator E-IV8 was an unbiased estimator of
ACEd1+1,d0−ACEd1,d0 under design option B. See Table 5.13. The table shows minimal
levels of bias at all levels of sample size, strength of confounding, and size of dose
complier stratum. The as-treated estimator was dropped and estimators E-ITT and E-IV8
were taken further.
162
Table 5.13: Absolute bias of IV estimator (option B2) rounded to three decimal places,
with a continuous measure of treatment receipt and when dose responders were full
compliers. For those with F > 0, this assumed that participants received zero dose when
offered control and full dose when offered treatment. Results were averaged over ICCs,
cluster sizes and magnitudes of treatment effect sizes.
Sample size;
strength of confounding
Proportion of dose responders
0.4 0.5 0.6 0.7 0.8 0.9
100
0.2 −0.007 −0.001 −0.002 −0.002 0.000 −0.001
0.5 −0.016 −0.009 −0.007 −0.003 −0.002 0.000
0.8 −0.022 −0.011 −0.008 −0.005 −0.002 −0.001
200
0.2 −0.001 −0.002 0.000 −0.001 0.000 0.000
0.5 −0.005 −0.004 0.001 −0.001 −0.001 0.000
0.8 −0.009 −0.006 −0.005 −0.003 −0.002 0.000
500
0.2 −0.001 −0.001 0.000 −0.001 0.000 −0.001
0.5 −0.004 −0.001 −0.001 −0.001 −0.001 0.000
0.8 −0.007 −0.002 −0.002 0.000 −0.001 −0.001
1000
0.2 −0.001 0.000 0.000 0.000 0.000 0.000
0.5 −0.001 −0.001 −0.001 0.000 0.000 0.000
0.8 −0.003 −0.001 −0.001 −0.001 0.000 0.000
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Table 5.14: Model SE / true SE of IV estimator (option B2) rounded to three decimal
places, with a continuous measure of treatment receipt and when dose responders were
full compliers. For those with F > 0, this assumed that participants received zero dose
when offered control and full dose when offered treatment. Results were averaged over
ICCs, cluster sizes and magnitudes of treatment effect sizes.
Sample size;
strength of confounding
Proportion of dose responders
0.4 0.5 0.6 0.7 0.8 0.9
100
0.2 0.979 0.988 0.983 0.986 0.982 0.978
0.5 0.977 0.980 0.985 0.985 0.988 0.986
0.8 0.975 0.979 0.977 0.987 0.986 0.981
200
0.2 1.005 1.009 1.000 1.000 0.997 1.001
0.5 0.999 1.002 1.000 1.004 0.996 0.999
0.8 0.997 1.001 1.002 1.001 1.010 0.999
500
0.2 1.021 1.020 1.019 1.010 1.014 1.016
0.5 1.012 1.019 1.025 1.018 1.015 1.027
0.8 1.021 1.008 1.010 1.016 1.017 1.011
1000
0.2 1.024 1.027 1.021 1.019 1.024 1.023
0.5 1.026 1.026 1.018 1.020 1.024 1.021
0.8 1.019 1.022 1.015 1.015 1.024 1.025
SE estimation
Summaries of the ratio between model-based SE and true SE for estimator E-IV8 (Table
5.14) were similar to earlier summaries when treatment receipt was binary. The estima-
tor’s model-based SEs increased with sample size; E-IV8’s model SEs were closer to the
true values at small sample sizes than E-ITT’s (see simulation substudy 1).
Monte Carlo standard error
Summaries of the MCSE under design option A (estimator E-ITT) and under design
option B2 (estimator E-IV7) were always less than 0.01. This was similar to simulation
substudy 1 – see Tables 5.7 and 5.8.
Relative efficiency
The efficiency of estimator E-ITT (design option A) relative to estimator E-IV8 (design
option B2) is summarised by the four types of dose compliers, starting with the full
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dose compliers (Table 5.15). The results for the full dose compliers were very similar
to those when simulating binary treatment receipt (see Table 5.9). Once again, cells
where estimation of efficacy under design option B2 was more precise are coloured in
grey. Generally, the results showed that design option B2 was favoured when size of
dose complier stratum, cluster size, and ICC were large. The results demonstrated a
large range of relative efficiency ratios (0.381-1.997) across the simulated trial scenarios.
Design option A was almost always favoured when contamination (proportion of dose
always takers) was large, i.e. more than 40%. In these data simulations this level is
equivalent to a proportion of dose compliers of 0.6 or less. The picture was mixed at 20%
and 30% contamination (design option B2 favoured at high levels of cluster size and
ICC). At 10% contamination, design option B2 was favoured at most levels of clustering.
At low strengths of clustering (small cluster size and ICC of 0.01 or 0.02) design option
A was usually favoured, except in some cases when contamination was very low. As
clustering increased, estimation under design option B2 became more efficient. For
example, when either cluster size or ICC was of a moderate level, overall design option
B2 was favoured in roughly half the scenarios where contamination was 30% or under.
At moderate to large cluster sizes (10 or 20) and ICCs (0.05 or 0.1), design option B2
was usually favoured when contamination was 30% or under. Within levels of size of
dose complier stratum and ICC, as cluster size increased so did the efficiency ratio. This
relationship became more marked as other parameters increased.
Subsequent tables represent generalisations of these results. In these tables the limits
on the distributions of dose under offer of control and the difference in potential dose
(for the dose compliers) are relaxed. Table 5.16 provides relative efficiency ratios for the
simulations of a population containing strong partial dose compliers. These simulations
assumed that participants received a dose of between zero and two under offer of control
and that dose compliers received a dose under offer of active treatment of between eight
and 10. Comparing these results with those for a population with full dose compliers,
design option A was favoured at more levels of size of dose complier stratum, cluster
size, and ICC. In fact, design option B2 was mainly favoured only when cluster size was
10 or 20, or ICC was 0.05 or 0.1. At these levels and when the proportion of dose always
takers was 30% or less, estimation of efficacy under design option B2 tended to be more
efficient.
Further generalisations of the distributions of dose under offer of control and dose under
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offer of active treatment demonstrated a continuing added advantage for design option
A. Table 5.17 shows relative efficiency ratios for a population with moderate strength
dose compliers. In this population dose compliers received a dose under offer of control
of between zero and five and a dose under offer of active treatment of between five
and 10. Design option B2 was only favoured at the highest levels of cluster size and
ICC, and when the proportion of dose never takers was 20% or less. Table 5.18 shows
the efficiency ratio for a population with weak dose compliers, where both dose under
offer of control and dose under offer of active treatment were between zero and 10. The
results showed that estimation under design option A was more efficient than under
option B2 at every level of size of dose complier stratum, cluster size and ICC.
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Table 5.15: Relative efficiency of design options A and B2 for a continuous measure of treatment receipt, where dose responders were full dose
responders. For those with F > 0, this assumed that participants received zero dose when offered control and full dose when offered treatment. Cells
represent ratios of mean estimated standard errors of design option A divided by design option B2. The results are summarised by sample sizes and
sizes of dose responder stratum (rows), and intraclass correlation coefficients and cluster sizes (k) (columns). Results were averaged over magnitudes
of effect size and strength of confounding.
Sample size;
size of dose responder stratum
ICC=0.01 ICC=0.02 ICC=0.05 ICC=0.1
k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20
100
0.4 0.381 0.413 0.464 0.396 0.441 0.520 0.434 0.532 0.659 0.518 0.633 0.845
0.5 0.490 0.535 0.604 0.516 0.560 0.658 0.564 0.683 0.843 0.646 0.814 1.093
0.6 0.606 0.642 0.719 0.618 0.683 0.797 0.685 0.817 1.012 0.786 0.997 1.307
0.7 0.705 0.772 0.837 0.752 0.791 0.929 0.805 0.947 1.192 0.939 1.185 1.541
0.8 0.815 0.864 0.949 0.864 0.933 1.053 0.925 1.095 1.371 1.080 1.371 1.767
0.9 0.907 0.979 1.076 0.946 1.035 1.204 1.055 1.238 1.511 1.222 1.529 1.997
200
0.4 0.400 0.435 0.463 0.413 0.460 0.515 0.459 0.536 0.645 0.536 0.666 0.850
0.5 0.516 0.552 0.586 0.535 0.579 0.650 0.586 0.687 0.806 0.682 0.854 1.080
0.6 0.608 0.661 0.698 0.639 0.688 0.780 0.699 0.827 0.994 0.822 1.033 1.286
0.7 0.715 0.764 0.827 0.751 0.824 0.910 0.813 0.970 1.131 0.938 1.203 1.506
0.8 0.821 0.876 0.951 0.853 0.919 1.034 0.938 1.090 1.307 1.090 1.359 1.734
0.9 0.916 0.988 1.044 0.949 1.046 1.162 1.020 1.225 1.502 1.214 1.540 1.963
500
0.4 0.416 0.441 0.458 0.420 0.463 0.531 0.469 0.553 0.665 0.541 0.692 0.847
0.5 0.518 0.550 0.579 0.534 0.591 0.645 0.589 0.678 0.825 0.686 0.851 1.067
0.6 0.624 0.656 0.693 0.648 0.706 0.777 0.699 0.833 0.987 0.825 1.023 1.313
0.7 0.717 0.753 0.812 0.752 0.828 0.914 0.826 0.960 1.169 0.947 1.196 1.496
0.8 0.818 0.866 0.938 0.854 0.937 1.039 0.938 1.112 1.305 1.082 1.384 1.748
0.9 0.907 0.981 1.042 0.965 1.058 1.179 1.059 1.251 1.504 1.232 1.532 1.976
1000
0.4 0.407 0.440 0.463 0.428 0.462 0.528 0.467 0.554 0.662 0.536 0.682 0.882
0.5 0.524 0.550 0.587 0.531 0.585 0.653 0.594 0.693 0.823 0.683 0.848 1.098
0.6 0.611 0.643 0.693 0.636 0.689 0.763 0.710 0.826 0.985 0.815 1.024 1.299
0.7 0.720 0.753 0.817 0.756 0.820 0.903 0.809 0.962 1.142 0.950 1.217 1.510
0.8 0.809 0.878 0.947 0.843 0.947 1.047 0.931 1.106 1.335 1.110 1.352 1.751
0.9 0.925 0.964 1.032 0.936 1.059 1.186 1.069 1.218 1.483 1.232 1.534 1.973
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Table 5.16: Relative efficiency of design options A and B2 for a continuous measure of treatment receipt, for strong partial dose responders. For those
with F > 0, this assumed that participants received a dose of between zero and two when offered control and between eight and 10 when offered
treatment. Cells represent ratios of mean estimated standard errors of design option A divided by design option B2. The results are summarised by
sample sizes and sizes of dose responder stratum (rows), and intraclass correlation coefficients and cluster sizes (k) (columns). Results were averaged
over magnitudes of effect size and strength of confounding.
Sample size;
size of dose responder stratum
ICC=0.01 ICC=0.02 ICC=0.05 ICC=0.1
k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20
100
0.4 0.326 0.357 0.398 0.335 0.376 0.438 0.374 0.449 0.555 0.424 0.557 0.707
0.5 0.422 0.450 0.512 0.432 0.482 0.556 0.478 0.571 0.710 0.549 0.700 0.904
0.6 0.518 0.551 0.608 0.521 0.574 0.672 0.583 0.684 0.849 0.658 0.859 1.113
0.7 0.598 0.653 0.720 0.624 0.686 0.790 0.678 0.822 1.004 0.805 1.017 1.317
0.8 0.701 0.751 0.830 0.708 0.787 0.901 0.777 0.931 1.151 0.920 1.164 1.534
0.9 0.776 0.818 0.933 0.786 0.865 1.019 0.891 1.074 1.294 1.027 1.291 1.702
200
0.4 0.337 0.368 0.388 0.356 0.385 0.436 0.384 0.454 0.553 0.444 0.571 0.728
0.5 0.432 0.460 0.490 0.443 0.472 0.563 0.485 0.579 0.691 0.565 0.708 0.918
0.6 0.530 0.553 0.598 0.529 0.594 0.648 0.597 0.701 0.852 0.685 0.863 1.098
0.7 0.607 0.645 0.691 0.619 0.690 0.770 0.695 0.829 0.986 0.808 1.010 1.272
0.8 0.690 0.753 0.801 0.718 0.779 0.878 0.808 0.927 1.107 0.909 1.167 1.477
0.9 0.779 0.833 0.877 0.796 0.877 0.982 0.878 1.051 1.270 1.030 1.335 1.697
500
0.4 0.335 0.365 0.384 0.361 0.392 0.432 0.394 0.467 0.556 0.462 0.571 0.721
0.5 0.442 0.465 0.495 0.450 0.494 0.561 0.501 0.584 0.694 0.569 0.737 0.921
0.6 0.519 0.568 0.599 0.542 0.593 0.659 0.592 0.696 0.840 0.701 0.870 1.114
0.7 0.600 0.655 0.697 0.638 0.700 0.767 0.705 0.818 0.985 0.808 1.025 1.283
0.8 0.683 0.744 0.787 0.725 0.795 0.875 0.800 0.930 1.127 0.922 1.166 1.503
0.9 0.770 0.839 0.893 0.800 0.904 0.995 0.899 1.058 1.280 1.030 1.266 1.676
1000
0.4 0.348 0.367 0.396 0.362 0.400 0.449 0.394 0.469 0.552 0.452 0.573 0.750
0.5 0.436 0.465 0.496 0.446 0.501 0.550 0.502 0.599 0.697 0.576 0.738 0.926
0.6 0.524 0.556 0.594 0.539 0.588 0.679 0.607 0.707 0.839 0.699 0.870 1.117
0.7 0.610 0.642 0.701 0.637 0.692 0.785 0.704 0.814 0.993 0.813 1.027 1.316
0.8 0.686 0.737 0.810 0.715 0.809 0.874 0.789 0.933 1.141 0.917 1.161 1.471
0.9 0.784 0.826 0.878 0.804 0.909 0.972 0.882 1.064 1.260 1.036 1.297 1.679
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Table 5.17: Relative efficiency of design options A and B2 for a continuous measure of treatment receipt, for moderate strength partial dose responders.
For those with F > 0, this assumed that participants received a dose of between zero and five when offered control and between five and 10 when
offered treatment. Cells represent ratios of mean estimated standard errors of design option A divided by design option B2. The results are summarised
by sample sizes and sizes of dose responder stratum (rows), and intraclass correlation coefficients and cluster sizes (k) (columns). Results were
averaged over magnitudes of effect size and strength of confounding.
Sample size;
size of dose responder stratum
ICC=0.01 ICC=0.02 ICC=0.05 ICC=0.1
k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20
100
0.4 0.231 0.255 0.287 0.238 0.268 0.315 0.268 0.324 0.403 0.304 0.402 0.512
0.5 0.305 0.325 0.371 0.312 0.349 0.404 0.345 0.415 0.519 0.399 0.511 0.663
0.6 0.374 0.400 0.442 0.377 0.418 0.491 0.422 0.500 0.621 0.479 0.629 0.819
0.7 0.433 0.475 0.527 0.453 0.500 0.577 0.494 0.601 0.741 0.586 0.746 0.970
0.8 0.510 0.547 0.608 0.516 0.576 0.662 0.567 0.681 0.845 0.676 0.854 1.131
0.9 0.569 0.600 0.684 0.576 0.635 0.748 0.653 0.787 0.950 0.755 0.950 1.254
200
0.4 0.243 0.266 0.282 0.257 0.280 0.317 0.278 0.330 0.404 0.323 0.417 0.533
0.5 0.312 0.334 0.357 0.320 0.343 0.412 0.353 0.423 0.507 0.412 0.520 0.678
0.6 0.385 0.402 0.437 0.385 0.434 0.475 0.435 0.515 0.625 0.501 0.635 0.808
0.7 0.441 0.470 0.506 0.452 0.504 0.563 0.509 0.609 0.725 0.592 0.742 0.936
0.8 0.503 0.552 0.584 0.524 0.571 0.646 0.592 0.681 0.816 0.666 0.860 1.089
0.9 0.571 0.609 0.643 0.583 0.644 0.723 0.644 0.774 0.934 0.755 0.981 1.254
500
0.4 0.244 0.266 0.280 0.263 0.286 0.316 0.287 0.342 0.409 0.337 0.420 0.532
0.5 0.321 0.339 0.362 0.328 0.361 0.411 0.365 0.429 0.511 0.415 0.541 0.678
0.6 0.377 0.414 0.437 0.394 0.435 0.484 0.433 0.510 0.618 0.515 0.641 0.821
0.7 0.438 0.478 0.510 0.466 0.512 0.561 0.516 0.601 0.724 0.591 0.755 0.947
0.8 0.498 0.545 0.577 0.529 0.584 0.645 0.585 0.684 0.829 0.675 0.860 1.109
0.9 0.564 0.616 0.657 0.589 0.662 0.731 0.661 0.779 0.945 0.757 0.933 1.236
1000
0.4 0.254 0.269 0.290 0.264 0.293 0.329 0.287 0.344 0.406 0.331 0.421 0.555
0.5 0.317 0.341 0.362 0.324 0.366 0.404 0.366 0.440 0.513 0.419 0.543 0.684
0.6 0.381 0.405 0.435 0.393 0.430 0.498 0.442 0.519 0.618 0.512 0.641 0.825
0.7 0.445 0.469 0.511 0.465 0.507 0.575 0.515 0.599 0.732 0.597 0.757 0.973
0.8 0.501 0.540 0.595 0.522 0.592 0.642 0.578 0.686 0.841 0.673 0.855 1.085
0.9 0.575 0.606 0.646 0.589 0.668 0.716 0.649 0.784 0.926 0.761 0.954 1.239
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Table 5.18: Relative efficiency of design options A and B2 for a continuous measure of treatment receipt, for weak partial dose responders. For those
with F > 0, this assumed that participants received a dose of between zero and 10 when offered control and between zero and 10 when offered
treatment. Cells represent ratios of mean estimated standard errors of design option A divided by design option B2. The results are summarised by
sample sizes and sizes of dose responder stratum (rows), and intraclass correlation coefficients and cluster sizes (k) (columns). Results were averaged
over magnitudes of effect size and strength of confounding.
Sample size;
size of dose responder stratum
ICC=0.01 ICC=0.02 ICC=0.05 ICC=0.1
k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20 k = 5 k = 10 k = 20
100
0.4 0.004 0.007 0.013 0.007 0.010 0.016 0.008 0.011 0.018 0.015 0.014 0.019
0.5 0.015 0.014 0.025 0.016 0.024 0.022 0.018 0.026 0.035 0.018 0.027 0.047
0.6 0.034 0.043 0.065 0.053 0.047 0.050 0.039 0.074 0.077 0.064 0.068 0.086
0.7 0.093 0.097 0.106 0.074 0.127 0.113 0.115 0.137 0.186 0.141 0.153 0.233
0.8 0.154 0.172 0.201 0.147 0.175 0.217 0.165 0.184 0.282 0.188 0.272 0.374
0.9 0.206 0.216 0.245 0.206 0.203 0.262 0.233 0.280 0.349 0.270 0.336 0.453
200
0.4 0.016 0.022 0.021 0.023 0.018 0.027 0.021 0.039 0.042 0.028 0.039 0.039
0.5 0.052 0.071 0.075 0.059 0.047 0.105 0.067 0.094 0.102 0.091 0.092 0.151
0.6 0.117 0.127 0.126 0.128 0.144 0.147 0.113 0.168 0.218 0.163 0.209 0.269
0.7 0.155 0.168 0.183 0.161 0.183 0.207 0.184 0.223 0.269 0.212 0.267 0.345
0.8 0.188 0.207 0.217 0.197 0.214 0.244 0.223 0.257 0.308 0.251 0.325 0.415
0.9 0.219 0.231 0.248 0.224 0.247 0.279 0.246 0.299 0.362 0.287 0.373 0.486
500
0.4 0.083 0.087 0.097 0.091 0.098 0.102 0.090 0.102 0.137 0.110 0.140 0.185
0.5 0.118 0.124 0.135 0.121 0.135 0.153 0.131 0.161 0.192 0.153 0.200 0.252
0.6 0.143 0.156 0.165 0.149 0.166 0.185 0.164 0.195 0.238 0.198 0.247 0.315
0.7 0.169 0.184 0.197 0.180 0.198 0.217 0.200 0.233 0.281 0.229 0.294 0.371
0.8 0.194 0.213 0.224 0.207 0.230 0.254 0.229 0.269 0.325 0.264 0.339 0.434
0.9 0.222 0.242 0.259 0.233 0.260 0.289 0.261 0.308 0.374 0.298 0.368 0.487
1000
0.4 0.096 0.102 0.110 0.099 0.111 0.125 0.109 0.129 0.153 0.124 0.158 0.211
0.5 0.122 0.132 0.139 0.125 0.141 0.157 0.141 0.171 0.199 0.161 0.211 0.268
0.6 0.149 0.158 0.170 0.153 0.168 0.195 0.172 0.204 0.243 0.201 0.252 0.325
0.7 0.175 0.184 0.200 0.182 0.199 0.226 0.202 0.237 0.290 0.236 0.300 0.386
0.8 0.198 0.214 0.236 0.206 0.234 0.254 0.229 0.272 0.335 0.266 0.341 0.432
0.9 0.228 0.241 0.257 0.234 0.266 0.286 0.259 0.313 0.367 0.303 0.379 0.494
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5.4 Discussion
The results showed that, as hypothesised, for a cluster randomised trial design with
allocation at level of therapist where clinicians delivered only one therapy, the ITT
estimator (accounting for clustered data) provided an unbiased estimate of efficacy (for
ATE). This design was named option A. For an individual randomised trial design where
therapists delivered both therapies and treatment receipt was measured, the as-treated
estimator was biased for efficacy and the IV estimator was unbiased (for CACE). This
latter approach was termed design option B2. For low sample sizes, the IV estimator’s
SE was closer to the truth than the ITT one. For the largest simulated sample sizes the
difference was smaller but the IV estimator appeared to slightly overestimate the SE.
For a binary measure of treatment receipt, the relative efficiency of the two approaches
was driven by the cluster structure in design option A and the proportion of compliers
in the population in design option B2. As all of these parameters increased, efficiency
ratios became greater. When there was very little contamination, design option B2
was favoured. Additionally, when the cluster size was moderate or large (10 or 20
in these data simulations) and the ICC was moderate or large (0.05 or 0.1), design
option B2 had the advantage when contamination was 30% or less. At the very largest
combinations of cluster size and ICC, design option B2 was favoured. When there was
non-receipt of treatment in the intervention arm, the results were very similar but the
link between size of complier stratum and amount of contamination changed. This non-
compliance reduced the size of the complier stratum for estimating efficacy at a given
level of contamination. For example, at 20% non-compliance a size of complier stratum
of 0.7 equated to 10% contamination. Therefore, at a given level of contamination, the
presence of non-compliance effectively reduced the strength of the instrument, thereby
reducing the relative efficiency ratio. For a continuous measure of treatment receipt,
the difference in potential dose between the counterfactual worlds drove the relative
efficiency of the two design options. The greater this difference, the more similar the
results were to those for binary treatment receipt. As this difference decreased, efficiency
ratios at given levels of cluster size, ICC and size of dose complier stratum tended towards
favouring design option A.
The results were consistent with the knowledge that cluster randomisation reduces the
efficiency of the estimator of ATE in proportion to the product of the ICC and cluster size
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minus one. This is because every extra participant that is recruited in a cluster randomised
trial provides less information than that participant would do in an individual randomised
trial, due to correlation of outcomes within clusters. The efficiency costs in design option
B were the size of the always taker / dose always taker stratum and, for a continuous
measure of treatment receipt, weakness of dose compliance (within those participants
who would receive greater dose under offer of treatment compared to offer of control). A
CACE estimator calculates treatment effect within a subsample of participants who would
comply with protocol. As this group of latent compliers becomes smaller, the instrument
becomes weaker and the variability of the sampling distribution increases. For continuous
treatment receipt, the precision of the estimator of ACEd1+1,d0 −ACEd1,d0 is determined
by how precisely the gradient of the relationship between the difference in dose between
the counterfactual worlds and the size of the treatment effect can be estimated. The
relaxation of restrictions on the distributions of dose under offer of control and difference
in counterfactual doses had the effect of introducing greater amounts of contamination
and non-compliance respectively. This led to less variance in the difference between
counterfactual doses and therefore less precision in the magnitude of the relationship
between this and treatment effect.
These data simulations have compared two design options with unbiased estimators,
held treatment heterogeneity equal between these options, and compared their relative
efficiency at plausible levels of a number of parameters. The advice is by no means
clear-cut – in some situations cluster randomisation as advocated in the literature is the
preferred approach, in other situations it is not. In Chapter 6 the relative efficiency ratios
will be plotted in a form that enables the reader to understand how the parameters that
drove relative efficiency affected these ratios. The chapter will describe how the results
have been made available online. In addition, a trial based on the D6 trial and two
hypothetical trials based on typical levels of parameters seen in the other motivating trials




6.1 Background and aims
In Chapter 5 I investigated design approaches for addressing the problem of contamination
in RCTs of complex interventions that target efficacy. In this chapter I provide those
planning trials with advice regarding optimal design in these RCTs. The following types
of trial and contamination process are assumed:
• There are only two trial arms: active arm and control,
• There is no treatment non-compliance in the active arm,
• Contamination is such that contaminated participants either get full active treat-
ment or some dose of it,
• The contamination process is the one most commonly perceived as a problem
in mental health research; i.e. therapy in both arms with contamination due to
therapists being trained in both interventions and delivering the intervention in
the control arm.
I compare the same two design options as described in Chapter 5. These were:
A. Cluster randomisation at the level at which contamination was anticipated (assu-
med to entirely prevent contamination), with estimation of the ATE (efficacy) and
accounting for clustering of outcome data,
B. Individual randomisation, acceptance that contamination will occur, measurement
of treatment receipt for all participants, and use of a randomisation-based estimator
of the complier average causal effect (efficacy).
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Earlier I referred to the second of these approaches as design option B2. I now refer
to it as design option B in order to simplify the labels (having dropped the as-treated
estimator of design option B1). The scoping review of Chapter 2 showed that design
option A is prominent in mental health trials but found no instances of the use of design
option B. This could imply that trialists and funders lack necessary information on the
merits of the approaches in order to make informed decisions about their use. The results
from the simulation studies in Chapter 5 could fill this knowledge gap and thus inform
the choice between design options A and B. Therefore I sought to develop a tool that
provides investigators with information about the more efficient design option in trials
with expected contamination that target efficacy. In particular, I aimed to provide an
online interface that makes it easy for the user to judge the relative performance of the
two competing options given important planning parameter choices.
To recap Chapter 5, I compared the two design options using Monte Carlo simulations
and set parameters to levels that were considered plausible in mental health trials. I
completed the simulations in two parts, one with binary treatment receipt and one
with continuous treatment receipt. I demonstrated that the estimators under the two
trial design options were unbiased and consistent, then assessed their relative efficiency.
Therefore the main output from the research was the ratio of estimated treatment effects’
standard errors between estimators associated with design options A and B. I was able to
identify parameters affecting relative efficiency of the design options from the simulation
studies. For binary treatment receipt, these were ICC and cluster size for design option
A, and proportion of latent compliers for design option B. When there was no non-
compliance, the proportion of latent compliers was simply one minus the proportion of
the control arm who received treatment (i.e. one minus the proportion of contaminators).
For a continuous measure of treatment receipt, the important parameters were ICC and
cluster size for design option A, and the proportion of dose compliers and magnitude
of response for design option B. Magnitude of response was the size of the difference
in potential doses between treatment offers for those participants who would receive
a greater dose under offer of treatment compared to offer of control. Results were
summarised in the form of tables, which were stratified by these parameters.
The first aim of this chapter is to demonstrate the efficiency ratios graphically. The second
aim is to describe the development of an online application (the “decision support tool”)
that provides the results from the simulations. The chapter will begin by describing how
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the results from Chapter 5 can be demonstrated graphically. This involves assessing the
relationship between key design parameters and the relative efficiency of the estimator
linked to design option A compared to the one associated with design option B. The
chapter will then describe the development of the online decision support tool and
provide instructions for its use. Finally, I provide a demonstration of the tool by assessing
the better design option for three trials. These include a trial based on the information
from the D6 study and two hypothetical trial examples: one with binary treatment receipt
and one with continuous treatment receipt. All three target the estimation of treatment
efficacy.
6.2 Graphical demonstration of simulation results
Given the finding that, for a binary measure of treatment receipt, there were three
parameters that drove the efficiency ratio for a trial of a particular sample size (ICC,
cluster size and amount of contamination), I decided to show the relative efficiency of
the design options in three dimensions. In the three-dimensional plots, horizontal planes
determined the level of clustering (x- and y-axes were ICC and cluster size, respectively)
and vertical position was defined by proportion not contaminated in the control arm
(i.e. proportion of latent compliers; z-axis). I aimed to plot a surface of equivalence
(isosurface) to indicate the plane at which the standard errors for treatment effect under
the two design options were the same (i.e. efficiency ratio of one). This was done in
R using the ‘contour3d’ function, which is part of the ‘misc3d’ package. This function
computes and renders isosurfaces using the marching cubes algorithm (Lorensen and
Cline, 1987). In essence, this method determines the three-dimensional space which
represents some level of an outcome (e.g. level of relative efficiency of one). It does
this by assuming a linear change between points and then interpolating where the
outcome level of interest is situated. Points are then connected using triangle models
of constant density surfaces (e.g. triangular surfaces that represent a level of relative
efficiency of one). In totality, these triangles provide the isosurface. As a result, the
isosurface maintains connectivity between slices (across the 3D space), surface data, and
information on the gradient of the surface. A greater number of three-dimensional points
at which the outcome level of interest is known enables the isosurface to be plotted with
greater resolution.
As a demonstration of this, I tried plotting a 3D isosurface for the efficiency ratios that
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were calculated for a sample size of 500, treatment effect sizes of 0.5, and strength of
confounding of 0.5. This last parameter represented a moderate standardised difference
in error terms between complier strata. In order to create this plot, I saved efficiency
ratios for the subset defined by the levels of sample size, treatment effect sizes and
strength of confounding as a three-dimensional array and then fed this to the ‘contour3d’
function. I combined the resulting plot of the isosurface with a wireframe which provided
axis labels. I drew visible edges of the wireframe in solid black and non-visible edges as
dashed lines. The resulting plot is shown in Figure 6.1. The space above the isosurface
represents the levels of ICC, cluster size and proportion of non-contaminators at which
the standard error for estimation of efficacy is greater for design option A than for design
option B. Therefore, above the surface estimation under design option B is more efficient
and below the surface estimation under design option A is more efficient. The figure
shows that estimation under design option B is more efficient at large proportions of
non-contaminators (i.e. little contamination), unless the degree of clustering is very
small in which case design option A is favoured (the isosurface hits the top of the box at
this level of clustering). As the amount of clustering increases (i.e. greater ICC or cluster
size), the space at which design option B is favoured becomes greater. This means that
as strength of clustering increases, design option B is favoured at increasing amounts of
contamination.
6.3 Online decision support tool
6.3.1 Specification and design
There were three main requirements for the application. Firstly, it should allow the
user to enter the levels of the various input parameters that were chosen in the data
simulations while providing guidance regarding possible choices for these parameters.
This did not include the main parameter for strength of confounding, as this had no
bearing on the relative efficiency of the estimators. Secondly, it should provide the mean
efficiency ratio (SE under design option A divided by SE under option B) that was found
in the data simulations for the level of input parameters that was chosen by the user.
Thirdly, the application should provide a plot of the isosurface (for the levels of sample
size and treatment effect sizes as chosen by the user) and then plot on the figure the
point in three-dimensional space that represented the levels of ICC, cluster size, and
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(a) Three-dimensional plot from frontal perspective of the isosurface representing
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 contaminators
(b) Three-dimensional plot from rear perspective of the isosurface representing equiva-
lence of estimator standard errors between design options.
Figure 6.1: Three-dimensional plot (seen from opposite angles) of the isosurface repre-
senting equivalence of estimator standard errors between design options (SEA / SEB)
for a binary measure of treatment receipt. Sample size was 1000, treatment effect sizes
were 0.8, and strength of confounding was 0.5.
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would enable the user to place a trial in the context of the 3D surface plot. Finally, the
three-dimensional plot should include toggles allowing the user to change the viewing
angle of the figure.
As described in the previous paragraph, the input parameters did not include the strength
of confounding. This was fixed at its moderate level (i.e. all results shown in the
application assumed that strength of confounding was 0.5). In addition it was assumed
that the active arm of the trial was not subject to non-compliance in the results shown in
the application. This was done to be consistent between the binary and continuous scales
on which treatment receipt was measured (non-compliance per se was not simulated for
the continuous measure of treatment receipt) and because the utility of the application
was specifically for deciding how to address the problem of contamination. Therefore,
I designed the tool so that the user could enter the levels of sample size, treatment
effect sizes, ICC, cluster size, proportion of non-contaminators/dose compliers, and, for
a continuous measure of treatment receipt, magnitude of dose compliance.
The application was developed in Shiny, an open source R package for developing
online applications. In creating this application I wrote four R scripts that controlled its
appearance and functionality:
• “ui.R” script – this is required by Shiny and determines the appearance of the
application and the levels of the particular inputs that the user can choose (see
Appendix B.1),
• “server.R” script – this is required by Shiny and renders the functionality of the
application (e.g. passes the levels of input parameters that were set by the user to
the function that plots the 3D figure; see Appendix B.2),
• An R function for printing the efficiency ratio at parameter levels specified by the
user (see Appendix B.3),
• An R function for plotting the 3D figure (see Appendix B.4).
6.3.2 Graph toggles
The application included toggles to change the viewing angle of the isosurface plot, alter
the zoom, and reset all these controls to their original values. Figure 6.2 demonstrates
what the viewing angle toggles do. Arrow (a) represents the rotation in the vertical plane
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Figure 6.2: Three-dimensional plot of the wireframe box with arrows representing
changes in viewing angle for two of the toggles.
(as the toggle is increased the viewing angle moves up) and arrow (b) shows rotation in
the horizontal plane (as the toggle is increased the viewing angle moves round to the
left).
6.3.3 Online publication
The application has been placed on a server hosted by RStudio and is free to use. It has
been published online at: https://nicholasmagill.shinyapps.io/shiny_app/.
It can be viewed on a screen of any size.
The application has three tabs: user instructions, results (efficiency ratios) for a binary
measure treatment receipt, and results for a continuous measure of treatment receipt.
The following section provides the user instructions, as given online to users of the tool.
6.3.4 User instructions
This tool compares the efficiency of two design options with consistent estimators of
efficacy (the effect of treatment receipt on outcome) in randomised controlled trials
where treatment contamination is expected. Contamination is defined as receipt of active
intervention within the control arm of a trial. The design options are:
A. Cluster randomisation at the level at which contamination is anticipated to occur
with an estimator of ATE that accounts for clustering of data,
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B. Individual level randomisation, measurement of treatment receipt, and use of a
randomisation-based estimator of efficacy.
Monte Carlo simulations were used to compare these design options. The scenario
that is addressed here is a trial with two arms: active intervention and control. It is
assumed that there is no treatment non-compliance in the active arm. Participants in
the control arm receive either the control treatment, full active treatment, or some dose
of active treatment. In design option A, cluster randomisation is assumed to prevent
contamination entirely and not to cause bias itself. Any contamination is due to a clinician
being trained in both active and control interventions and delivering the active treatment
to participants in the control arm.
The tool is presented in two parts. First, with a binary measure of treatment receipt,
and second, with a continuous measure of treatment receipt. For a binary measure of
treatment receipt, the efficacy estimand is the effect of treatment within a sub-population
of participants who would receive treatment when offered it and would receive control
when offered it (i.e. the complier average causal effect). For a continuous measure
of treatment receipt, the estimand being used is the effect of treatment within a sub-
population of participants who would receive the maximum dose of treatment when
offered it and no dose when offered control.
The aim of the tool is to provide the ratio of the standard errors of estimates of efficacy
under the design options: SEA / SEB. A ratio of greater than one would imply that the
variance of the estimator of ATE under design option A is greater than that of efficacy
under design option B. Or put another way, a ratio of greater than one means that
the efficacy estimator of design option B is more precise. The tool provides this ratio
at the levels of various parameters, as set by the user. For binary treatment receipt,
these parameters are sample size, size of standardised treatment effects, level of ICC,
size of clusters, proportion of non-contaminators (this parameter represents the path
from random treatment allocation to treatment receipt). For continuous treatment
receipt, parameters are sample size, size of treatment effects, ICC, size of clusters,
size of dose complier stratum, and the magnitude of the response within this stratum
(size of difference between the counterfactual doses). I define the dose compliers as
those participants who would receive a greater dose of treatment under offer of active
intervention compared to control. The tool also plots a three-dimensional figure of the
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surface of equivalence between the two design options (i.e. the plane at which the
precisions of the two design options’ estimators are equivalent). It is plotted in three
dimensions because there are three key variables that drive the relative efficiency of
design option A compared to option B: the level of the ICC, cluster size, and proportion
of non-contaminator/dose complier stratum.
The user must first choose the sample size options (100, 200, 500 or 1000) and standar-
dised treatment effect sizes (0.2, 0.5 or 0.8). The setting of these parameters enables
the generation of the 3D surface plot on the right-hand side of the screen. If the user
opts for a binary measure of treatment receipt then he or she needs to determine the ICC
(0.01, 0.02, 0.05 or 0.1), cluster size (5, 10 or 20), and proportion of non-contaminators
(0.4, 0.5, 0.6, 0.7, 0.8 or 0.9). This proportion is also the proportion of latent compliers,
or the population who would receive treatment when offered and would not receive it
when offered control. These three parameters are used to plot a coordinate (red ball)
in three-dimensional space in the figure. The user may need to use the viewing angle
toggles beneath the figure to visualise the position of this point in relation to the surface.
If the user decides to use a continuous measure of treatment receipt, he or she needs
to choose the ICC, cluster size, size of dose complier stratum (the proportion of the
population who would receive a greater dose under offer of treatment compared to
control; 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9), and the magnitude of response within this stratum.
This final parameter represents the difference in dose of active treatment under offer of
treatment compared to control for the dose compliers. This parameter can be set to one
of four levels, which are defined by the minimum dose of active treatment under its offer
and the maximum dose of it under offer of control:
• Full dose compliers: participants receive full dose under offer of treatment and
nothing under offer of control,
• Strong partial dose compliers: participants receive a dose of between 80% and
100% of maximum dose under offer of treatment and between 0% and 20% under
control,
• Moderate strength partial dose compliers: participants receive a dose of between
50% and 100% of maximum dose under offer of treatment and between 0% and
50% under control,
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• Weak partial dose compliers: participants receive a dose of between 0% and 100%
of maximum dose under offers of treatment and control.
6.4 Demonstration of the decision support tool
I imagine an investigator who is planning a new trial to estimate the efficacy of an
experimental therapy compared to a standard therapy. The planning question is how to
address the problem of treatment contamination in the design of the trial. Contamination
is anticipated if therapists were to be trained in both the new and comparator therapies. It
is expected that if this were to happen therapists would provide some control participants
with the new therapy or perhaps some dose of it. The design options being considered
are those described above (design options A and B). These designs enable unbiased and
consistent estimation of efficacy. The online tool can be used to make the decision of
which design option is more efficient.
In order the demonstrate the decision making process I use three trial examples. These
are one based on D6 and two hypothetical trials: one with binary treatment receipt
and one with continuous treatment receipt. These trials constitute examples of existing
evidence that can inform parameter choices (treatment effect size, ICC, cluster size,
proportion of non-contaminators). For the hypothetical trials, I selected parameter levels
that could be considered plausible based on the results of the scoping review in Chapter
2. For the sake of this demonstration, I imagine that all three trial examples aimed to
investigate efficacy. I make the same trial assumptions as described earlier. These were
that the trial has two arms; there is no treatment non-compliance (no subpopulation of
never takers); participants in the control arm receive either full treatment, no treatment,
or some dose of treatment; and cluster randomisation prevents contamination and does
not cause bias itself.
6.4.1 Planning a trial with a binary measure of treatment receipt
Trial based on D6 study
I imagined an investigator who was planning a new trial that handles the contamination
process that D6 was not able to address and targets efficacy. Therefore, D6 represents
existing evidence that can be used to inform parameter choices needed as input for the
online tool. The design of D6 (according to the trial protocol) anticipated an ICC of 0.05,
182
cluster size of 15, and standard treatment effect sizes of 0.5. On this basis and assuming
20% drop-out before follow-up along with the loss of two surgeries per arm, the overall
sample size requirement was calculated as 432 participants. I entered a sample size of
500, treatment effect sizes of 0.5, ICC of 0.05, and cluster size of 20 into the decision
support tool.
The trial’s designers did not anticipate the possible level of contamination had it randomly
allocated treatment to individuals as opposed to clusters. The tool shows that when the
proportion of the control arm who are not contaminated is 60%, the efficiency ratio is
slightly greater than one. This output is shown in Figure 6.3. The output shows the
efficiency ratio (1.035) and some advice indicating that, because the ratio is more than
one, design option B is more efficient. It also provides a plot of the isosurface at the
chosen levels of sample size and treatment effect sizes viewed from a side-on perspective.
A red ball indicates the three-dimensional space at which the trial is positioned. As a
sensitivity analysis, the tool suggests that when the proportion of non-contaminators is
50% or less, design option A is more efficient.
Hypothetical trial with typical levels of relevant parameters
I imagined an investigator who was designing another trial that was targetting efficacy
and needed to address contamination in the design. I used the evidence from the scoping
review in Chapter 2 in order to choose parameter levels. The review suggested that a
typical CRCT was anticipated to have an ICC of 0.05 and cluster size of 10. I entered
these parameter levels, an effect size of 0.5, and a sample size of 200 into the decision
support tool.
The tool shows that when the proportion of non-contaminators is 80%, the efficiency
ratio is more than one. The output from the tool is shown in Figure 6.4. The output
shows that the efficiency ratio (1.096) is more than one and indicates that design option
B is more efficient. It provides a plot of the isosurface at the chosen levels of sample
size and treatment effect sizes. The hypothetical trial is represented by a red ball, which
is positioned above the surface. As a sensitivity analysis, the tool provides evidence
that when the proportion of non-contaminators is 70% or less, design option A is more
efficient.
Subsequent to choosing the design, the investigator should then perform a sample size
calculation based on level of power, significance level and treatment effect size. Under
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design option A, the sample size calculation would need to inflate for clustering. Under
design option B, the calculation would need to target the efficacy estimator.
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Figure 6.3: Application of the decision support tool to a trial based on the D6 study and defining treatment receipt as binary. At a proportion of
non-contaminators of 50%, the ratio of standard errors (under design option A divided by design option B) is more than one and therefore the red
ball is above the isosurface. This implies that estimation under design option B would be more efficient.
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Figure 6.4: Application of the decision support tool to a hypothetical trial with binary treatment receipt and plausible levels of sample size, ICC,
cluster size and proportion of non-contaminators. The ratio of standard errors (under design option A divided by design option B) is more than one
and therefore the red ball is above the isosurface. This implies that estimation under design option B would be more efficient.
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6.4.2 Planning a trial with a continuous measure of treatment receipt
(dose)
I imagined an investigator who was planning a trial with a continuous measure of
treatment receipt (e.g. number of treatment sessions) and attempting to address conta-
mination in the design. In this case the tool lets the user consider different levels of partial
contamination. The parameters that relate to design option A (ICC and cluster size) are
the same as in the previous section, but those relating to design option B are different.
They are now the size of the dose complier stratum and the magnitude of response within
this stratum. As a reminder, this second parameter represented the size of the difference
in potential treatment receipt between the offers of treatment and control amongst those
participants where this difference would be positive. It also allows for more sources of
non-adherence including non-compliance in the active arm. The estimands now being
compared are ATE (design option A) and the effect of treatment within a sub-population
of participants who would receive the maximum dose of treatment when offered it and
no dose when offered control (design option B).
I used the same levels of ICC, cluster size and sample size as described in the previous
section. I also used the same expected proportion of dose compliers as the proportion
of non-contaminators in the previous section (i.e. 80%). This was with the aim of
demonstrating the impact of a change in the magnitude of dose compliance on the
efficiency ratio. When the dose compliance parameter was set to “full”, the relative
efficiency of the design options was similar to that in the previous section. This is because
at this level all dose compliers receive full dose under offer of treatment and no dose
under offer of control. When I reduced the level of this parameter slightly (i.e. set it to
represent “strong partial dose compliers”), the ratio of the standard errors dropped to
0.942. The output from the tool, with parameters set to the levels described, is shown
in Figure 6.5. The fact that this ratio was now less than one demonstrates that a small
departure from full dose compliance can have a significant impact on the ratio. The




This chapter has described the plotting of results from Chapter 5 in the form of three-
dimensional isosurface figures. For a given sample size and treatment effect sizes,
these plots show the space (i.e. levels of ICC, cluster size, and proportion of non-
contaminators/dose compliers) at which the two design options are favoured. The
chapter has also described the development of an online application that provides the
user with information that can be used to decide which of the two competing design
options is more efficient under a given research scenario. In particular, it provides the
efficiency ratio between design options A and B at a level of the various input parameters
that is set by the viewer. The application is reactive (the information that is displayed is
dependent on the levels of parameters chosen by the user), free to use, and has been
published on the Shiny servers.
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Figure 6.5: Application of the decision support tool to a hypothetical trial with continuous treatment receipt and plausible levels of sample size, ICC,
cluster size, proportion of dose compliers and magnitude of dose compliance within this stratum. The ratio of standard errors (under design option A
divided by design option B) is less than one and therefore the red ball is below the isosurface. This implies that estimation under design option A
would be more efficient.
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Chapter 7
Estimating treatment efficacy under
treatment contamination:
Application to the D6 trial
7.1 Background
I identified asymptotically unbiased estimators of efficacy estimands in Chapter 4. IV and
stratification estimators can be used to estimate CACE (binary treatment receipt) and IV
methods can be used to estimate ACEd1+1,d0−ACEd1,d0 (continuous treatment receipt) in
the presence of non-compliance in the active arm and contamination in the control arm.
Previously I detailed the causal assumptions required by these estimators and explained
how they can be expanded to accommodate clustered outcome data. In Chapter 5
I demonstrated that design option B (randomisation of individuals, measurement of
treatment receipt, and use of randomisation-based efficacy estimator) might be more
efficient when contamination is weak as quantified by either a small proportion of the
control arm receiving the active intervention (binary treatment receipt) or those in the
control arm receiving small doses of active intervention (continuous treatment receipt).
The D6 trial was introduced as a motivating example in Section 1.6. The trial investigated
the effect of primary care nurse-led motivational interviewing with CBT skills compared
to attention control on HbA1c. The intention was for the experimental treatment to
challenge and modify psychological issues and barriers to self-care. The fidelity asses-
sments presented in Chapter 3 showed that non-adherence with randomised intervention
(participants allocated to the D6 intervention arm receiving only the control condition
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and participants allocated to the control condition receiving some aspect of the attention
control intervention) did indeed take place in this trial. Thus contamination occurred
despite steps undertaken to prevent it.
This chapter addresses the second part of the secondary research objective. This was to
carry out secondary data analyses of the D6 study that use binary or continuous adherence
measures to estimate the efficacy of the D6 intervention. Thus I apply design and analysis
approach B in practice and compare findings with the original intention-to-treat analysis.
7.2 Aims and hypotheses
For a binary measure of D6 intervention receipt, this chapter aims to answer the question:
what is the effect of D6 intervention on primary outcome (glycated haemoglobin, HbA1c)
amongst that subpopulation of participants who would receive treatment when offered
it and would not receive it when offered attention control? This involves constructing
an individual-level measure of adherence (treatment receipt). The aim was to use the
MITI and BECCI data that were introduced and described in Chapter 3 to generate a
binary exposure variable. This measure will be used to estimate CACE, i.e. the effect
of treatment amongst those whose disease management would adhere to protocol (i.e.
latent compliers). This will be estimated for HbA1c at all post-randomisation time
points (nine, 15 and 18 months after allocation). It was predicted that the estimates
of efficacy would be larger than those of effectiveness. It was also predicted that, like
the effectiveness estimates that I described in Chapter 1, these would not demonstrate
statistical significance.
For a continuous measure of D6 intervention receipt, the questions were as follows. Firstly,
what effect is associated with a one-unit increase in dose between the counterfactual
situations? Secondly, what is the estimated causal effect for the maximal difference in
dose between the counterfactual situations? The aim was to use the treatment fidelity
data to construct a continuous measure of individual-level treatment receipt. This was
then used to estimate ACEd1+1,d0 − ACEd1,d0 for HbA1c at all three post-randomisation
time points.
The aim was to use the MITI and BECCI data that were introduced and described in
Chapter 3 to generate the endogenous (exposure) variable. The exposure variable was
191
constructed as either categorical or continuous and then appropriate estimators were
applied in order to calculate efficacy for both.
7.3 Method
7.3.1 Statistical issues
As mentioned, the main statistical issue that must be addressed in any efficacy analysis of
the D6 trial is the presence of non-adherence. In the following sections I will set out the
generation of binary and continuous measures of adherence using the treatment fidelity
assessment sample from Chapter 3. I will describe the estimators that were used in the
estimation of efficacy (these were introduced in Chapter 4). There were five of these
estimators of efficacy (IV and stratification estimators), of which I applied four to the
binary adherence measure and one to the continuous adherence measure. I will also
explain the methods used for selection of covariates in models.
There were two further statistical issues that were addressed: the presence of missing
values in adherence and outcome measures, and the clustering of outcomes due to
randomisation of primary care surgeries. The estimators I used assumed that missing
adherence values were missing completely at random (MCAR) and made different
assumptions regarding missing outcome values. I will explain these assumptions for
each model. Whilst the trial was cluster randomised at the level of the primary care
surgery, some nurses treated patients in two surgeries which implied the existence of two
levels of clustering. Similarly to the primary analysis of the trial, I assumed that nurse
clustering would be stronger than surgery clustering (Ismail et al., 2018). I therefore
treated the twin GP surgeries as one unit which was equivalent to treating nurse as the
primary clustering unit. I will describe how I accounted for this clustering in the analyses
using methods that I introduced in Section 4.4.2.
7.3.2 Generation of adherence measures
I considered the MITI and BECCI scales for construction of a binary measure of adherence
and only the MITI for quantifying adherence on a continuous scale. I also distinguished
adherence with different components of the complex intervention. Specifically, I explored
the domains of the MITI, which measured adherence to principles of MI, and the BECCI
Practitioner Score (Moyers et al., 2010; Lane et al., 2005), which measured adherence
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to the CBT skills part of the intervention. The definitions of these domains are shown in
Table 7.1.
Table 7.1: MITI and BECCI domains with definitions.
Domain Definition
MITI
Evocation Extent to which the clinician conveys an understanding
that motivation for change and the ability to move to-
wards that change lie mostly with the patient
Collaboration Extent to which the clinician behaves as if the interview
is occurring between two equal partners
Autonomy/Support Extent to which the clinician supports and actively fos-
ters client perception of choice
Global Spirit Mean of evocation, collaboration and autonomy /
support
Global Empathy Extent to which the clinician understands or makes an
effort to grasp the client’s perspective and feelings
Reflection/Question Ratio Total number of reflections divided by total number of
questions
Percent Open Questions Percentage of total number of questions that were open
Percent Complex
Reflections
Percentage of total number of reflections that were
complex
Percent MI-Adherent Percentage of clinician behaviours that were adherent
with MI of the total number of adherent and non-
adherent behaviours
BECCI
Practitioner Score Global measure of skills involved in behaviour change
counselling
Binary measure of adherence
I decided to use MITI Global Spirit domain and BECCI Practitioner Score in constructing
a binary measure of adherence. This was because MITI Global Spirit is a particularly
important domain for the MITI as it represents many aspects of adherence to MI. As
described in Table 7.1, it represents the mean of the Evocation, Collaboration and
Autonomy/Support subscales (Moyers et al., 2010). Together these make up a large
part of the concept of MI. It is measured on a scale of one to five, where one indicates
absence of Evocation, Collaboration, and Autonomy/Support. The BECCI Practitioner
Score is the mean of the 11 items that constitute the scale. It captures the skill of the
clinician in aiming to change the behaviour of a patient who is active and engaged with
the treatment (Lane et al., 2005). The D6 trial investigators chose to use this measure to
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assess clinicians’ ability to provide the CBT skills aspect of the D6 intervention.
I reviewed the literature for a method of using the MITI Global Spirit and BECCI Practiti-
oner Score to define treatment adherence. The authors of the MITI defined thresholds
for “Beginning proficiency” and “Competency” for each of the domains (Moyers et al.,
2010). For the Global Spirit the “Beginning proficiency” threshold was an average of
3.5 and for “Competency” was an average of 4. These thresholds were based on expert
knowledge and were not driven by data. Several randomised controlled trials and pilot
studies have used the “Beginning proficiency” threshold as a definition for receipt of
treatment (e.g. Simon and Ward, 2014; Larsen et al., 2014; Whittle et al., 2015). I
decided to use this lower threshold rather than the upper one because of the nature of the
D6 intervention. The treatment was given in conjunction with standard care, meaning
that primary care nurses provided patients with advice (e.g. medication adherence) that
might be considered as contrasting to the principles of MI.
There are no recommended thresholds for use with the BECCI Practitioner Score. Howe-
ver, the definitions of the five levels of each item are: 0=not at all; 1=minimally; 2=to
some extent; 3=a good deal; 4=a great extent. I chose the midpoint between “minimally”
and “to some extent” (i.e. 1.5) and defined any scores about this as demonstrating receipt
of CBT skills.
In summary, any therapy session recordings that were rated as higher than 3.5 on the
MITI Global Spirit domain or greater than 1.5 on the BECCI Practitioner Score were
classed as demonstrating adherence to D6 intervention and therefore showed receipt
of psychological treatment. Recordings with fidelity ratings that were both lower than
these thresholds were classified as showing no treatment receipt. The indicator variable
for treatment receipt was coded zero for non-receipt and one for receipt. This was used
as the exposure variable in the IV estimators. Similar variables were also created for
treatment receipt in each trial arm separately (i.e. observed measures of compliance
and contamination) with the difference that these were coded as missing for the trial
arm that was not being investigated (e.g. treatment receipt in standard care arm was
given missing values for all those allocated to D6 intervention). These were used as the
exposure variables in the stratification estimators.
The treatment receipt variable was constructed at the level of the participant, i.e. it
represented whether they had been assessed as having received any treatment. Therefore,
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a patient was regarded as having received treatment if this was the outcome of at least
one audiotape rating.
Continuous measure of adherence
For the continuous measure of treatment receipt, MITI Global Spirit was used as an
overall measure of treatment adherence. This was because the main part of the D6
intervention was MI and the main skills of this were included in the measure of Global
Spirit. Mean Global Spirit was used as the exposure variable for any participants who
had two tape ratings.
7.3.3 Predictors of treatment receipt and missingness
I explored predictors of treatment receipt across both trial arms. Any variables found to
be predictive were then included as covariates in the IV models to improve power. The
indicator variable for treatment receipt used the definition given in the previous section.
Separately, I attempted to identify predictors of the latent classes of always takers and
never takers. I did this by searching for predictors of treatment receipt in the control arm
(to identify predictors of the always takers class) and then searching for predictors of
treatment receipt in the D6 intervention arm (to identify predictors of never takers). Any
variables found to be predictive of these classes were then included as covariates in the
models for always takers and never takers in the stratification analysis. The aim of this
was to increase the ability of the stratification models to identify the latent compliers.
I also explored predictors of HbA1c missingness to accommodate observed variables
driving missingness in the analyses approaches. Missingness of HbA1c at the primary
endpoint (18 months) was coded as zero for missing and one for non-missing.
Pairwise associations between these variables and the main baseline demographic and
clinical variables were investigated using logistic regression. The baseline variables avai-
lable in D6 were gender, marital status, ethnicity, borough, education, age, employment,
duration of diabetes and baseline HbA1c. Levels of the categorical variables in this list
were coded in the same manner as they were in the primary analysis of the trial.
7.3.4 Efficacy estimators
A list of estimators that were applied to the D6 primary outcome (HbA1c) data is given in
Table 7.2 (all of these were introduced in Chapter 4). The first four rows are estimators
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that will be applied to a binary measure of treatment receipt; the fifth will be applied to
a continuous measure of treatment receipt. Estimators E-IV7 and E-IV8 used software
that fitted the 2SLS model in one go and therefore used the treatment fidelity assessment
sample. For this reason I will summarise this sample in the results section and make
comparisons between this sample and the full trial sample. The other estimators, which
fitted separate models for treatment receipt and outcome, used all available adherence
data and the full trial sample.
Table 7.2: List of estimators from Chapter 4 that were applied to D6 primary outcome
data.
Estimator name






Modified Bloom/ratio estimator with
bootstrap standard errors, incorporating
binary measure of treatment receipt in
both trial arms
E-IV6 Section 4.5.2, Bloom/ratio estimator with binary mea-
sure of treatment receipt in both trial arms
E-IV7 Section 4.5.2, Two-stage least squares estimator with bi-
nary measure of treatment receipt in both
trial arms
E-STR3 Section 4.5.1 Structural equation mixture model (prin-
cipal stratification) with binary measure
of treatment receipt in both trial arms
E-IV8 Section 4.5.2 Two stage least squares estimator with
continuous measure of treatment receipt
in both trial arms
7.3.5 Software implementation
HbA1c data were modelled using IV estimators and one stratification estimator (using
the principal stratification framework). The IV estimators were performed in Stata 14
(StataCorp, 2015) and stratification models were fitted in MPlus v7.11 (Muthén and
Muthén, 2012).
Main analysis of efficacy with binary treatment receipt
I chose the Bloom/ratio estimator (E-IV6) for the main analysis of efficacy with binary
treatment receipt (i.e. estimation of CACE). As a reminder, the ratio is defined as the
estimator of effect of random treatment allocation on outcome (i.e. ITT effect) divided
by the estimated proportion of latent compliers. The reasons for choosing this estimator
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as the main analysis were twofold. Firstly, it made the least restrictive missing data
assumptions. By modelling the effects of random treatment allocation on treatment
receipt and outcome separately, the estimators could make full use of the available data
and include any baseline predictors of outcome missingness. Secondly, it allowed the
inclusion of baseline variables that were predictive of outcome, thereby increasing power.
This included all the covariates that were used in the original ITT analysis carried out by
the trial team with the exception of time since here analyses were performed separately at
each time point. This meant that the variables borough, recruitment phase, and baseline
HbA1c were included as covariates. Borough and baseline HbA1c were expected to be
predictive of outcome; recruitment was performed in two phases hence its inclusion in
the model. The other benefit of this was that it allowed a direct comparison to be made
with the effectiveness analysis which included these covariates (i.e. the primary analysis
of D6; Ismail et al., 2018).
In order to execute the Bloom/ratio estimator, two regressions were run. Firstly, treatment
receipt was regressed on random treatment allocation and the estimated difference in
treatment receipt between the trial arms (i.e. proportion of latent compliers) was saved.
Then, outcome was regressed on treatment allocation together with any other variables
that were predictive of outcome or its missingness and the estimated trial arm difference
(the ITT estimate) was saved. A bootstrap program was used to estimate the ratio of these
estimates (ITT estimate / proportion of latent compliers) and then compute the standard
error for this. The seed was set to 1987, with 200 replications, and resampling at the level
of the cluster (nurse). This accounts for clustering of outcome data due to randomisation
of primary care surgery / nurse units. Two hundred replications is the upper limit of
the range recommended as necessary for normal-approximation confidence intervals
(Mooney and Duval, 1993). The code for this model can be found in Appendix C.1. This
estimator assumes that missing data are MAR where only observed outcome data and
covariates predict missingness. Because the program regressed treatment receipt and
outcome separately it made full use of data for each. Therefore the regression model for
outcome utilised the full trial sample.
Sensitivity analyses of efficacy with binary treatment receipt
For binary treatment receipt, I applied a number of other estimators in order to assess
the sensitivity of the results to inclusion of covariates and assumptions regarding missing
outcome data.
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I wrote a Stata program to perform the modified Bloom/ratio estimator with treatment
receipt allowed to predict missing outcome data and bootstrap standard errors (estimator
E-IV5). The program regressed treatment receipt on random treatment allocation and
saved the estimated intercept (proportion of contaminators) and slope (difference in
proportions receiving treatment between the trial arms; also the proportion of latent com-
pliers) as local macros. The observed means of HbA1c stratified by treatment allocation
and treatment receipt were also saved. These saved estimates and means were combined
to form a ratio as given in Equation 4.11 in Chapter 4. Stata’s ‘bootstrap’ command was
used to sample from this ratio in order to obtain standard errors. The same seed, number
of replications, and level of resampling (to account for clustered data) were used as
before. The Stata code that was used for this is included in Appendix C.2. This estimator
assumes that missing data are MAR where observed outcome data and binary adherence
predict missingness. It does not allow the inclusion of covariates in the model for the
ITT effect. Likewise to estimator E-IV6, this estimator modelled treatment receipt and
outcome separately, implying that the model for outcome used the full trial sample.
The 2SLS estimator (E-IV7) was calculated using Stata’s ‘ivregress’ command. The
exposure variable was binary treatment receipt and the instrument was random treatment
allocation. Standard errors were constructed using the clustered sandwich estimator,
where clusters were nurses, in order to take account of nurse clusters. Model covariates
were any variables that were found to be predictive of treatment receipt and HbA1c
missingness. Also included were the covariates that were predictive of outcome. These
were the covariates included in the ITT analysis by the trial team and were listed in the
model for estimator (E-IV6). This estimator assumes MAR where observed outcome
and the covariates can predict missingness. Because it simulataneously performs both
steps of the 2SLS, the estimator utilised only data from the treatment fidelity assessment
sample.
The stratification estimator used a mixture model with three latent classes representing
the always takers, never takers, and latent compliers. Latent class membership predicted
receipt of treatment in the standard care arm (contamination) and receipt of active
treatment in the D6 intervention arm (observed compliance). These two parameters
were set in such a way that the thresholds enabled perfect prediction by latent class. For
example, among the always takers both thresholds were set to the logit value of -15 which
meant that members of that class had probability one of receiving treatment under both
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allocation to standard care and D6 intervention. The structural model regressed HbA1c
on the covariates used in the ITT estimation (borough, randomisation phase, baseline
HbA1c) as well as any variables that were identified as predictors of missingness of HbA1c
at follow-up. The structural model also regressed membership of the always takers class
on any variables that had been found to be predictive of treatment receipt in the standard
care arm. Separately it regressed membership of the never takers class on variables
found to be predictive of treatment receipt in the D6 intervention arm. This was done to
increase precision of the identification of latent compliers (i.e. the remaining class having
identified always and never takers) and therefore increase power. The models were fitted
under the assumptions of MAR and LI. Under MAR, any baseline variables found to be
predictive of missingess were included as covariates in the structual model. Under LI, a
dummy variable for outcome response (0=missing, 1=non-missing) was generated and
regressed on the same covariates that were in the model for outcome. The compound
exclusion restriction was implemented by restricting the parameter for the effect of trial
arm on this response variable to be zero for the always takers and never takers. It was
not possible to account for clustering of outcome data (due to nurse-patient clusters)
in the MPlus mixture model. The code for the model that estimated efficacy at nine
months after randomisation under the assumption of latent ignorability can be found in
Appendix C.3. The structural part of the SEM includes separate models for latent class
membership and outcome. Therefore this estimator used data from the full trial sample.
Continuous treatment receipt
The two-stage least squares estimator for a continuous exposure variable (E-IV8) was
also generated using Stata’s ‘ivregress’ command. The exposure variable was MITI Global
Spirit, where a value of one represented no receipt of treatment and a one-unit increase
in dose represented a moderate difference in receipt of MI between the counterfactual
worlds. The instrumental variable was random treatment allocation. Covariates included
those used in the ITT model (borough, randomisation phase, baseline HbA1c) and any
variables that were found to be predictive of missingness at follow-up to facilitate a
relaxed MAR assumption. Standard errors were constructed using the clustered sandwich
standard error, where clusters were nurses. The software simulataneously performs both




7.4.1 Patient sample characteristics
A brief summary of the sample for whom fidelity assessments were available was given
in Chapter 3. A fuller description is given here to allow comparison with the trial’s
target population. Participants were mostly in mid-life, were evenly split between the
genders, with no ethnicity being in the majority. About half were married or cohabiting,
a large minority had no formal educational qualifications, and most were not in work.
Full details are given in Table 7.3. The sample of participants with at least one fidelity
assessment did not show any evidence of trial arm imbalance in terms of age, gender,
ethnicity, relationship status, duration of illness, and baseline body mass index (BMI).
There was some evidence that the D6 intervention group had received a higher level of
education and were more likely to be in employment than the standard care group. In
addition, there was some suggestion of a relationship between borough and trial arm for
this sample.
The sample for whom fidelity assessments were available was similar to the full trial
sample in terms of age, gender, relationship status, education level, employment, duration
of diabetes (years), baseline HbA1c, and BMI. The fidelity assessment sample comprised
a slightly greater proportion of participants of white ethnicity (and lower proportion of
African/Caribbean ethnicity), and a smaller proportion of participants from Southwark
(and greater proportion from Lewisham) with none from Bexley (in contrast to a small
proportion from there in the trial sample).
7.4.2 Adherence with allocated treatments
Using the definition of binary adherence described earlier, 64 (86.5%) participants were
deemed to have received treatment in the D6 intervention arm and 38 (49.4%) were
regarded as having received it in the standard care arm. Using the terminology of
principal stratification, this meant that the estimated proportion of never takers in the
population was 13.5% and of always takers was 49.4%. This meant that the estimated
proportion of latent compliers was 37.1%.
Unadjusted odds ratios between baseline variables and treatment receipt (across both
trial arms) are given in Table 7.4. The table shows that none of the continuous or
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Table 7.3: Summary of patient characteristics for the treatment fidelity assessment
sample.





Age (years; mean; SD) 59.2 (11.9) 59.7 (10.4)
Gender (n; %) Male 37 (48.1) 37 (50.0)
Female 40 (51.9) 37 (50.0)
Ethnicity (n; %) White 35 (45.5) 33 (44.6)
African / Caribbean 28 (36.4) 32 (43.2)
Asian / other 14 (18.2) 9 (12.2)
Relationship status (n;
%)
Married / cohabiting 40 (52.6) 36 (48.6)
Separated / divorced /
widowed
18 (23.7) 23 (31.1)
Single 18 (23.7) 15 (20.3)
Education level (n; %) A levels or higher 17 (22.7) 22 (30.6)
O level / GCSE /
equivalent
22 (29.3) 30 (41.7)
No formal qualifications 36 (48.0) 20 (27.8)
Employment (n; %) In employment 27 (35.1) 33 (44.6)
Not in employment 50 (64.9) 41 (55.4)
Borough (n; %) Lambeth 19 (24.7) 40 (54.1)
Southwark 20 (26.0) 1 (1.4)
Lewisham 33 (42.9) 10 (13.5)
Wandsworth 5 (6.5) 23 (31.1)
Bexley 0 (0) 0 (0)
Duration of diabetes (ye-
ars; median; IQR)
9 (5-12) 10 (7-13)
HbA1c (mmol/mol;
mean; SD)
80.3 (20.9) 79.8 (16.6)
Body mass index (kg /
m2; mean; SD)
31.5 (6.3) 31.4 (5.7)
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Table 7.4: Unadjusted odds ratios for possible predictors of treatment receipt.
Variable Level Odds ratio Inference*
Age 0.98 z = -1.27; p = .21
Gender Male
Female 0.78 z = -0.70; p = .48
Ethnicity White
African / Caribbean 1.43




Separated / divorced /
widowed
0.85
Single 1.31 χ2(2) = 0.72; p = .70
Education level A levels or higher
O level / GCSE / equivalent 0.70
No formal qualifications 0.34 χ2(2) = 5.89; p = .05
Employment In employment





Bexley - χ2(3) = 10.31; p = .02
Duration of
diabetes (years)
1.00 z > −0.01; p > 0.99
HbA1c
(mmol/mol)
0.99 z = -1.41; p = .16
Body mass index
(kg / m2)
0.96 z = -1.40; p = .16
* Tests of the null hypothesis that all odds ratios were equal to one (for each variable).
dichotomous baseline variables predicted treatment receipt. However, tests of the null
hypothesis that odds ratios were equal to one were borderline significant for ethnicity,
education level, and significant for borough. A test of the null hypothesis for relationship
status was not significant.
Investigating predictors of treatment receipt for the two trial arms separately, I found
that two baseline variables were weakly predictive of treatment receipt in the control
arm. These were gender (odds ratio 0.45, z = -1.70; p = .09, 95% CI 0.18, 1.13) and
education (test of null hypothesis that odds ratios were equal to one, χ2(2) = 5.71,
p = .06). Two variables were predictive of treatment receipt in the D6 intervention arm.
These were both strongly predictive and were borough (test of null hypothesis that odds
ratios were equal to one, χ2(1) = 8.59, p < .01) and baseline BMI (odds ratio 1.22,
z = 2.80; p = .01, 95% CI 1.06, 1.41).
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7.4.3 Missingness of HbA1c and predictors of it
Considering the full trial sample HbA1c data at all time points, the proportion of missing-
ness ranged between 33-58%. The proportion of missing data was greatest at 15 months
after randomisation and lowest at 18 months (this was the trial’s primary endpoint). It
was slightly higher in the standard care group than intervention group at 15 months;
the proportions were similar at nine and 18 months. This description was similar to the
proportion of HbA1c missingness in the treatment fidelity assessment sample, with the
caveat that overall missingness was a few percentage points lower in the fidelity analysis
dataset.
Unadjusted odds ratios between baseline variables and HbA1c response (i.e. non-
missingness) for the full trial sample at 18 months after randomisation are given in
Table 7.5. The table shows that none of the continuous or dichotomous baseline variables
predicted HbA1c response, with the exception of baseline HbA1c which was borderline
significant. A test of the null hypothesis that odds ratios were equal to one was highly
significant for ethnicity. Tests of the null hypotheses were not significant for relationship
status, education, and borough.
There was no evidence that treatment receipt predicted missingness of HbA1c at 18
months after randomisation. Amongst those participants who did not receive treatment,
35 (71.4%) had non-missing outcome data whilst this figure was 72 (70.6%) amongst
those who did receive treatment.
7.4.4 Effectiveness assessment
HbA1c for both the full trial and the treatment fidelity assessment samples is summarised
by trial arm and time point in Table 7.6. Means and 95% confidence intervals for the full
trial sample are plotted in Figure 7.1. For the full trial sample, the first part of the table
and the figure show that mean HbA1c decreased in both trial arms over time during the
first 15 months of follow-up. The level of HbA1c increased slightly between months 15
and 18. At all time points the means were similar between the trial arms.
Estimates of effectiveness using an ITT analysis for the full trial sample are given in Table
7.7. There was no evidence for a difference in HbA1c between trial arms at any time
point. This raised the question of whether an estimator of efficacy instead of effectiveness
might show a larger effect.
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Table 7.5: Unadjusted odds ratios for possible predictors of HbA1c response at 18 months
after randomisation.
Variable Level Odds ratio Inference*
Age 1.00 z = -0.05; p = .96
Gender Male
Female 1.17 z = 0.66; p = .51
Ethnicity White
African / Caribbean 2.22




Separated / divorced /
widowed
0.85
Single 1.25 χ2(2) = 1.22; p = .54
Education level A levels or higher
O level / GCSE / equivalent 0.91
No formal qualifications 0.95 χ2(2) = 0.09; p = .96
Employment In employment





Bexley 0.22 χ2(4) = 6.20; p = .18
Duration of
diabetes (years)
1.01 z = 0.69; p = .49
HbA1c
(mmol/mol)
0.99 z = -1.93; p = .05
Body mass index
(kg / m2)
1.02 z = 0.84; p = .40
* Tests of the null hypothesis that all odds ratios were equal to one (for each variable).
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Table 7.6: Summary of HbA1c (mmol/mol) at outcome time points for both the full trial
and treatment fidelity assessment samples.
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Table 7.7: Estimated difference in HbA1c (mmol/mol) between treatment groups at



























-0.15 2.60 z = -0.06;
p = .96
-5.24, 4.95
Treatment fidelity assessment sample
Nine months after
randomisation










0.98 2.77 z = 0.35;
p = .72
-4.45, 6.41
Estimates were calculated separately at the three post-randomisation time points.
Covariates were the same as those included in the primary analysis: trial arm, borough,
recruitment phase, baseline HbA1c. Clustering of outcome data was accounted for using
































Baseline 9 15 18
Time (months)
Standard care D6
95% CI 95% CI
Glycated haemoglobin by trial arm and time
Figure 7.1: Plot of means and 95% confidence intervals of standard care and D6 inter-
vention arms over time for the primary analysis (full trial) sample.
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The trends in HbA1c for only those participants who had a record of treatment fidelity were
a little different to those for the full trial sample (Table 7.6). There were approximately
half as many data points in the fidelity analysis sample as the full trial sample. Baseline
HbA1c levels were similar between the samples. However, HbA1c declined more steeply
over the first nine months in the standard care group in the fidelity analysis sample
compared to the larger sample. Therefore, at nine months after randomisation there
appeared to be a small difference in HbA1c levels between the trial arms, with the
standard care group demonstrating better control of HbA1c. At 15 months this gap was
maintained but at 18 months the difference had disappeared.
For the treatment fidelity assessment sample, the inferential ITT analysis demonstrated
weak evidence of a difference between the trial arms at nine months after randomisation
(Table 7.7). The estimate was positive implying that HbA1c was greater (i.e. worse)
in the D6 intervention arm. This difference diminished somewhat at 15 months and
particularly at 18 months; the differences were not significant at both of these time
points. This meant that there were some differences in the estimates at nine and 15
months between the full trial and treatment fidelity assessment samples. The difference
was small at 18 months.
7.4.5 Efficacy assessment
Efficacy estimates at the three post-randomisation time points for each of the estimators
where treatment receipt was defined on a binary scale are given in Table 7.8. What
follows is a description of the efficacy analyses using a binary measure of treatment
receipt. I have split this into the main analysis using estimator E-IV6 followed by sensivity
analyses using the other estimators proposed in Chapter 4 (estimators E-IV5, E-IV7, E-
STR3). Finally, I describe the efficacy analysis with continuous treatment receipt using
estimator E-IV8.
Main analysis of efficacy with binary treatment receipt variable
Estimator E-IV6 - Bloom/ratio estimator with bootstrap standard error
Estimates of CACE using estimator E-IV6 were positive (in direction of higher/worse
HbA1c in the D6 intervention arm) at all three time points. The numerator part of the
ratio, which was the regression of outcome on random treatment allocation, covaried for
the same baseline variables that were used in the ITT analysis together with variables
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Table 7.8: Estimated differences in HbA1c (mmol/mol) between treatment groups at
outcome time points using efficacy estimators with binary measure of treatment receipt.

















Main analysis of efficacy
E-IV6* 9 months 3.73 12.65 z = 0.30,
p = .77
-21.06, 28.53
15 months 5.77 9.67 z = 0.60,
p = .55
-13.19, 24.73
18 months 1.19 11.67 z = 0.10,
p = .92
-21.69, 24.07
Sensitivity analyses of efficacy
E-IV5 9 months 8.92 13.43 z = 0.66,
p = .51
-17.40, 35.24
15 months 9.68 17.21 z = 0.56,
p = .57
-24.04, 43.40
18 months -1.87 9.01 z = -0.21,
p = .84
-19.52, 15.79
E-IV7* 9 months 25.84 11.11 z = 2.33,
p = .02
4.07, 47.62
15 months 12.45 8.13 z = 1.53,
p = .13
-3.49, 28.39






9 months 0.63 6.41 z = 0.10,
p = .92
-11.94, 13.20
15 months 2.16 6.58 z = 0.33,
p = .74
-10.73, 15.05






9 months -4.78 13.95 z = -0.34,
p = .73
-32.12, 22.55
15 months 1.03 7.12 z = 0.14,
p = .89
-12.92, 14.97
18 months 7.14 8.07 z = 0.89,
p = .38
-8.68, 22.96
* Covariates in the model for outcome included borough, recruitment phase, baseline HbA1c,
ethnicity and education.
† Covariates in the model for outcome included borough, recruitment phase, baseline HbA1c
and ethnicity.
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that were found to be predictive of observed treatment receipt. These estimates should
be compared to the effectiveness estimates for the full trial sample (see first part of
Table 7.7). The efficacy estimates showed a similar pattern to the effectiveness estimates
(largest at 15 months and smallest at 18 months) and were larger at all time points. The
precision of the efficacy estimates was considerably less than that of the effectiveness
estimates.
Sensitivity analyses of efficacy
Estimator E-IV5 - modified Bloom/ratio estimator (incorporating observed adhe-
rence) with bootstrap standard errors
Estimates of CACE using estimator E-IV5 were positive (in direction of higher or worse
HbA1c in the D6 intervention arm) at nine and 15 months and negative at 18 months.
Likewise to efficacy estimator E-IV6, these estimates should be compared to the first
set of effectiveness estimates (the full trial sample). Efficacy estimates at all three
time points were in the same direction as the effectiveness estimates and standard
errors were considerably larger. It should be noted that these estimators did not covary
for baseline variables that were predictive of outcome (and featured as covariates in
the effectiveness estimators) or for baseline variables that were predictive of outcome
missingness. In addition, the ratio estimator of efficacy allowed observed adherence to
predict missingness of outcome which the ITT analysis did not.
Estimator E-IV7 - two-stage least squares estimator
Estimates of CACE using estimator E-IV7 were positive (in direction of worse HbA1c in D6
intervention arm) at all time points. Estimates were considerably larger than estimates
for the previous IV estimators of CACE. Estimates should be compared to the effectiveness
estimates for the treatment fidelity assessment sample. The efficacy estimates were in
the same direction and showed the same pattern, i.e. largest at nine months (when it
was statistically significant) and diminishing after this. Precision was substantially lower
at all time points.
Estimator E-STR3 - stratification estimator with structural models for outcome, al-
ways takers class, and never takers class
Estimates of CACE using estimator E-STR3 were positive (in direction of worse HbA1c
in D6 intervention arm) at all time points under the assumption of MAR. The smallest
estimated effect was at nine months and largest at 18 months. Under the assumption of
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LI, the results at 15 and 18 months were similar to those under the assumption of MAR,
but the estimate at nine months was in the opposite direction and slightly larger. For
the MAR models, the estimated proportions of latent compliers ranged between 37.1%
and 42.3% over the three time points; for the LI models, this range was 26.4% to 41.0%.
The stratification estimates under the assumption of MAR can be roughly compared to
the effectiveness estimates for the full trial sample. The stratification efficacy estimates
were larger in magnitude than the effectiveness estimates but patterns across time points
were different. This may be because the models are not entirely comparable as the
stratification estimators use different covariates in the structural model for outcome (they
include predictors of class membership). Standard errors were larger than those of the
effectiveness estimates, particularly at nine months under the LI assumption.
Analysis of efficacy with continuous treatment receipt variable
Estimator E-IV8 - two-stage least squares estimator
The estimates of efficacy using estimator E-IV8 are shown in Table 7.9. They estimate
the causal treatment effect on HbA1c associated with a one-unit increase in the difference
of MITI Global Spirit between the counterfactual situations. This is to say that they
estimate ACEd1+1,d0–ACEd1,d0 . The pattern of estimates can be compared to the pattern
of effectiveness estimates for the treatment fidelity assessment sample (i.e. magnitude
of effect was greatest at nine months then reduced). At 18 months, the results imply
that the predicted effect of treatment at the maximal difference in dose between the
counterfactual situations was 5.67 mmol/mol (SE 6.79, z = 0.83, p = .40, 95% CI
-7.64, 18.99). Estimated causal treatment effects (and 95% confidence intervals) for
the maximum difference in dose between the counterfactual worlds at all three post-
randomisation time points are shown in Figure 7.2.
7.5 Discussion
In this section I will summarise the main results from the efficacy analyses. I will then
return to the statistical issues that I identified at the beginning of the methods section
of this chapter. For binary treatment receipt, I will explore the impacts of inclusion
of covariates in models and assumptions regarding missing data. I will interpret the
estimates of efficacy for a continuous measure of treatment receipt and explore the
estimator’s assumptions. Finally, I will draw some conclusions on the D6 trial and
210
Table 7.9: Estimated differences in HbA1c (mmol/mol) at outcome time points using


















E-IV8* 9 months 5.27 2.12 z = 2.49,
p = .01
1.13, 9.42
15 months 2.89 2.04 z = 1.42,
p = .16
-1.11, 6.89
18 months 1.42 1.70 z = 0.83,
p = .40
-1.91, 4.75






























Estimated treatment effect by time
Figure 7.2: Plot of estimated causal treatment effects associated with maximal difference




Overall, the efficacy estimators provided little evidence of a treatment effect and no
evidence of treatment benefit in the D6 trial. When treatment receipt was binary, the main
efficacy estimates at the three post-randomisation time points were positive, meaning
that the level of HbA1c in the experimental treatment group was estimated to be slightly
greater, and therefore worse, than in the standard care group. Point estimates of efficacy
and standard errors were larger than those of effectiveness at the same time points. The
main efficacy analysis showed that estimates peaked at 15 months. This pattern was
consistent with the estimates of treatment effectiveness. These findings were entirely
consistent with my predictions at the beginning of this chapter. When treatment receipt
was continuous, the estimated effects were also positive at all time points. The largest
estimated treatment effect was at nine months after randomisation (and was statistically
significant); after this, results diminished with time. The pattern of estimates was similar
to an effectiveness analysis that was restricted to those participants who made up the
treatment fidelity assessment sample. These findings were roughly consistent with my
predictions, although the significant result at nine months after randomisation was a
surprise. I will consider this further below.
The main statistical issues were how to estimate efficacy in the presence of non-adherence
to randomised treatment allocation, the presence of missing adherence and outcome
measures, and clustering due to randomisation of primary care sugeries. All estimators
assumed that missing adherence data were MCAR, or equivalently it was assumed that
the non-missing data constituted a random subsample of the full trial sample. I addressed
clustering by either bootstrap sampling at the level of the cluster (for the ratio estimators)
or using the clustered sandwich estimator (for the 2SLS models). The estimators that I
applied to D6 differed in whether or not they could accommodate baseline predictors
of outcome. Estimators E-IV6, E-IV7, E-STR3 and E-IV8 allowed inclusion of such
covariates in the model for outcome. They also differed in the strictness of their missing
outcome data assumptions. Certain estimators could accommodate outcome data from
participants whose adherence measures were missing (i.e. E-IV5, E-IV6, E-STR3). Some
estimators were able to accommodate predictors of missing outcome (i.e. E-IV6, E-IV7,
E-STR3, E-IV8).
When treatment receipt was binary, the main analysis used an estimator that used all
available data, allowed the inclusion of baseline predictors of outcome, and enabled
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a relaxed MAR assumption. Other estimators explored the sensitivity of estimates to
changes in these model specifications. The main difference was whether or not estimators
made use of outcome data from participants whose adherence measures were missing.
The effectiveness analyses showed that effect estimates were greater for the treatment
fidelity assessment sample than the full trial sample. This was particularly true at nine
months (when the estimate was significant) and 15 months after randomisation. These
effects were likely an artefact of the MCAR assumption about HbA1c data that were
discarded. This also provides an explanation as to why the 2SLS estimates were larger
than the other efficacy estimates. Estimators that allowed the inclusion of baseline
predictors of outcome tended to demonstrate greater precision than those that did
not. This would seem to be particular important in the estimation of efficacy, given
the unavoidable loss in precision in comparison to estimators of effectiveness. Finally,
comparing precision between the IV and stratification models, the latter’s standard
errors tended to be slightly smaller than those of the IV models. This was most likely
a consequence of the fact that these models included predictors of membership of
the principal strata. All of these models made the assumption that treatment was
appropriately categorised. This is to assume that all participants whose treatment was
below a certain level did not receive D6 intervention and all those whose treatment was
above that level did receive it. If this categorisation were false, this would undermine
the exclusion restriction.
When the treatment receipt variable was continuous (using MITI Global Spirit), the
predicted treatment effects at the maximum difference in potential dose between the
counterfactual situations decreased with time. The estimated treatment effect at nine
months after randomisation was statistically significant, but not in the direction of
treatment benefit. This was consistent with the pattern of effectiveness estimates for
the treatment fidelity assessment sample. It suggested that the discarding of outcome
data for those with missing adherence measures led to bias. The model with continuous
treatment receipt assumed that MITI Global Spirit provided an accurate measure of the
exposure variable and that the relationship between the difference in potential dose
and the treatment effect was linear. This second assumption can only be tested with a
much larger sample. The utility of predicted treatment effect at the maximum difference
in potential dose may be limited as this applies to the small or perhaps non-existent
subpopulation who would receive no psychological treatment if offered control and a
full version of the treatment under its offer.
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All of the models fitted in this chapter provided randomisation-based estimators. This
means that comparisons were between groups that were defined by the outcome of
random treatment allocation. All of these estimators assumed that there was no treatment
effect amongst the latent classes of never takers and always takers. Put another way,
this assumed that there was no effect of treatment offer on outcome other than through
receipt of active intervention when offered it. This assumption is not empirically testable
but may be vulnerable in a trial where clinicians and patients could not be kept blind,
such as the D6 study. A limitation of this research was the methodology that I used to
measure treatment receipt. As described in Chapter 3, I sampled from and rated one
or two audio recordings of treatment per patient from sessions two, three and four of
a treatment that could comprise as many as 12 sessions. The sample did not cover all
trial participants and it is also possible that this sample did not provide a full picture
of treatment fidelity over the whole course of the treatment regimen. In addition to
this, the ratings of treatment fidelity did not cover other important aspects of process
evaluation such as number of sessions attended and therapist alliance.
The lack of a treatment effect in the D6 trial adds to the mixed evidence for diabetes-
specific, nurse-delivered psychological therapy that exists in the literature. This research
is consistent with the findings of Jansink et al. (2013a), who tested nurse-led structured
diabetes care (which included nurses being trained in MI) in comparison to usual care in
the general practice setting. They found no evidence of an effect of this intervention on
levels of HbA1c. This is in contrast to Ismail et al. (2008) who found that motivational
enhancement therapy plus CBT in comparison to usual care led to a reduction in HbA1c
of 5.0 mmol/mol for patients with type 1 diabetes.
The effectiveness analysis concluded that there was no effect of the offer of treatment
while this analysis found that there was no effect of its receipt. The fidelity analysis
described in Chapter 3 found that primary care nurses may not be suited to the acquisition
and delivery of psychological skills, despite intensive training. This chapter has concluded
that there was no evidence of a benefit of receipt of nurse-led psychological treatment




8.1 Overview of thesis
This thesis has explored many aspects of the problem of treatment contamination in
trials of complex interventions in mental health. It started by investigating the processes
driving contamination in this area of medical research, its quantity, the steps researchers
take to minimise the problem, and the extent to which its avoidance impacts on outcomes.
In its early stages it also assessed the extent of the problem in a particular trial, D6, that
motivated the research. The trial assessed the effectiveness of psychological treatment
for people with poorly controlled T2D. The trial was chosen to motivate this research
because anecdotal evidence and the primary treatment fidelity assessment suggested
that there may have been some treatment receipt amongst patients in the control arm.
The research provided an opportunity to assess treatment fidelity for a large subsample
of participants and then to estimate the effect of treatment receipt on outcome.
This research has focused throughout on the estimation of efficacy in the context of a trial
with contamination, although these methods can easily be adapted to address treatment
non-receipt in the active intervention arm (non-compliance) as well. I summarised exis-
ting randomisation-based efficacy estimators for evaluating this in individual randomised
trials. I then developed a novel estimator of efficacy in trials with contamination and
non-compliance measured on a continuous scale. These estimators were later applied to
D6 for a secondary (efficacy) analysis of the trial’s primary outcome measures. I used
Monte Carlo simulation to compare two design options for addressing the problem of
contamination (one of which utilised the aforementioned efficacy estimators). An online
decision support tool that utilises the results was developed and published.
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8.2 Main findings
8.2.1 Primary research objective
The primary research objective was to compare the efficiency of two competing trial design
options that address the problem of contamination and estimate efficacy. I compared
cluster randomisation at the level at which contamination was expected combined
with an estimator of ATE (ITT analysis) with individual randomisation along with an
estimator of either CACE or ACEd1,d0 (IV analysis). The ITT estimator accounted for the
clustering of outcome data that was a consequence of randomisation being applied at
the level of clinician (nested clustering, as each cluster level occurs in only one treatment
arm). Cluster randomisation was assumed to prevent any contamination. In the second
design option a record of treatment receipt was made for all participants, enabling the
estimation of treatment effect amongst those participants who would receive a greater
level of treatment under its offer than they would under offer of control (treatment receipt
could be on a binary or continuous scale). This estimator also accounted for clustering of
outcome data caused by the fact that each clinician treated multiple participants (crossed
clustering, as cluster levels occur in both treatment arms). The ITT and IV estimators
provided unbiased estimates of respective efficacy estimands.
When treatment receipt was on a binary scale, the results demonstrated that there were
three factors that determined the relative efficiency of the estimators under the two trial
design scenarios. These were the ICC and cluster size under the cluster randomisation
design, and size of the latent complier stratum (one minus the proportion of conta-
minators when there was no non-compliance) under the alternative design. For large
proportions of latent compliers (low amounts of contamination) estimation of CACE
was often more efficient, apart from at the lowest levels of simulated ICCs and cluster
sizes. As the strength of clustering increased (i.e. greater levels of ICC or cluster size, or
both), the estimation of CACE was progressively favoured. The findings were broadly
consistent with those in the report on contamination in trials of educational interventions
(Keogh-Brown et al., 2007). I described the methods of their research in detail at the
end of Section 1.5.3. Briefly, that research compared required sample size in order to
achieve 80% statistical power to detect a particular effect between CRCTs analysed with
an ITT estimator and individual randomised trials where contamination occurred with an
estimator of CACE. They did not describe the contamination process that they mimicked.
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However, its effect can be presumed to be similar to the one I have investigated, i.e.
participants either receiving active or control treatment when allocated to control. They
found that when cluster size was 10 and ICC was 0.04, a greater sample size was required
for the CRCT design option up to a level of contamination in the individual randomised
trial design option that was just under 30%. In other words, at these magnitudes of
cluster size and ICC, and when contamination was less than this level, the individual
randomised trial design (with estimation of CACE) was more efficient. Likewise, I found
that when cluster size was 10 and ICC was 0.05 (these levels being closest to those used
in Keogh-Brown et al., 2007)), the individual randomised trial design was more efficient
up a level of contamination that was between 20-30%. Keogh-Brown et al. (2007) found
that when cluster size was 30 and ICC was 0.04, the required sample size was greater for
the CRCT option at all levels of contamination that they investigated (i.e. the amount of
contamination at which the individual randomised trial required more participants was
some level greater than 30%). In comparison, I found that when cluster size was 20 and
ICC was 0.1, the individual randomised design option was more efficient up to between
50-60% contamination.
When there were both treatment contamination and non-compliance (i.e. more non-
adherence), there were fewer combinations of ICC and cluster size under which estimation
of CACE was more efficient. This was because the IV approach was weaker than before –
the presence of never takers reduced the proportion of latent compliers, thereby making
the estimation of CACE less precise at a given level of contamination. I found that neither
sample size nor treatment effect size were directly related to the relative efficiency of the
two design options.
When treatment receipt was on a continuous scale, relative efficiency between the two
design options was driven by strength of clustering under the cluster randomisation
design, and the size of the dose complier stratum and magnitude of dose compliance
within this subpopulation under the alternative design. The magnitude of dose com-
pliance parameter represented the size of the counterfactual difference in treatment
receipt between the offers of treatment and control amongst those participants where
this difference would be positive (I named this subpopulation dose compliers). When
all control participants received a dose of zero and all active intervention participants
received a full dose, the relative efficiency results were similar to those found when
treatment receipt was binary. This was because the underlying conditions between binary
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treatment receipt and continuous treatment receipt with all participants either recei-
ving full dose or no dose are equivalent. As the magnitude of dose compliance became
weaker, the efficiency of the cluster randomisation design option (clusters defined by
level at which contamination occurred and estimation of ATE) was favoured under more
levels of the other relevant parameters. The reason for this was that as dose compliance
became weaker, the dose compliers were receiving greater doses of treatment under
offer of control and lower doses of treatment under its offer. In effect, this meant more
treatment contamination and non-compliance, which favoured the cluster randomised
design option.
8.2.2 Secondary research objective
The secondary research objective was in two parts. The first was to summarise and
develop randomisation-based estimators of efficacy in an individual randomised trial
with contamination. The second was then to apply these methods to the analysis of the D6
trial, having previously constructed individual-level measures of treatment receipt. When
treatment receipt is measured on a binary scale, an efficacy estimand that has received a
large amount of attention in the literature is CACE. This is the effect of treatment offer
amongst those participants who would receive treatment when offered it and would not
receive it when offered control. When treatment receipt is measured on a continuous
scale, I defined the estimand ACEd1,d0 as the effect of treatment offer amongst those
participants who would receive some dose of active treatment under offer of treatment
(d1) and another dose of active treatment under offer of control (d0).
I summarised two main analysis approaches for estimating CACE: stratification estimators
(using the principal stratification framework) and IV estimators. The estimators are
unbiased under similar sets of assumptions (more on this in Section 8.3.3). One relative
strength of the stratification estimator over use of IVs is that it enables the assumption
regarding the missing data generating process to be further relaxed, in particular allowing
latent compliance status to predict missingness. One drawback of this estimator is a
lack of commands or functions in the most commonly used statistical software packages
that allow its calculation (the estimation must be performed using a mixture model in
specialist structural equation software such as MPlus).
I described the development of a novel estimator of treatment effect in a randomised
trial with a continuous measure of treatment receipt in both the treatment and control
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arms. This work built upon the analytical methods proposed by Maracy and Dunn
(2011). The new estimator makes four assumptions. Firstly, exchangeability of potential
dose and potential outcome between levels of random treatment allocation. Secondly,
independence of treatment allocation and the difference in the error terms between
counterfactual outcomes. When there is no difference between potential dose, this is
the exclusion restriction and, when there is a difference, this assumes that there is no
unaccounted variability in ATEs within levels of latent compliers. Thirdly, monotonicity,
which is to assume that nobody would receive a greater dose under offer of control than
treatment. Finally, a linear dose-response relationship. Under these assumptions, the
causal estimand can then be estimated using IV methods. The interpretation of this
parameter is the causal effect of treatment on outcome that is associated with a one-unit
increase in the difference between the counterfactual doses. The parameter may be
easier to interpret when it is converted into an effect that is determined by a particular
difference between the counterfactual doses, for example the effect associated with full
dose.
I applied these estimators of efficacy, for continuous and binary measures of treatment
receipt, to the D6 trial. The results showed no evidence of an effect of treatment receipt
on outcome. I demonstrated a number of approaches that can be taken towards missing
data assumptions. However, the results showed little sensitivity to these assumptions,
which was likely related to the finding that there was no relationship between treatment
receipt and missingness.
8.2.3 Tertiary research objective
The tertiary research objective was to review problems and solutions associated with
contamination in trials of complex interventions in mental health research. I conducted
a large and comprehensive scoping review of contamination in this setting, which was
the first of its kind in this area of medicine. The results of the review showed that
those designing trials perceived five main processes leading to contamination. In a large
majority of the trials, contamination was driven by two processes in particular. The first
was staff delivering the active intervention to patients in the control arm (as simulated
in Chapter 5). This might be due either to a given clinician delivering both active and
control treatments or to a clinician who is not involved in providing active treatment
learning details of the intervention and passing this on to control participants. The second
major process was communication between trial arms, which could be between clinicians
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or participants. Out of a total of 238 trials, I found 25 that measured and reported
treatment receipt on a binary scale in the control arm. The mid-point in the reported
levels of contamination was 13% (IQR 5-33%; range 0-72%). The results suggested
that the problem in mental health trials may be more limited than some researchers
and funders expect. Having said this, the range suggests that there may be some trial
designs, interventions, or populations where it is of particular concern. The review found
that those designing trials use a variety of trial conduct solutions to minimise or prevent
contamination. Common examples were to design the trial so that each clinician was
responsible for providing a single treatment, monitoring the treatment being delivered
to control participants, and holding treatment sessions at different times or in different
places, amongst others. The review featured four trials that had each allocated treatment
at both cluster and individual levels. I obtained treatment effect estimates for subtrials
that were defined by the level at which treatment was allocated. For each trial I then
compared the magnitudes of effect sizes between the subtrials. I found no evidence
of a difference, which suggested the following possibilities: cluster randomisation did
not prevent contamination, the anticipated amount of it had been overstated, or cluster
randomisation led to a similar degree of bias to that caused by contamination.
8.3 Implications for trials
8.3.1 Statistical design
The results from this research provide those designing trials with a tool for choosing the
more efficient statistical design option to address the problem of treatment contamination
when estimating efficacy. In order to provide researchers with this information, the
results from the Monte Carlo simulations in Chapter 5 have been placed online at https:
//nicholasmagill.shinyapps.io/shiny_app/. The findings build on those of
Keogh-Brown et al. (2007), who also compared the same design options that were
assessed in this research. These results can be summarised further and combined with
those of a comparison of two methods for addressing contamination when estimating
effectiveness (from Slymen and Hovell, 1997), in order to provide a general set of
guidelines for tackling the problem through trial design. The two design options that
were compared by Slymen and Hovell (1997) were:
A. Random treatment allocation at the cluster level combined with estimator of ACE
(ITT analysis) that accounts for clustered data,
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B. Random treatment allocation at the level of the individual, inflation of sample
size to account for the statistical power lost due to the estimated effect size being
biased towards the null, and use of estimator of ACE (ITT analysis).
Design option B was described in Section 1.5.1. Slymen and Hovell (1997) compared
sample size requirements under these two designs at a number of levels of cluster size,
ICC, and contamination. In other words, they assessed the relative efficiencies of the
methods as a consequence of the costs (in terms of statistical power) of cluster size and
ICC (design option A) and contamination (design option B). They calculated sample size
requirements for a trial with a continuous outcome for the two design options as follows:
A. N ′ = N[1+ I(k− 1)], where N is required sample size when randomising indivi-
duals,
B. N ∗ = N/p, where N is required sample size when randomising individuals and p
is the proportion of control participants receiving the active treatment.
In their results they calculated the ratio between the required sample sizes (N ′/N ∗) at
levels of cluster size (2; 10; 30; 100; 500), ICC (0.05; 0.1; 0.2; 0.4) and contamination
(10%; 20%; 30%; 40%; 50%). They then summarised this by cluster randomisation
inflation factor (D := 1+I(k−1); described in Section 1.5.1) and amount of contamination
(Table 1 of Slymen and Hovell, 1997). I have used those results to calculate, for a
particular level of contamination, the approximate level of the inflation factor (to one
decimal place) above which it was more efficient to randomise individuals and inflate
sample size. This is summarised in the left half of Figure 8.1. In the same figure I have
summarised the results from this research in terms of the level of the inflation factor at
which it became more efficient to randomise individuals and estimate CACE as opposed
to using cluster randomisation (and estimating ATE) for given levels of contamination.
This is shown in the right half of the figure.
The figure shows that, for both the estimation of effectiveness and efficacy, when conta-
mination is low (i.e. 10%) the cluster randomisation option is favoured under modest
inflation factors, i.e. low levels of clustering. As the amount of contamination increases,
so does the statistical cost of the individual randomisation options, and therefore the
range of inflation factors at which cluster randomisation is favoured increases. The range
of inflation factors within which the cluster randomisation option is favoured is smaller













































































































































































































































































































































































































implies an extra efficiency cost of inflating the sample size in an individual randomi-
sed trial and estimating ACE compared to a trial with individual randomisation and
estimation of CACE.
Throughout this thesis I have focused on trials in the field of mental health research.
However, these findings regarding optimal statistical design of trials with expected
contamination have utility in other areas of medical research. This is demonstrated by
the fact that the research of Slymen and Hovell (1997) was in the context of adolescent
consumption of tobacco and alcohol. It is also illustrated by the areas of medical research
where interventions have been shown to be at risk of contamination. In Chapter 1
I described relevant literature in the domains of educational intervenions, geriatric
medicine and cancer screening. As a consequence, the findings I have described regarding
the design of trials targetting efficacy may have some application in these areas.
8.3.2 Conduct
Any sample size inflation using the statistical design options above will lead to an increase
in the financial cost and duration of the research. Another set of design options that
those researchers designing trials should consider are trial conduct methods. These
are design options that affect the implementation of the trial (e.g. type of treatment,
arrangements for its delivery, recruitment criteria) and can be used specifically to prevent
delivery of treatment within the control arm. They comprise design methods that are
straightforward in comparison to those of statistical design and, if effective, may reduce
or negate the need to alter statistical design. This research aimed to describe the conduct
methods that trials in mental health take in order to address the problem. Very little
literature has assessed these options previously, with the survey of Keogh-Brown et al.
(2007) the only notable example.
The main recommendation is that researchers must first consider the process (or pro-
cesses) driving contamination before planning what to do about the problem. There
is some evidence that trialists are already doing this (in mental health trials at least)
given that the trial conduct solutions that were most commonly used related to the two
contamination processes that were found to occur most frequently: staff delivering the
active intervention to control participants and communication between trial arms (see
Table 2.4 in Chapter 2).
The summary and description in this research of trial conduct solutions for minimising
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contamination is the first time this has been attempted. Researchers are advised to
consider these in the design stage of a trial. The caveat is that the findings do not
provide any information as to the effectiveness of these conduct solutions in preventing
contamination.
8.3.3 Analysis
A requirement for any efficacy analysis of a trial with contamination is that there must
be a measure of treatment receipt for participants in the control arm. In practice, many
trials where contamination is expected to be a problem will also encounter treatment
non-receipt in the intervention arm, implying that the previous statement is true for
the whole trial. The ease of doing this depends on the study. For example, in D6 the
evaluation of treatment fidelity involved assessing the content of treatment sessions. This
was labour intensive and required specialist skills. However, assessments of treatment
receipt may be much simpler than this, for instance measurement of therapy session
attendance or asking participants whether they received a particular intervention outside
the realm of the trial.
It is recommended that the estimation of efficacy should avoid the use of as-treated or
per protocol analyses, both of which must make very strong assumptions about absence
of selection bias in order for the estimator to be unbiased. Instead it is recommended that
researchers consider estimators of CACE. This estimand can be evaluated under a set of
assumptions that are more plausible than the as-treated or per protocol analyses. Of these
assumptions, two may be problematic in the context of contamination in mental health
trials. These are the assumption of no interference and the exclusion restriction. The
breaking of the first of these is sometimes referred to as spillover (VanderWeele, 2015).
This may happen when an outcome is affected by communication between individuals,
which I found to be one of the more prominent processes leading to contamination.
There is a large and developing literature on causal estimands and estimators in this field
(Tchetgen and VanderWeele, 2012; Vanderweele et al., 2013). The notation becomes
more complicated than described in this research because potential outcomes now depend
on the exposure status of more than one individual. There are multiple estimands that
can be considered, for example the direct effect of treatment on outcome whilst holding
others’ exposure status constant. Another example is the spillover (indirect) effect of
another’s treatment on a particular individual’s outcome whilst holding this individual’s
exposure constant. There is a difference between these estimands and the parameter that
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I have been considering. The estimands from the spillover literature are interested in the
effect of the offer of treatment on outcome. When the assumption of no interference is
broken, this parameter is then partitioned into direct and indirect effects. The efficacy
parameter that I have been considering is simply the effect of treatment offer amongst
those individuals who would receive it if offered and would not receive it if offered
control. Specifically, it is concerned with the total effect of treatment offer within a
subpopulation defined by participants’ treatment receipt, i.e. the sum of direct and
indirect effects of treatment within these individuals.
The other assumption which may be problematic is the exclusion restriction. This may
be vulnerable in unblinded trials, which are common in mental health research. It is
plausible to imagine the offer of treatment alone affecting some participants’ behaviour
in a manner that may also be related to outcome. A documented example of this is
“resentful demoralisation” where trial participants could become frustrated by not being
offered their desired treatment (Onghena, 2005). Those in the control group are often
cited in this context. It is realistic to imagine that this feeling could lead to a change
in behaviour (e.g. healthier lifestyle) that could affect outcome. On a separate point,
incorrect categorisation of continuous treatment receipt could also break the exclusion
restriction.
More generally, I note that I have found no examples of mental health trials that have
addressed contamination using an analysis of CACE, unlike other areas of medical
research.
8.3.4 Reporting
A recommendation from this research is that trials should report more fully the processes
leading to contamination, the quantity of it, and a description of what was done to
ameliorate the problem than is commonly done at present. In the scoping review of
problems and solutions associated with contamination only 12% of trials that were
reviewed reported treatment receipt in the control arm, and many were vague about the
process that was considered to be driving the problem. Further methodological research
on the problem will remain a challenge unless these aspects of trials are better reported.
This is likely to be true not only in mental health but also in other research areas where
contamination is a problem, for example educational interventions and disease screening.
Solutions to the sparseness of reporting partly stem from expectations regarding the
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content of publications (e.g. the CONSORT guidelines) but also relate to the ways in
which trials are designed to assess treatment receipt. On the first of these, there are
currently two relevant CONSORT extensions that cover contamination, one for cluster
randomised trials (Campbell et al., 2012) and one for trials of nonpharmacological treat-
ments (Boutron et al., 2017). At present the CONSORT extension for cluster randomised
trials includes one item that requires authors to state the rationale for the use of cluster
randomisation. This is followed by two examples of the use of cluster randomisation
to prevent contamination. The item could perhaps be expanded to include a require-
ment for an explanation of how contamination is expected to occur, if this is part of the
rationale for randomising clusters. The CONSORT extension for nonpharmacological
treatments includes an item on “details of whether and how adherence of participants to
interventions was assessed or enhanced” (item 5d; Boutron et al., 2017, p. 43). This
item could be updated to include specific mention of whether and how adherence of
participants to the control treatment was assessed.
The second recommendation regarding the reporting of contamination relates to how
trials are designed to assess treatment adherence. At present many trials evaluate
treatment receipt amongst a small number of participants in only the active intervention
arm and make the assumption that treatment receipt in the control arm is not possible.
It is recommended that, where efficacy is the causal estimand and resources allow,
adherence should be assessed in both treatment and control arms, preferably for a large
sample of participants.
8.4 Contribution to statistical methods for dealing with con-
tamination and non-compliance
I have summarised existing statistical methods for addressing the problem of treatment
non-adherence in RCTs. This has included the defining of target treatment effects and
approaches to estimating these when treatment receipt is on a binary scale. I have
specified the conditions under which estimators of these effects are causal. I have also
described methods that account for clustering of outcome data and approaches for
addressing assumptions surrounding missing outcome values. My novel contribution
was the development of an estimand for the causal effect of treatment offer amongst a
subpopulation who would receive some dose of active treatment under its offer and some
dose of active treatment under offer of control. I explained the necessary assumptions for
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its calculation and described how it could be estimated. I then demonstrated best practice
for estimation of causal estimands in the presence of binary or continuous measures of
treatment receipt by applying these to the D6 trial.
The statistical methods I have explored for dealing with contamination and non-compliance
have focused on a particular set of circumstances. The methods apply to superiority
trials with two arms where participants receive either the experimental or comparator
treatment (or perhaps some dose of the active treatment). They have been restricted to
studies with a continuous outcome. A large part of the causal inference literature has pla-
ced the same restrictions on methods for estimating efficacy in trials with non-adherence.
However, some progress has been made in relaxing these. For example, Fischer et al.
(2010) developed structural mean models for estimating efficacy in trials with two active
treatments have Gillespie et al. (2015) have applied these to non-inferiority trials. They
demonstrated how the 2SLS method can be used to estimate efficacy. In particular, they
fitted a model to estimate treatment effects within the intervention and comparator arms,
where the difference between these effects was the estimate of efficacy. The final step
was to assess whether the confidence interval for the efficacy estimate was within the
non-inferiority margin. Other progress has been made in applying randomisation-based
efficacy estimators to binary outcome data (Cook et al., 2018). The method used the
two-stage residual inclusion approach and was demonstrated in a surgical trial with
non-adherence. The first stage of this method is to regress treatment received on random
allocation and save the residuals. The second stage is to use a Poisson model (for estima-
tion of relative risk) and regress binary outcome on treatment allocation and a covariate
representing the residuals from the first stage. This provides an estimator of the risk ratio
of treatment receipt on outcome that adjusts for any confounding of this target pathway.
Elsewhere, Clarke and Windmeijer (2010) explored how structural mean models could
be used to identify LATEs in trials with binary outcomes. They summarised the required
assumptions for estimating such effects with additive and multiplicative models.
Methods have been developed for estimating efficacy in trials with treatment switching
(participants moving between trial arms) in the context of time-to-event data. The
challenges here are to model the outcome as well as the treatment switching, which
is treated as censoring (i.e. any participant’s follow-up after the switch is excluded;
Watkins et al., 2013). Inverse probability weightings can be used to adjust for censoring,
i.e. those participants who are not censored are assumed to be representative of those
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who are censored (conditional on model covariates) and are therefore upweighted. This
assumption rests on there being no unmeasured confounders of the relationship between
switching and potential time to event when there is no switch. The weights are then
used in the model for the outcome. In addition, other methods have been proposed for
applying IV methods to censored outcome data. For example, Tchetgen et al. (2015)
developed methods that are analogous to the 2SLS and ATR (control function) methods
that I have described. In the context of survival outcomes, these methods involve using
predicted values or residuals in the additive hazard outcome model.
Many of the extensions to methods for estimating efficacy in trials have been developed
in recent years. My research provides a contribution to this set of methods with particular
application to the analysis of trials in mental health.
8.5 Contribution to the field of diabetes treatment in the con-
text of psychological medicine
Type 2 diabetes is a chronic disease with serious implications for patients and the orga-
nisation of healthcare services. For patients, complications can include heart disease,
stroke and diabetic retinopathy; the disease is associated with a reduction in life expec-
tancy of 10 years (Melmed et al., 2016). For a healthcare provider such as the NHS the
costs of treatment of chronic diseases are potentially large, especially T2D given that
its prevalence in the UK increased threefold to 4.5% between 1991-2013 (Hillier and
Pedula, 2001). The better management of chronic diseases, in particular outside hospital,
is considered a priority for the NHS (Goodwin et al., 2010). In this context the D6 trial
tested the effect of nurse-delivered psychological treatment within the setting of primary
care for people with T2D and poorly controlled blood glucose. This research project has
made contributions to this field through the assessment of treatment fidelity amongst
a large sample of trial participants and an efficacy analysis of the effect of treatment
receipt on primary outcome (HbA1c).
The treatment fidelity assessment (Chapter 3) showed that after MI and CBT skills training,
nurses had basic competencies in some psychological techniques, although there also
seemed to be some delivery of psychological treatment by nurses in the control arm. This
built upon the findings of a smaller fidelity assessment that was carried out as part of the
primary analysis of D6 (Ismail et al., 2018). That assessment sampled therapy session
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recordings by nurses rather than participants and rated only a 20-minute window within
each one. Group differences were smaller in comparison to the assessment reported
here and often did not reach statistical significance. The findings of the assessment with
the larger sample demonstrated the merits of sampling recordings by participants and
rating the whole of each session. Similar RCTs should assess treatment fidelity in a large
sample of participants and should evaluate both treatment receipt in the intervention
arm and the absence of intervention in the control arm. This enables an assessment of
what treatments participants received and therefore allows further analysis of treatment
receipt and mechanism.
There were many factors that may have contributed to limited development in skills,
including individual nurse characteristics and organisational factors such as lack of sup-
port and appropriate surgery infrastructure (Graves et al., 2016). Future studies should
focus on selection strategies for nurses that maximise chances of success, enhance the
training of nurses, give further consideration to the choice of the comparator treatments
of standard care and attention control, or contemplate the possibility that primary care
nurse acquisition of high-level MI and CBT skills is not a viable approach to improved
self-management among diabetic patients with persistent suboptimal control.
The main conclusion of the efficacy analysis (Chapter 7) was that no evidence of an
effect of treatment receipt on glycated haemoglobin was observed. This was based on a
definition of treatment receipt that stemmed from the assessment of primary care nurses’
delivery of psychological skills. It was also observed that participants in both trial arms
demonstrated a modest improvement in glycaemic control. This may have been related
to participants in both trial arms receiving more contact time with nurses. A possible
explanation for the concurrence of lack of efficacy and the small improvement across
both trial arms was the combination of characteristics of the trial population as a whole.
The population, whose median duration of diabetes was nine years, may not have been
capable of response to intervention and further improvement in glycaemic control. Such
a population had most likely already been offered considerable medical input and might
have included people who do not engage well with services.
In summary, primary care nurses struggled to acquire and deliver psychological skills
such as MI and CBT to a high level, despite the use of an intensive, manualised trai-
ning programme with ongoing supervision by an experienced clinical psychologist. The
effectiveness and efficacy analyses showed no effect of treatment on glycated haemoglo-
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bin. Further studies may be needed to determine whether, for patients to benefit from
such therapies, a different skill set may be needed in the healthcare professional or a
re-organisation of nurse practitioner time to allow for greater engagement in training
and delivery.
8.6 Strengths and limitations
The research described in this thesis constitutes a comprehensive study of the challenges
of and methods for addressing the problem of contamination in RCTs in mental health
and includes novel methods and findings. On the primary research objective, it is the most
extensive comparison of two trial design options for addressing contamination to date.
It is the first to provide a decision support tool for researchers who are considering what
do about the problem. On the secondary research objective, the work has described a
novel estimator of efficacy in the context of a trial with continuous measures of treatment
receipt in both treatment and control arms. It is the first study that I am aware of that
has used randomisation-based estimators of efficacy in the presence of contamination in
a mental health trial. On the tertiary research objective, it comprises the largest review
of contamination in trials and the first time this has been done in mental health.
The research has some notable limitations, generally with respect to the types of trials
that are being considered and the definition of contamination. There were also more
specific weaknesses in terms of the Monte Carlo simulations and the trial that was chosen
as a motivating example throughout. The research has defined contamination as the
receipt of intervention amongst participants in the control arm. This definition could
be broadened to include contamination between experimental intervention arms, for
example in a trial testing two active treatments. In addition, this research has only
considered superiority trials. This could be extended to non-inferiority trials, where the
effects of contamination would be to provide false evidence of equivalence between
treatments.
The data simulations were limited to one type of contamination, namely the crossover of
staff from treatment to control arms. I did not simulate trial data under the other main
process that can drive contamination, which is when it occurs due to communication
between patients or clinicians between different trial arms. The main challenge of
doing this would be to mimick realistically the spread of information between and
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within clusters. The investigation of bias in cluster compared to individual randomised
trials in the report of contamination in educational interventions attempted to do this
(Keogh-Brown et al., 2007). However, the authors took a “common sense” rather than
empirically-based approach to selecting levels for relevant parameters. It is not clear how
realistic levels could be selected for parameters representing the diffusion of information.
On a separate point, the comparison with the Keogh-Brown et al. (2007) research
highlights a strong assumption that I made in the data simulations: the lack of bias
associated with cluster randomisation. This could be investigated in future research.
Finally, on the subject of the data simulations, a weakness of the research is arguably
the comparison of ATE and CACE. These estimands are distinct as demonstrated by the
populations they apply to. An estimator of ATE applies to the whole population, whereas
one of CACE can be said to apply to the complier subpopulation. The justification for
comparing these target parameters was that they both constituted valid approaches to
efficacy under the respective designs of cluster and individual randomisation. However,
some investigators might take the view that ATE is the more general estimand and hence
prefer cluster randomisation and the ITT estimator irrespective of efficiency arguments.
There were some limitations regarding the design of the data simulations. First, I chose
a data generating mechanism which included a cluster-level random effect for outcome
at baseline and a random effect at the level of the cluster (therapist) for outcome at
follow-up. These effects reflected clustering due to participants sharing environments and
therapists, respectively. The baseline variable was included in analyses, thereby adjusting
for baseline cluster effects. It would have been possible to simulate clustering in other
ways by, for example, including a cluster-specific random effect that influences outcome
at both baseline and follow-up for an individual from a particular cluster. In this case, it
would have been necessary to adjust each individual’s follow-up outcome for the baseline
cluster mean as well as the individual’s baseline outcome. I could also have considered
more than two levels of clustering, for example the effect of shared environment in
addition to therapist clusters (where therapists are nested within communities) on
outcome after treatment. I specified a moderately simple data generating mechanism
in order for the methods and findings to be realistic and useful to those planning trials.
There may be some interest in investigating other data generating mechanisms in the
future according to specific trial designs and scenarios in which contamination is a
problem. Second, I simulated some trial scenarios that were not of interest to trialists
under the trial design process for addressing contamination that I recommended. As a
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reminder, my suggested plan is first to calculate sample size for an individual randomised
trial with no contamination according to particular levels of treatment effect size, power
and significance. Following this, the simulation results reported here should be used to
compare statistical efficiency between the design options associated with the presence
of cluster randomisation or contamination. In the data simulations I generated data
under many trial scenarios, which were defined by the levels of various input parameters.
These scenarios were balanced due to the fact that data were generated at combinations
of every level of these parameters. This meant that there were some trial scenarios that
were implausible according to the planning process recommended above. For example,
a researcher would never plan a trial with power of 80%, a small standardised effect
size (of 0.2) and a sample size of 100. Although some of these trial scenarios are not
practicable, the generation of data under all scenarios allowed me to plot complete
isosurfaces for the equivalence of efficiency between design options.
D6 was chosen as the motivating example because of anecdotal evidence of treatment
contamination. This happened despite the trial being cluster randomised, a design that
was chosen in part to prevent treatment receipt in the control arm. The trial was also
chosen because it enabled a measure of treatment receipt to be collected for a large
subsample of participants. In reality, such a measure was generated for only 151 out
of 334 participants (45.2%). Of these, there existed data for only 107 participants on
both treatment receipt and outcome at 18 months after randomisation (the primary
endpoint). The fact that the sample was small led to estimates of efficacy with large
standard errors. There were a number of aspects to the efficacy analysis of the trial that
suggested some uncertainty that the estimators calculated the causal effect of treatment
on outcome. In particular, assumptions remain that there was no effect of treatment
offer amongst never and always takers (the exclusion restriction) and, for the continuous
measure of treatment receipt, that the correct functional relationship between dose and
treatment effect was linear. The first of these, which is untestable, may be vulnerable
in an unblinded trial such as D6. This is because of the possibility that the offer alone
of psychological treatment may influence outcome by some route other than receipt of
treatment, for example by prompting participants to make better use of usual care or
improve aspects of lifestyle such as diet and exercise. In addition, there is uncertainty
regarding the correct measure of treatment receipt. If the true form is continuous then its
dichotomisation will result in the breaking of the exclusion restriction. Finally, without
a much larger sample size, it is impossible to assess the true shape of the relationship
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between treatment receipt and effect.
8.7 Future work
The limitations of the work that addressed the primary research objective provide some
clear avenues for further research. For instance, there would be utility in extending the
scope of the data simulations to include the scenario where contamination is driven
by communication amongst patients or clinicians in different trial arms. This would
require some information about the extent and speed of the spread of information from
the treatment to the control groups and subsequently between participants within the
control group. I am not aware of any information within the literature on this. It may be
necessary to use surveys of trialists or even a pilot study to investigate relevant simu-
lation parameters and their likely levels. As mentioned earlier, future data simulations
investigating the relative efficiency of trial design options for addressing contamination
should consider modelling the biases associated with cluster randomisation. These biases
have been well described in the past (Puffer et al., 2003; Hahn et al., 2005). Finally,
it would be informative to compare the financial costs of the various approaches for
addressing contamination in trials that are designed to estimate either effectiveness or
efficacy. This is likely to be a concern for funders but there is currently no information in
the literature on this subject.
The work on efficacy estimators has highlighted some potential extensions to the methods.
The estimands that I have considered relate to treatment efficacy, which was defined as
the effect of treatment receipt amongst either the whole population or the compliers. One
possible extension in the context of contamination would be to explore a new estimand,
the contrast between offer of active treatment and receipt of control. This could be
defined as the effect of treatment offer within the latent compliers and never takers:
LATEc,n := E[Yi(R = 1)− Yi(R = 0)|Ti(1)− Ti(0) = 1, Ti(1) = Ti(0) = 0]
where the subscripts ‘c’ and ‘n’ refer to latent compliers and never takers respectively. The
combination of latent compliers and never takers are observed as a mixture of treatment
receivers and non-receivers when offered active treatment, and observed as control
receivers when offered control. This target effect is a LATE and could be estimated as the
average of the effects amongst compliers (CACE) and amongst never takers (assumed to
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be zero), weighted by the proportions of these subpopulations:
ÛLAT Ec,n :=pˆ ·ØCAC E + (1− pˆ) · 0
=pˆ · E[Yi(R = 1)− Yi(R = 0)|Ti(1)− Ti(0) = 1]
where p = pcpc+pn (i.e. proportion of compliers divided by summed proportions of com-
pliers and never takers).
On a more general level, there is a need for further research into treatment contamination
in mental health trials. For instance, there is still little understanding in many cases
about precisely why contamination occurs. I am not aware of a trial that has assessed
and described in detail the processes that drove contamination. There may also be
some utility in describing the characteristics of those participants whose treatment is
contaminated. By contrast, this research has only attempted to estimate their proportion.
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The sections of this appendix refer to the scoping review of problems and solutions
associated with contamination in mental health trials. This was the subject of Chapter 2.
A.1 Ovid search procedure
The steps used in the Ovid search procedure for trials of complex interventions in mental
health where contamination was a problem are listed below.
1. (randomized controlled trial or randomised controlled trial).pt,dt.
2. controlled clinical trial.pt,dt.





8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not humans).sh.
10. 8 not 9
11. (complex adj3 intervention).af.
12. (complex adj3 treatment).af.
13. (complex adj3 training).af.
14. (multicomponent adj3 intervention).af.
15. (multicomponent adj3 treatment).af.
16. (multicomponent adj3 training).af.
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17. (multifaceted adj3 intervention).af.
18. (multifaceted adj3 treatment).af.
19. (multifaceted adj3 training).af.
20. (social adj3 intervention).af.
21. (social adj3 treatment).af.
22. (social adj3 training).af.
23. (psychological adj3 intervention).af.
24. (psychological adj3 treatment).af.
25. (psychological adj3 training).af.
26. (psychological adj3 therapy).af.
27. (psychosocial adj3 intervention).af.
28. (psychosocial adj3 treatment).af.
29. (psychosocial adj3 training).af.
30. psychotherap*.af.
31. therapist.af.
32. (behavio?ral adj3 intervention).af.
33. (behavio?ral adj3 treatment).af.
34. (behavio?ral adj3 training).af.
35. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or
25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
36. (treatment adj6 contaminat*).af.
37. (arm adj6 contaminat*).af.
38. (control adj6 contaminat*).af.
39. (group*1 adj6 contaminat*).af.
40. (outcome adj6 contaminat*).af.
41. (trial adj6 contaminat*).af.
42. (patient*1 adj6 contaminat*).af.
43. (intervention adj6 contaminat*).af.
44. (treatment adj6 spillover).af.
45. (arm adj6 spillover).af.
46. (control adj6 spillover).af.
47. (group*1 adj6 spillover).af.
48. (outcome adj6 spillover).af.
49. (trial adj6 spillover).af.
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50. (patient*1 adj6 spillover).af.
51. (intervention adj6 spillover).af.
52. 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or
50 or 51
53. (blood adj3 contaminat*).af.
54. (microb* adj3 contaminat*).af.
55. 53 or 54
56. 52 not 55
















73. (genes or genetic*).ti.
74. (genes or genetic*).sh.




79. 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or
72 or 73 or 74 or 75 or 76 or 77 or 78
80. 57 not 79





85. 82 or 83 or 84
86. 81 and 85
A.2 Pro forma for information/data extraction
Each article that was found using the search procedure above was assessed using five
inclusion criteria. Articles that met all five criteria were then assessed for bias, trial design,
contamination process and particular parameters of interest. The inclusion criteria and
assessment items are listed below.
Inclusion criteria
Is it within the context of a specific randomised controlled clinical trial? (Yes; no)
Is it a complex intervention? I.e. an intervention where multiple components work
together to produce some extra benefit. (Yes; no)
Does it discuss the process that lead to contamination of the control arm? (Yes; no)
Is it in English? (Yes; no)
Is it mental health related (target population; intervention; primary outcome)? (Yes; no)
Assessment of bias
Jadad score (0-5)
Was allocation sequence adequately generated? (Selection bias) (Done; not done; un-
clear)
Was allocation adequately concealed? (Selection bias) (Done; not done; unclear)
Did randomisation occur after consent was obtained? (Selection bias) (Done; not done;
unclear)
Were baseline measures completed before randomisation? (Selection bias) (Done; not
done; unclear)
Were baseline outcome measurements similar across trial arms? (Selection bias) (Done;
not done; unclear)
Were baseline characteristics similar across trial arms? (Selection bias) (Done; not done;
unclear)
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Was knowledge of allocation adequately prevented during study? (Performance bias)
(Done; not done; unclear)
Was assessment blinded? (Assessor bias) (Done; not done; unclear)
Were incomplete outcome data adequately addressed? (Attrition bias) (Done; not done;
unclear)
Was there evidence of similar attrition in the trial arms? (Attrition bias) (Done; not done;
unclear)
Was study free from selective outcome reporting? (Reporting bias) (Done; not done;
unclear)
Was study free from other risks of bias? (Other biases) (Done; not done; unclear)
If it is a late phase trial, is a sample size calculation report? (Done; not done; unclear)
If it is a cluster RCT (and late phase), was sample size inflated for clustering? (Done;
not done; unclear)
If qualifying, trial design
Type of trial (early phase; late phase)
What is the target population? (Free text)
Definition of intervention. (Free text)
Definition of comparison group. (Free text)
Number of trial arms. (Numeric)
What is the primary outcome? (Free text)
Length of follow-up (months). (Free text)
Unit of randomisation. (Individual; cluster)
If cluster randomisation, what is the cluster? (Free text)
At what level is the intervention provided? (Participant; clinician; school class; organisa-
tion; community)
Contamination (describing contamination process)
How was contamination anticipated or thought to have taken place? (free text)
Was it considered to have resulted from communication? (yes; no)
If yes, was communication thought to occur at the same level as the intervention was
provided? (yes; no)
When was contamination anticipated / observed to take place? (Any time after interven-
tion; During delivery of intervention; During data collection; Unclear)
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Was there empirical evidence that was thought to represent the effect of contamination
(or lack of)? (yes; no)
If yes, what was this evidence? (free text)
Were any actions (apart from cluster randomisation) proposed to address contamination?
(yes; no)
If yes, what were these? (free text)
Was cluster randomisation used to avoid contamination? (yes; no)
If yes, what was the rationale for the choice of the cluster? (free text)
Simulation parameters
From sample size calculation:
• Predicted average cluster size. (Numeric)
• Predicted range of cluster sizes
• Predicted intraclass correlation coefficient
• Predicted design effect (1+ICC(K-1))
• Planned power (for main analysis)
• Alpha level
• One or two-sided test. (One-sided; two-sided)
• Anticipated drop-out
• Sample size intention
• Anticipated treatment effect. (Numeric)
• Type of effect (Cohen’s d; difference in proportions; difference in means; odds
ratio; hazard ratio)
• Standardised treatment effect for power calculation
Achieved sample size
Size of control group
Observed ICC for cluster randomised/group intervention trials
Observed mean cluster size for cluster randomised trials
Treatment effect (numeric)
Type of effect (estimated/observed Cohen’s d; estimated/observed difference in proporti-
ons; estimated/observed odds ratio; estimated/observed hazard ratio; estimated/obser-
ved rate ratio)
Any non-relevant fields were marked “Not given”; any unaddressed fields were marked
“Not given”; anything that was not described clearly enough was marked “Unclear”.
259
A.3 Articles from which data were abstracted in the scoping
review
References for the 234 articles that constituted the final set of the scoping review are
listed below.
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The sections of this appendix refer to the decision support tool that was developed using
Shiny. This was the subject of Chapter 6.
B.1 “ui.R” script
The R code for the “ui.R” script is given below. This determines the appearance of the
Shiny application and the levels of the particular inputs that the user can choose.











helpText("This tool compares the efficiency of two design options with
consistent estimators of efficacy (the effect of treatment receipt on
outcome) in randomised controlled trials where treatment contamination is
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expected. Contamination is defined as receipt of active intervention
within the control arm of a trial. The design options are:
"),
helpText(HTML("<ol type=A>
<li>Cluster randomisation at the level at which contamination is anticipated
to occur with an estimator of average treatment effect (ATE) that
accounts for clustering of data,</li>
<li>Individual level randomisation, measurement of treatment receipt, and use
of a randomisation-based estimator of efficacy.</li>
</ol>")),
helpText("Monte Carlo simulations were used to compare these design options.
It is assumed that:",
tags$ul(
tags$li("There are only two trial arms: active intervention and control,"),
tags$li("There is no treatment non-compliance (active intervention arm) in
either design option,"),
tags$li("Participants in the control arm receive either the control
treatment, full active treatment, or some dose of active treatment,"),




helpText("The tool is presented in two parts. First, with a binary measure of
treatment receipt, and second, with a continuous measure of treatment
receipt. For a binary measure of treatment receipt, the efficacy estimand
is the effect of treatment within a sub-population of participants who
would receive treatment when offered it and would receive control when
offered it (i.e. the complier average causal effect). For a continuous
measure of treatment receipt, the estimand being used is the effect of
treatment within a sub-population of participants who would receive the




helpText(tags$b("Purpose of the tool")),
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helpText(HTML("The aim of the tool is to provide the ratio of the standard
errors of estimates of efficacy under the design options: SE<sub>A</sub>
&divide SE<sub>B</sub>. A ratio of greater than one would imply that the
variance of the estimator of ATE under design option A is greater than
that of efficacy under design option B. Or put another way, a ratio of
greater than one means that the efficacy estimator of design option B is
more precise."
)),
helpText("The tool provides this ratio at the levels of various parameters,
as set by the user. For binary treatment receipt, these parameters are
sample size, size of standardised treatment effects, level of ICC, size
of clusters, proportion of non-contaminators (this parameter represents
the path from random treatment allocation to treatment receipt). For
continuous treatment receipt, parameters are sample size, size of
treatment effects, ICC, size of clusters, size of dose complier stratum,
and the magnitude of the response within this stratum (size of difference
between the counterfactual doses). I define the dose compliers as those
participants who would receive a greater dose of treatment under offer of
active intervention compared to control. The tool also plots a
three-dimensional figure of the surface of equivalence between the two
design options (i.e. the plane at which the precisions of the two design
options' estimators are equivalent). It is plotted in three dimensions
because there are three key variables that drive the relative efficiency
of design option A compared to option B: the level of the ICC, cluster
size, and proportion of non-contaminators/dose complier stratum."
),
br(),
helpText(tags$b("How to use the tool")),
helpText("The user must first choose the sample size options (100, 200, 500
or 1000) and standardised treatment effect sizes (0.2, 0.5 or 0.8). The
setting of these parameters enables the generation of the 3D surface plot
on the right-hand side of the screen. If the user opts for a binary
measure of treatment receipt then he or she needs to determine the ICC
(0.01, 0.02, 0.05 or 0.1), cluster size (5, 10 or 20), and proportion of
non-contaminators (0.4, 0.5, 0.6, 0.7, 0.8 or 0.9). This proportion is
also the proportion of latent compliers, or the population who would
receive treatment when offered and would not receive it when offered
control. These three parameters are used to plot a coordinate (red ball)
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in three-dimensional space in the figure. The user may need to use the
viewing angle toggles beneath the figure to visualise the position of
this point in relation to the surface."
),
helpText("If the user decides to use a continuous measure of treatment
receipt, he or she needs to choose the ICC, cluster size, size of dose
complier stratum (the proportion of the population who would receive a
greater dose under offer of treatment compared to control; 0.4, 0.5, 0.6,
0.7, 0.8 or 0.9), and the magnitude of response within this stratum. This
final parameter represents the difference in dose of active treatment
under offer of treatment compared to control for the dose compliers. This
parameter can be set to one of four levels, which are defined by the
minimum dose of active treatment under its offer and the maximum dose of
it under offer of control:",
tags$ul(
tags$li("Full dose compliers: participants receive full dose under offer of
treatment and nothing under offer of control,"),
tags$li("Strong partial dose compliers: participants receive a dose of
between 80% and 100% of maximum dose under offer of treatment and between
0% and 20% under control,"),
tags$li("Moderate strength partial dose compliers: participants receive a
dose of between 50% and 100% of maximum dose under offer of treatment and
between 0% and 50% under control,"),
tags$li("Weak partial dose compliers: participants receive a dose of between
0% and 100% of maximum dose under offers of treatment and control (where
each participant within this stratum receives a greater dose under offer
of treatment than control).")
)
)
) #End of wellPanel
) #End of column
) #End of fluidRow
), #End of tabPanel
## Binary measure of treatment receipt ##




helpText("Please enter levels for the following input parameters."),
helpText("Modifying the following two parameters will change the location of
the surface in the plot:"),
selectInput("n_part1",
label = "Choose sample size",
choices = c("100", "200", "500", "1000"),
selected = "100"),
selectInput("beta_part1",
label = "Choose (standardised) treatment effect size",
choices = c("0.2", "0.5", "0.8"),
selected = "0.2"),
helpText("Modify the following three parameters (as well as the previous two)
to compare the design options (the trial scenario will then be shown as a
coordinate on the plot):"),
selectInput("ksi_part1",
label = "Choose intraclass correlation coefficient",
choices = c("0.01", "0.02", "0.05", "0.1"),
selected = "0.01"),
selectInput("k_part1",
label = "Choose cluster size",
choices = c("5", "10", "20"),
selected = "5"),
sliderInput("p1_part1",





helpText(tags$b("It is recommended that the user try different values for the
intraclass correlation coefficient, cluster size and proportion of
compliers in order to judge the sensitivity of the results to these
parameter choices."))
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) #End of wellPanel
), #End of column
column(7,
helpText("The ratio of SEs (SE(A) / SE(B)) was:"),
textOutput("text_part1"),
textOutput("text2_part1"),
helpText("The surface in the figure below represents the equivalence in
efficiency between the two design options. Below the surface favours the
efficiency of design option A; above the surface favours option B. Note
that you may need to change the viewing angle (using the toggles below)
in order to judge the location of the coordinate.")
), #End of column
column(7,
imageOutput("image_part1")




) #End of column
) #End of fluidRow
), #End of tabPanel
## Continuous measure of treatment receipt ##
tabPanel("Continuous measure of treatment receipt",
fluidRow(
column(5, wellPanel(
helpText("Please enter levels for the following input parameters."),
helpText("Modifying the following two parameters will change the location of
the surface in the plot:"),
selectInput("n_part2",
label = "Choose sample size",




label = "Choose (standardised) treatment effect size",
choices = c("0.2", "0.5", "0.8"),
selected = "0.2"),
helpText("Modify the following three parameters (as well as the previous two)
to compare the design options (the trial scenario will then be shown as a
coordinate on the plot):"),
selectInput("ksi_part2",
label = "Choose intraclass correlation coefficient",
choices = c("0.01", "0.02", "0.05", "0.1"),
selected = "0.01"),
selectInput("k_part2",
label = "Choose cluster size",
choices = c("5", "10", "20"),
selected = "5"),
sliderInput("p1_part2",





helpText("Note that the proportion of dose compliers is the size of the
stratum of participants who would receive a greater dose of active
intervention under offer of treatment than under offer of control."),
selectInput("F_range_part2",
label = "Choose magnitude of response for those participants who would
receive greater dose under offer of treatment compared to control",
choices = c("Full dose compliers"=0, "Strong partial dose compliers"=2,
"Moderate strength partial dose compliers"=5, "Weak partial dose
compliers"=10),
selected = 0),
helpText("This parameter refers to the level of the difference in potential
(counterfactual) dose between the offers of treatment and control. \"Full
dose compliers\" receive full dose under offer of treatment and nothing
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under offer of control; \"Strong partial dose compliers\" receive a dose
of between 80% and 100% of maximum dose under offer of treatment and
between 0% and 20% under control; \"Moderate strength partial dose
compliers\" receive a dose of between 50% and 100% of maximum dose under
offer of treatment and between 0% and 50% under control; \"Weak partial
dose compliers\" receive a dose of between 0% and 100% of maximum dose
under offers of treatment and control (where each participant within this
stratum receives a greater dose under offer of treatment than control)."),
helpText(tags$b("It is recommended that the user try different values for the
intraclass correlation coefficient, cluster size, proportion of dose
compliers and magnitude of compliance (within the dose complier stratum)
in order to judge the sensitivity of the results to these parameter
choices."))
) #End of wellPanel
), #End of column
column(7,








#helpText("The surface in the figure below represents the equivalence in
efficiency between the two design options. Below the surface favours the
efficiency of design option A; above the surface favours option B. Note
that you may need to change the viewing angle (using the toggles below)
in order to judge the location of the coordinate.")
), #End of column
column(7,
#if (input$F_range_part2 < 4) {
imageOutput("image_part2")





) #End of column
) #End of fluidRow
) #End of tabPanel
) #End of narbarPage
) #End of UI
B.2 “server.R” script
The R code for the “server.R” script is given below. This renders the functionality of the
Shiny application, e.g. passes levels of input parameters that are set by the user to the
function that plots the 3D figure.
#Shiny app - simulated dataset with contamination only
# server.R
library(shiny)
#Source scripts, loading of data, and loading of libraries goes outside the
shinyServer function (because this is only run once):








### Part 1: Binary measure of treatment receipt ###












) #End of renderPlot












p12_part1=input$p1_part1, delta2_part1=0.5) < 1) {
paste("The ratio, which is less than one, suggests that design option option




k2_part1=input$k_part1, p12_part1=input$p1_part1, delta2_part1=0.5) > 1) {
paste("The ratio, which is more than one, suggests that design option option
B is more efficient.")
}
}) #End of renderText
#The next items provide the controls for viewing of the 3D graph:
output$resetable_input_part1 <- renderUI({
times <- input$reset_input_part1
















), #End of column
column(6,
sliderInput("screen.z_part1",





) #End of column
) #End of fluidRow
) #End of div
}) #End of renderUI
### Part 2: Continuous measure of treatment receipt ###
#This gives the 3D plot:
output$image_part2 <- renderPlot({












} #End of if
}, width=700) #End of renderPlot













k2_part2=input$k_part2, p12_part2=input$p1_part2, delta2_part2=0.5) < 1) {
paste("The ratio, which is less than one, suggests that design option option





p12_part2=input$p1_part2, delta2_part2=0.5) > 1) {
paste("The ratio, which is more than one, suggests that design option option
B is more efficient.")
}
}) #End of renderText
output$help_text_part2 <- renderText({
if (input$F_range_part2 == 0 | input$F_range_part2 == 2) {
paste("The surface in the figure below represents the equivalence in
efficiency between the two design options. Below the surface favours the
efficiency of design option A; above the surface favours option B. Note
that you may need to change the viewing angle (using the toggles below)
in order to judge the location of the coordinate.")
}
else if (input$F_range_part2 == 5 | input$F_range_part2 == 10) {
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paste("It is not possible to plot the plane of equivalence given the levels
of parameters that have been selected. This is because trial design
option A is more efficient at every simulated level of intraclass
correlation coefficient, cluster size, proportion of dose compliers, and
level of magnitude of difference in potential treatment receipt between
the trial arms for those participants who would receive greater dose
under offer of treatment compared to control.")
}
}) #End of renderText
#The next items provide the controls for viewing of the 3D graph:
output$resetable_input_part2 <- renderUI({
times <- input$reset_input_part2















), #End of column
column(6,
sliderInput("screen.z_part2",





) #End of column
) #End of fluidRow
) #End of div
}) #End of renderUI
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} #end of function(input, output)
) #end of shinyServer
B.3 Print output script
The R code for a function that prints the efficiency ratio at particular levels specified by
the user is given below.
# Print SE ratio function:
print_output_part1 <- function(n2_part1, beta2_part1, ksi2_part1, k2_part1,
p12_part1, delta2_part1) {
load("data/bothparts_SE.Rda")
#load("U:/PhD/Simulations (primary research question)/Shiny
app/data/bothparts_SE.Rda")
print(subset(bothparts_SE,subset=n_part1==n2_part1 & beta_part1==beta2_part1
& ksi_part1==ksi2_part1 & k_part1==k2_part1 & p1_part1==p12_part1 &
delta_part1==delta2_part1)$SE_ratio_part1)
} #End of function
B.4 3D plot script
The R code for a function that plots the 3D figure is given below.
#Code for creating 3D plot of simulated data with a marked coordinate.
library("misc3d")
library("rgl")
plot3dfnc_part1 <- function(n3_part1, beta3_part1, pt.x2_part1, pt.y2_part1,
pt.z2_part1, screen.x2_part1, screen.y2_part1=0, screen.z2_part1,
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zoom2_part1) {
# x: Ksi, ICC (1, 2, 5, 10)
# y: K, cluster size (1.25, 2.5, 5)
# z: Strength of IV (0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0)
load("data/bothparts_SE.Rda")








4 rows of ksi, 3 columns of k, 6 tables of p1
array111
#3D Plot of above:
xlim <- c(1, 10) # ksi
ylim <- c(1.25, 5) # cluster size
zlim <- c(0, 5) # strength of IV
v111 <- contour3d(array111, x=ksi*100, y=k/4, z=p1*5, 1, color = "lightblue",
color2 = "lightblue", alpha=0.7, draw = FALSE, add=TRUE) # alpha is
transparency
library("lattice")
#pt.x <- 10 # Ksi, ICC (1, 2, 5, 10)
#pt.y <- 2.5 # K, cluster size (1.25, 2.5, 5)
#pt.z <- 4.5 # Strength of IV (0, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0,
4.5, 5.0)
w111 <- wireframe(matrix(zlim[1], 2, 2) ~ rep(xlim, 2) * rep(ylim, each = 2),
xlim = xlim, ylim = ylim, zlim = zlim,
aspect = c(diff(ylim) / diff(xlim), diff(zlim) / diff(xlim)),
xlab = "Intraclass \n correlation coefficient", ylab = "Cluster size",
zlab = "Strength \n of IV",
scales = list(arrows = FALSE, col = "black",
x = list(at=c(1,2,5,10),
labels=c("0.01","0.02","0.05","0.10") ), # ksi (0.01, 0.02, 0.05, 0.10)
y = list(at=c(1.25,2.5,5),




# strength of IV
screen = list(z = screen.z2_part1, x = screen.x2_part1, y = screen.y2_part1),
zoom=zoom2_part1,
par.settings = list(axis.line = list(col = "transparent")),
panel.3d.wireframe = function(x, y, z, rot.mat, distance,
xlim.scaled, ylim.scaled,
zlim.scaled, ...) {
panel.3dscatter(x=pt.x2_part1, y=pt.y2_part1, z=pt.z2_part1, rot.mat,
distance=distance,
xlim.scaled=xlim.scaled, ylim.scaled=ylim.scaled,
zlim.scaled=zlim.scaled, type="p", col=2, # col=2 gives the point the colour
red
cex=3, pch=16, .scale=TRUE, ...)
scale <- c(diff(xlim.scaled) / diff(xlim),
diff(ylim.scaled) / diff(ylim),
diff(zlim.scaled) / diff(zlim))
shift <- c(mean(xlim.scaled) - mean(xlim) * scale[1],
mean(ylim.scaled) - mean(ylim) * scale[2],
mean(zlim.scaled) - mean(zlim) * scale[3])
P <- rbind(cbind(diag(scale), shift), c(0, 0, 0, 1))
rot.mat <- rot.mat %*% P
drawScene(v111, screen = NULL, R.mat = rot.mat,
distance = distance, add = TRUE, scale = FALSE,





Application of efficacy estimators to
D6
The sections of this appendix refer to the code used for applying estimators of CACE to
the D6 trial data.
C.1 Stata code for estimator E-IV6 (Bloom/ratio) with boot-
strap standard error
The following Stata code was used for the main analysis of efficacy with binary treatment
receipt. The code represents a Stata bootstrap program for estimating the Bloom/ratio
estimator (E-IV6) at 18 months after randomisation with sampling at the level of the
nurse.
program iv_est_bloom_iv6, rclass
regress trt_rec2 trial_arm i.ethnicity_new i.education
local trial_arm_alpha = _b[trial_arm]
regress HbA1c9 trial_arm i.borough i.phase HBA1cm_base i.ethnicity_new i.education
local trial_arm_beta = _b[trial_arm]
return scalar iv = ‘trial_arm_beta’/‘trial_arm_alpha’
end
bootstrap r(iv), reps(200) seed(1987) cluster(nurse) : iv_est_bloom_iv6
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C.2 Stata code for estimator E-IV5 (modified Bloom/ratio) with
bootstrap standard error
The following Stata code was used as one of the sensitivity analyses of efficacy with binary
treatment receipt. The code represents a Stata bootstrap program for estimating the
modified Bloom/ratio estimator (E-IV5) at 18 months after randomisation with sampling
at the level of the nurse.
program iv_est_iv5, rclass
regress trt_rec2 trial_arm
local trial_arm = _b[trial_arm]
local trial_arm_contr = _b[_cons]
summarize HbA1c18 if trial_arm==0 & trt_rec2==1
local HbA1c18_01 = r(mean)
summarize HbA1c18 if trial_arm==0 & trt_rec2==0
local HbA1c18_00 = r(mean)
summarize HbA1c18 if trial_arm==1 & trt_rec2==1
local HbA1c18_11 = r(mean)
summarize HbA1c18 if trial_arm==1 & trt_rec2==0
local HbA1c18_10 = r(mean)





bootstrap r(iv), reps(200) seed(1987) cluster(nurse) : iv_est_iv5
C.3 MPlus code for STR3 estimator
The following MPlus code was used for one of the sensitivty analyses of efficacy with
binary treatment receipt. The code represents a mixture model estimating efficacy
(estimator E-STR3) at nine months after randomisation and assuming latent ignorability.
TITLE:
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D6 HbA1C - Efficacy analysis;
DATA:
File is “str3_model_v1.dat” ;
VARIABLE:
Names are d6no borough gender bl_BMI phase nurse HBA1cm_bl education HbA1c18
HbA1c15 HbA1c9 resp9 resp15 resp18 trial_arm trt_rec2 noncomp2 contam2
ethnicity_new
Classes C(3);
Categorical contam2 noncomp2 resp9;
Usevariables trial_arm HbA1c9 contam2 noncomp2
phase HBA1cm_bl resp9 gender bl_BMI
b2 b3 b4 b5 ed2 ed3 eth1 eth2;
Missing are all (99) ;
ANALYSIS:
Type = Mixture ;
DEFINE:
b2 = borough == 2;
b3 = borough == 3;
b4 = borough == 4;
b5 = borough == 5;
ed2 = education == 2;
ed3 = education == 3;
eth1 = ethnicity_new == 1;
eth2 = ethnicity_new == 2;
MODEL:
%OVERALL%
HbA1c9 ON trial_arm b2 b3 b4 b5 phase HBA1cm_bl eth1 eth2;
resp9 ON b2 b3 b4 b5 phase HBA1cm_bl eth1 eth2;
C#1 ON gender ed2 ed3;
C#2 ON bl_BMI b2 b3 b4 b5;





HbA1c9 ON trial_arm@0 ;
resp9 ON trial_arm@0 ;




HbA1c9 ON trial_arm@0 ;
resp9 ON trial_arm@0 ;




HbA1c9 ON trial_arm ;
resp9 ON trial_arm ;
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